THE OFFICIAL PATIENT’S SOURCEBOOK
on
NEUMONIA J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright Ó2002 by ICON Group International, Inc. Copyright Ó2002 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Tiffany LaRochelle Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher’s note: The ideas, procedures, and suggestions contained in this book are not intended as a substitute for consultation with your physician. All matters regarding your health require medical supervision. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation, in close consultation with a qualified physician. The reader is advised to always check product information (package inserts) for changes and new information regarding dose and contraindications before taking any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960The Official Patient’s Sourcebook on Pneumonia: A Revised and Updated Directory for the Internet Age/James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary and index. ISBN: 0-597-82993-4 1. Pneumonia-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem or as a substitute for consultation with licensed medical professionals. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors or authors. ICON Group International, Inc., the editors, or the authors are not responsible for the content of any Web pages nor publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this sourcebook for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications are copyrighted. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs or other materials, please contact us to request permission (e-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this sourcebook.
iv
Dedication To the healthcare professionals dedicating their time and efforts to the study of pneumonia.
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this sourcebook which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which directly or indirectly are dedicated to the study of pneumonia. All of the Official Patient’s Sourcebooks draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this sourcebook. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany LaRochelle for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for the Official Patient’s Sourcebook series published by ICON Health Publications.
Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for the Official Patient’s Sourcebook series published by ICON Health Publications.
vi
About ICON Health Publications In addition to pneumonia, Official Patient’s Sourcebooks are available for the following related topics: ·
The Official Patient's Sourcebook on Anthrax
·
The Official Patient's Sourcebook on Bacterial Waterborne Diseases
·
The Official Patient's Sourcebook on Blastomycosis
·
The Official Patient's Sourcebook on Botulism
·
The Official Patient's Sourcebook on Brainerd Diarrhea
·
The Official Patient's Sourcebook on Brucellosis
·
The Official Patient's Sourcebook on Chlamydia Pneumonia
·
The Official Patient's Sourcebook on Cholera
·
The Official Patient's Sourcebook on Diarrheagenic Escherichia Coli
·
The Official Patient's Sourcebook on Drug-resistant Streptococcus Pneumoniae
·
The Official Patient's Sourcebook on Enterotoxigenic E. Coli
·
The Official Patient's Sourcebook on Escherichia Coli
·
The Official Patient's Sourcebook on Foodborne Disease
·
The Official Patient's Sourcebook on Genital Candidiasis
·
The Official Patient's Sourcebook on Glanders
·
The Official Patient's Sourcebook on Group A Streptococcus
·
The Official Patient's Sourcebook on Group B Streptococcus
·
The Official Patient's Sourcebook on Haemophilus Influenzae Serotype B
·
The Official Patient's Sourcebook on Hansen's Disease
·
The Official Patient's Sourcebook on Helicobacter Pylori Infections
·
The Official Patient's Sourcebook on Legionellosis
·
The Official Patient's Sourcebook on Meningitis
·
The Official Patient's Sourcebook on Mycoplasma Pneumoniae
·
The Official Patient's Sourcebook on Oropharyngeal Candidiasis
·
The Official Patient's Sourcebook on Pneumonia among Children in Developing Countries
·
The Official Patient's Sourcebook on Salmonellosis
·
The Official Patient's Sourcebook on Shigellosis
·
The Official Patient's Sourcebook on Streptococcus Pneumoniae Disease
·
The Official Patient's Sourcebook on Toxic Shock Syndrome
·
The Official Patient's Sourcebook on Travelers Diarrhea
·
The Official Patient's Sourcebook on Typhoid Fever
·
The Official Patient's Sourcebook on Urinary Tract Infections
vii
To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
Contents
ix
Table of Contents INTRODUCTION...................................................................................... 1
Overview............................................................................................................... 1 Organization......................................................................................................... 3 Scope ..................................................................................................................... 3 Moving Forward................................................................................................... 5
PART I: THE ESSENTIALS ................................................. 7 CHAPTER 1. THE ESSENTIALS ON PNEUMONIA: GUIDELINES.............. 9
Overview............................................................................................................... 9 What Is Pneumonia? .......................................................................................... 10 What Is Pneumococcal Pneumonia? .................................................................. 11 How Is Pneumococcus Spread?.......................................................................... 12 What Are the Symptoms of Pneumococcal Pneumonia? ................................... 12 How Is Pneumococcal Pneumonia Diagnosed? ................................................. 13 How Is Pneumococcal Pneumonia Treated? ...................................................... 13 Can Pneumococcal Pneumonia be Prevented?................................................... 13 Does Pneumococcal Pneumonia Cause Complications? .................................... 14 What Research Is Going On? ............................................................................. 14 More Information ............................................................................................... 15 More Guideline Sources ..................................................................................... 16 Vocabulary Builder............................................................................................. 26
CHAPTER 2. SEEKING GUIDANCE ....................................................... 33
Overview............................................................................................................. 33 Associations and Pneumonia.............................................................................. 33 Finding More Associations................................................................................. 36 Finding Doctors.................................................................................................. 37 Finding Specialists.............................................................................................. 38 Selecting Your Doctor ........................................................................................ 39 Working with Your Doctor ................................................................................ 40 Broader Health-Related Resources ..................................................................... 41 Vocabulary Builder............................................................................................. 41
CHAPTER 3. CLINICAL TRIALS AND PNEUMONIA .............................. 43
Overview............................................................................................................. 43 Recent Trials on Pneumonia .............................................................................. 46 Benefits and Risks............................................................................................... 67 Keeping Current on Clinical Trials.................................................................... 70 General References.............................................................................................. 71 Vocabulary Builder............................................................................................. 72
PART II: ADDITIONAL RESOURCES AND ADVANCED MATERIAL.................................................. 75
x
Contents
CHAPTER 4. STUDIES ON PNEUMONIA ............................................... 77
Overview............................................................................................................. 77 The Combined Health Information Database ..................................................... 77 Federally Funded Research on Pneumonia......................................................... 80 E-Journals: PubMed Central .............................................................................. 92 The National Library of Medicine: PubMed .................................................... 100 Vocabulary Builder........................................................................................... 103
CHAPTER 5. PATENTS ON PNEUMONIA ............................................ 113
Overview........................................................................................................... 113 Patents on Pneumonia...................................................................................... 114 Patent Applications on Pneumonia.................................................................. 121 Keeping Current ............................................................................................... 123 Vocabulary Builder........................................................................................... 123
CHAPTER 6. BOOKS ON PNEUMONIA................................................ 125
Overview........................................................................................................... 125 Book Summaries: Federal Agencies .................................................................. 125 Book Summaries: Online Booksellers ............................................................... 128 The National Library of Medicine Book Index ................................................. 130 Chapters on Pneumonia.................................................................................... 133 General Home References ................................................................................. 134 Vocabulary Builder........................................................................................... 135
CHAPTER 7. MULTIMEDIA ON PNEUMONIA ..................................... 141
Overview........................................................................................................... 141 Video Recordings .............................................................................................. 141 Audio Recordings ............................................................................................. 142 Bibliography: Multimedia on Pneumonia ........................................................ 143 Vocabulary Builder........................................................................................... 145
CHAPTER 8. PERIODICALS AND NEWS ON PNEUMONIA .................. 147
Overview........................................................................................................... 147 News Services & Press Releases ....................................................................... 147 Newsletters on Pneumonia............................................................................... 152 Newsletter Articles ........................................................................................... 153 Academic Periodicals covering Pneumonia...................................................... 154 Vocabulary Builder........................................................................................... 156
CHAPTER 9. PHYSICIAN GUIDELINES AND DATABASES ................... 159
Overview........................................................................................................... 159 NIH Guidelines................................................................................................. 159 NIH Databases.................................................................................................. 160 Other Commercial Databases ........................................................................... 166 The Genome Project and Pneumonia ............................................................... 167 Specialized References....................................................................................... 171 Vocabulary Builder........................................................................................... 172
CHAPTER 10. DISSERTATIONS ON PNEUMONIA ............................... 173
Contents
xi
Overview........................................................................................................... 173 Dissertations on Pneumonia ............................................................................ 173 Keeping Current ............................................................................................... 175 Vocabulary Builder........................................................................................... 175
PART III. APPENDICES .................................................. 177 APPENDIX A. RESEARCHING YOUR MEDICATIONS.......................... 179
Overview........................................................................................................... 179 Your Medications: The Basics .......................................................................... 180 Learning More about Your Medications .......................................................... 181 Commercial Databases...................................................................................... 185 Contraindications and Interactions (Hidden Dangers) ................................... 191 A Final Warning .............................................................................................. 191 General References............................................................................................ 192 Vocabulary Builder........................................................................................... 193
APPENDIX B. RESEARCHING ALTERNATIVE MEDICINE ................... 197
Overview........................................................................................................... 197 What Is CAM? ................................................................................................. 197 What Are the Domains of Alternative Medicine?............................................ 198 Can Alternatives Affect My Treatment? ......................................................... 201 Finding CAM References on Pneumonia......................................................... 202 Additional Web Resources................................................................................ 214 General References............................................................................................ 224 Vocabulary Builder........................................................................................... 225
APPENDIX C. RESEARCHING NUTRITION ......................................... 227
Overview........................................................................................................... 227 Food and Nutrition: General Principles........................................................... 228 Finding Studies on Pneumonia ........................................................................ 232 Federal Resources on Nutrition........................................................................ 235 Additional Web Resources................................................................................ 235 Vocabulary Builder........................................................................................... 237
APPENDIX D. FINDING MEDICAL LIBRARIES.................................... 239
Overview........................................................................................................... 239 Preparation ....................................................................................................... 239 Finding a Local Medical Library ...................................................................... 240 Medical Libraries Open to the Public............................................................... 240
APPENDIX E. YOUR RIGHTS AND INSURANCE ................................. 247
Overview........................................................................................................... 247 Your Rights as a Patient................................................................................... 247 Patient Responsibilities .................................................................................... 251 Choosing an Insurance Plan............................................................................. 252 Medicare and Medicaid .................................................................................... 254 NORD’s Medication Assistance Programs ..................................................... 257 Additional Resources ........................................................................................ 258
xii Contents
Vocabulary Builder........................................................................................... 259
ONLINE GLOSSARIES.................................................... 261 Online Dictionary Directories.......................................................................... 270
PNEUMONIA GLOSSARY ............................................. 271 General Dictionaries and Glossaries ................................................................ 299
INDEX................................................................................... 301
Introduction
1
INTRODUCTION Overview Dr. C. Everett Koop, former U.S. Surgeon General, once said, “The best prescription is knowledge.”1 The Agency for Healthcare Research and Quality (AHRQ) of the National Institutes of Health (NIH) echoes this view and recommends that every patient incorporate education into the treatment process. According to the AHRQ: Finding out more about your condition is a good place to start. By contacting groups that support your condition, visiting your local library, and searching on the Internet, you can find good information to help guide your treatment decisions. Some information may be hard to find—especially if you don’t know where to look.2 As the AHRQ mentions, finding the right information is not an obvious task. Though many physicians and public officials had thought that the emergence of the Internet would do much to assist patients in obtaining reliable information, in March 2001 the National Institutes of Health issued the following warning: The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading.3
Quotation from http://www.drkoop.com. The Agency for Healthcare Research and Quality (AHRQ): http://www.ahcpr.gov/consumer/diaginfo.htm. 3 From the NIH, National Cancer Institute (NCI): http://cancertrials.nci.nih.gov/beyond/evaluating.html. 1 2
2
Pneumonia
Since the late 1990s, physicians have seen a general increase in patient Internet usage rates. Patients frequently enter their doctor’s offices with printed Web pages of home remedies in the guise of latest medical research. This scenario is so common that doctors often spend more time dispelling misleading information than guiding patients through sound therapies. The Official Patient’s Sourcebook on Pneumonia has been created for patients who have decided to make education and research an integral part of the treatment process. The pages that follow will tell you where and how to look for information covering virtually all topics related to pneumonia, from the essentials to the most advanced areas of research. The title of this book includes the word “official.” This reflects the fact that the sourcebook draws from public, academic, government, and peerreviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on pneumonia. Given patients’ increasing sophistication in using the Internet, abundant references to reliable Internet-based resources are provided throughout this sourcebook. Where possible, guidance is provided on how to obtain free-ofcharge, primary research results as well as more detailed information via the Internet. E-book and electronic versions of this sourcebook are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). Hard copy users of this sourcebook can type cited Web addresses directly into their browsers to obtain access to the corresponding sites. Since we are working with ICON Health Publications, hard copy Sourcebooks are frequently updated and printed on demand to ensure that the information provided is current. In addition to extensive references accessible via the Internet, every chapter presents a “Vocabulary Builder.” Many health guides offer glossaries of technical or uncommon terms in an appendix. In editing this sourcebook, we have decided to place a smaller glossary within each chapter that covers terms used in that chapter. Given the technical nature of some chapters, you may need to revisit many sections. Building one’s vocabulary of medical terms in such a gradual manner has been shown to improve the learning process. We must emphasize that no sourcebook on pneumonia should affirm that a specific diagnostic procedure or treatment discussed in a research study, patent, or doctoral dissertation is “correct” or your best option. This sourcebook is no exception. Each patient is unique. Deciding on appropriate
Introduction
3
options is always up to the patient in consultation with their physician and healthcare providers.
Organization This sourcebook is organized into three parts. Part I explores basic techniques to researching pneumonia (e.g. finding guidelines on diagnosis, treatments, and prognosis), followed by a number of topics, including information on how to get in touch with organizations, associations, or other patient networks dedicated to pneumonia. It also gives you sources of information that can help you find a doctor in your local area specializing in diagnosing and treating pneumonia. Collectively, the material presented in Part I is a complete primer on basic research topics for patients with pneumonia. Part II moves on to advanced research dedicated to pneumonia. Part II is intended for those willing to invest many hours of hard work and study. It is here that we direct you to the latest scientific and applied research on pneumonia. When possible, contact names, links via the Internet, and summaries are provided. It is in Part II where the vocabulary process becomes important as authors publishing advanced research frequently use highly specialized language. In general, every attempt is made to recommend “free-to-use” options. Part III provides appendices of useful background reading for all patients with pneumonia or related disorders. The appendices are dedicated to more pragmatic issues faced by many patients with pneumonia. Accessing materials via medical libraries may be the only option for some readers, so a guide is provided for finding local medical libraries which are open to the public. Part III, therefore, focuses on advice that goes beyond the biological and scientific issues facing patients with pneumonia.
Scope While this sourcebook covers pneumonia, your doctor, research publications, and specialists may refer to your condition using a variety of terms. Therefore, you should understand that pneumonia is often considered a synonym or a condition closely related to the following: ·
Anaerobic Pneumonia
·
Aspiration of Vomitus
4
Pneumonia
·
Aspiration Pneumonia
·
Bacterial Pneumonia
·
Classic Pneumococcal Pneumonia
·
Lobar Pneumonia
·
Necrotizing Pneumonia
·
Pyogenic Pneumonia
·
Walking Pneumonia - Atypical Pneumonia
In addition to synonyms and related conditions, physicians may refer to pneumonia using certain coding systems. The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) is the most commonly used system of classification for the world’s illnesses. Your physician may use this coding system as an administrative or tracking tool. The following classification is commonly used for pneumonia:4 ·
428.0 pneumonia, klebsiella
·
481 pneumococcal pneumonia
·
481 pneumonia, pneumococcal
·
482.1 pneumonia, pseudomonas
·
482.2 pneumonia, haemophilus influenzae
·
482.4 pneumonia, staphylococcal
·
482.9 pneumonia, bacterial
·
486.0 pneumonia, acute
·
507.0 aspiration pneumonia
·
507.0 pneumonia, aspiration
For the purposes of this sourcebook, we have attempted to be as inclusive as possible, looking for official information for all of the synonyms relevant to pneumonia. You may find it useful to refer to synonyms when accessing databases or interacting with healthcare professionals and medical librarians.
4 This list is based on the official version of the World Health Organization’s 9th Revision, International Classification of Diseases (ICD-9). According to the National Technical Information Service, “ICD-9CM extensions, interpretations, modifications, addenda, or errata other than those approved by the U.S. Public Health Service and the Health Care Financing Administration are not to be considered official and should not be utilized. Continuous maintenance of the ICD-9-CM is the responsibility of the federal government.”
Introduction
5
Moving Forward Since the 1980s, the world has seen a proliferation of healthcare guides covering most illnesses and conditions. Some are written by patients or their family members. These generally take a layperson’s approach to understanding and coping with an illness or disorder. They can be uplifting, encouraging, and highly supportive. Other guides are authored by physicians or other healthcare providers who have a more clinical outlook. Each of these two styles of guide has its purpose and can be quite useful. As editors, we have chosen a third route. We have chosen to expose you to as many sources of official and peer-reviewed information as practical, for the purpose of educating you about basic and advanced knowledge as recognized by medical science today. You can think of this sourcebook as your personal Internet age reference librarian. Why “Internet age”? All too often, patients with pneumonia will log on to the Internet, type words into a search engine, and receive several Web site listings which are mostly irrelevant or redundant. These patients are left to wonder where the relevant information is, and how to obtain it. Since only the smallest fraction of information dealing with pneumonia is even indexed in search engines, a non-systematic approach often leads to frustration and disappointment. With this sourcebook, we hope to direct you to the information you need that you would not likely find using popular Web directories. Beyond Web listings, in many cases we will reproduce brief summaries or abstracts of available reference materials. These abstracts often contain distilled information on topics of discussion. While we focus on the more scientific aspects of pneumonia, there is, of course, the emotional side to consider. Later in the sourcebook, we provide a chapter dedicated to helping you find peer groups and associations that can provide additional support beyond research produced by medical science. We hope that the choices we have made give you the most options available in moving forward. In this way, we wish you the best in your efforts to incorporate this educational approach into your treatment plan. The Editors
7
PART I: THE ESSENTIALS
ABOUT PART I Part I has been edited to give you access to what we feel are “the essentials” on pneumonia. The essentials of a symptom typically include the definition or description of the symptom, a discussion of who it affects, the diseases that are associated with a given symptom, tests or diagnostic procedures that might be specific to the symptom, and treatments for the symptom. Your doctor or healthcare provider may have already explained the essentials of pneumonia to you or even given you a pamphlet or brochure describing pneumonia. Now you are searching for more in-depth information. As editors, we have decided, nevertheless, to include a discussion on where to find essential information that can complement what your doctor has already told you. In this section we recommend a process, not a particular Web site or reference book. The process ensures that, as you search the Web, you gain background information in such a way as to maximize your understanding.
Guidelines
CHAPTER 1. GUIDELINES
THE
ESSENTIALS
ON
9
PNEUMONIA:
Overview Official agencies, as well as federally-funded institutions supported by national grants, frequently publish a variety of guidelines on pneumonia. These are typically called “Fact Sheets” or “Guidelines.” They can take the form of a brochure, information kit, pamphlet, or flyer. Often they are only a few pages in length. The great advantage of guidelines over other sources is that they are often written with the patient in mind. Since new guidelines on pneumonia can appear at any moment and be published by a number of sources, the best approach to finding guidelines is to systematically scan the Internet-based services that post them.
The National Institutes of Health (NIH)5 The National Institutes of Health (NIH) is the first place to search for relatively current patient guidelines and fact sheets on pneumonia. Originally founded in 1887, the NIH is one of the world’s foremost medical research centers and the federal focal point for medical research in the United States. At any given time, the NIH supports some 35,000 research grants at universities, medical schools, and other research and training institutions, both nationally and internationally. The rosters of those who have conducted research or who have received NIH support over the years include the world’s most illustrious scientists and physicians. Among them are 97 scientists who have won the Nobel Prize for achievement in medicine.
5
Adapted from the NIH: http://www.nih.gov/about/NIHoverview.html.
10 Pneumonia
There is no guarantee that any one Institute will have a guideline on a specific condition or disease, though the National Institutes of Health collectively publish over 600 guidelines for both common and rare conditions and disorders. The best way to access NIH guidelines is via the Internet. Although the NIH is organized into many different Institutes and Offices, the following is a list of key Web sites where you are most likely to find NIH clinical guidelines and publications dealing with pneumonia and associated conditions: ·
Office of the Director (OD); guidelines consolidated across agencies available at http://www.nih.gov/health/consumer/conkey.htm
·
National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines available at http://www.nlm.nih.gov/medlineplus/healthtopics.html
·
National Institute of Allergy and Infectious Diseases (NIAID); guidelines available at http://www.niaid.nih.gov/publications/
·
Centers for Disease Control and Prevention: various fact sheets on infectious diseases at http://www.cdc.gov/health/diseases.htm
Among the above, the National Institute of Allergy and Infectious Diseases (NIAID) is particularly noteworthy. The mission of the NIAID is to provide support for scientists conducting research aimed at developing better ways to diagnose, treat, and prevent the many infectious, immunologic and allergic diseases that afflict people worldwide.6 The NIAID is composed of four extramural divisions: the Division of AIDS; the Division of Allergy, Immunology and Transplantation; the Division of Microbiology and Infectious Diseases; and the Division of Extramural Activities. In addition, NIAID scientists conduct intramural research in laboratories located in Bethesda, Rockville and Frederick, Maryland, and in Hamilton, Montana. The following patient guideline was recently published by the NIAID on pneumonia.
What Is Pneumonia?7 Pneumonia is a lung disease that can be caused by a variety of viruses, bacteria, and sometimes fungi. The U.S. Centers for Diseases Control and 6 This paragraph has been adapted from the NIAID: http://www.niaid.nih.gov/facts/overview.htm. “Adapted” signifies that a passage has been reproduced exactly or slightly edited for this book. 7 Adapted from The National Institute of Allergy and Infectious Diseases (NIAID): http://www.niaid.nih.gov/factsheets/pneumonia.htm.
Guidelines 11
Prevention (CDC) estimate nearly 90,000 people in the United States died from one of several kinds of pneumonia in 1999. In the United States, pneumonia is the fifth leading cause of death [Natl Vital Stat Report 47 (25), 10/5/1999]. Rates of infection are three-times higher in African Americans than in whites and are 5- to 10-times higher in Native-American adults and 10-times higher in Native-American children [J Infect Dis;170:368-76, 1994]. On an international scale, acute respiratory infection ranks as the third most frequent cause of death among children less than 5 years old and was responsible for approximately 3.5 million deaths in 1998.
What Is Pneumococcal Pneumonia? Pneumococcal pneumonia is an infection in the lungs caused by bacteria called Streptococcus pneumoniae. S. pneumoniae, also called pneumococcus, can infect the upper respiratory tracts of adults and children and can spread to the blood, lungs, middle ear, or nervous system. CDC estimates S. pneumoniae causes 40,000 deaths and 500,000 cases of pneumonia annually in the United States. The yearly incidence of pneumococcal pneumonia is twice as high in African Americans than in whites and is responsible for 3,000 cases of meningitis (inflammation of spinal cord membranes), 50,000 cases of bacteremia (bacteria in the blood), and 7 million cases of otitis media (inner ear infection) [JAMA; 285:1729-1735, 2001]. According to the World Health Organization, S. pneumoniae is the leading cause of severe pneumonia worldwide in children younger than 5 years old, causing more than 1 million deaths in children each year [Pneumococcal Vaccines: WHO Position Paper: Wkly Epidemiol Rec, Vol 74, 177-183, 1999]. Pneumococcal pneumonia primarily causes illness in children younger than 2 years old and adults 65 years of age or older. The elderly are especially vulnerable to getting seriously ill and dying from this disease. In addition, people with certain medical conditions such as chronic heart, lung, or liver diseases or sickle cell anemia are also at increased risk for getting pneumococcal pneumonia as are people with HIV infection or AIDS or people who have had organ transplants and are taking medicines that lower their resistance to infection.
12 Pneumonia
How Is Pneumococcus Spread? The noses and throats of up to 70 percent of healthy people contain pneumococcus at any given time. It is spread from person to person by coughing, sneezing, or close contact. Researchers don’t know why it suddenly invades the lungs and the bloodstream to cause disease.
What Are the Symptoms of Pneumococcal Pneumonia? Pneumococcal pneumonia may begin suddenly, with a severe shaking chill usually followed by: ·
High fever
·
Cough
·
Shortness of breath
·
Rapid breathing
·
Chest pains
There may be other symptoms as well, such as: ·
Nausea
·
Vomiting
·
Headache
·
Tiredness
·
Muscle aches
In an otherwise healthy adult, pneumococcal pneumonia usually involves one or more parts of the lungs, known as lobes. Thus, it is sometimes called lobar pneumonia. The remainder of the respiratory system is comparatively not affected. In contrast, infants, young children, and elderly people more commonly develop a relatively mild infection in other parts of the lungs, such as around the air vessels (bronchi) causing bronchopneumonia.
Guidelines 13
How Is Pneumococcal Pneumonia Diagnosed? A doctor or other health care provider diagnoses pneumonia based on the following: ·
Symptoms
·
Physical examination
·
Laboratory tests
·
Chest x-ray
Because a number of bacteria, viruses, and other infectious agents can cause pneumonia, if you have any of the symptoms, you should get diagnosed early and start taking the right medicine if you have any of the symptoms. The presence of S. pneumoniae in the blood, saliva, or lung fluid helps lead to a diagnosis of pneumococcal pneumonia.
How Is Pneumococcal Pneumonia Treated? Health care providers usually prescribe antibiotics, such as penicillin, to treat this bacterial disease. The symptoms of pneumococcal pneumonia usually subside within 12 to 36 hours after treatment has begun. Bacteria such as S. pneumoniae, however, are resisting and fighting off the powers of antibiotics to destroy them. Such antibiotic resistance is increasing worldwide because these medicines have been overused or misused. Therefore, if you are at risk of getting pneumococcal pneumonia, you should talk with your doctor about taking steps to prevent it.
Can Pneumococcal Pneumonia be Prevented? The pneumococcal vaccine is the only way to prevent getting pneumococcal pneumonia. Vaccines are available for children and adults. The CDC National Immunization Program (NIP) recommends that you get immunized against pneumococcal pneumonia if you are in any of the following groups: ·
You are 65 years old or older.
14 Pneumonia
·
You have a serious long-term health problem such as heart disease, sickle cell disease, alcoholism, leaks of cerebrospinal fluid, lung disease (not including asthma), diabetes, or liver cirrhosis.
·
Your resistance to infection is lowered due to HIV infection or AIDS; lymphoma, leukemia, or other cancers; cancer treatment with x-rays or drugs; treatment with long-term steroids; bone marrow or organ transplant; kidney failure; nephrotic (kidney) syndrome; damaged spleen or no spleen.
·
You are an Alaskan-Native or from certain Native-American populations.
In February 2000, the U.S. Food and Drug Administration approved a pneumococcal vaccine for use in toddlers and children. It is the first pneumococcal vaccine approved for children younger than 2 years old [http://www.fda.gov/cber/inside/annrpt.htm,: CBER Annual Report FY2000 Issued:01-08-01, Posted: 03-15-01, Updated: 04-10-01]. NIP recommends that all children ages 2 to 23 months old get this vaccine.
Does Pneumococcal Pneumonia Cause Complications? In about 30 percent of people with pneumococcal pneumonia, the bacteria invade the blood stream from the lungs (http://www.cdc.gov/nip/publications/pink/pneumo2.pdf, pp. 249-263). This causes bacteremia, a very serious Pneumococcal pneumonia also can cause other lung problems and certain heart problems.
What Research Is Going On? The National Institute of Allergy and Infectious Diseases (NIAID) supports research on more effective prevention and treatment approaches to control pneumonia and its causes. These include ·
Developing and licensing vaccines and treatments for the disease-causing microbes (pathogens) that cause pneumonia
·
Stimulating research on the structure and function of these pathogens
·
Developing better and more rapid diagnostic tools
·
Understanding the long-term health impact respiratory pathogens have in various populations
·
Examining the effect of vaccines in high-risk populations
Guidelines 15
·
Determining how pneumococcus becomes resistant to antibiotics
The recently approved pneumococcal conjugate vaccine for children is partially the result of crucial NIAID research in the early development of the vaccine. This vaccine helps prevent pneumococcal diseases in babies and toddlers and is the latest advance in developing vaccines against common bacterial infections. This effort was led in large part by NIAID for more than 30 years. NIAID supports studies to develop improved pneumococcal conjugate vaccines for children worldwide. In one such study, NIAID researchers are working with The Gambia Government and scientists from several international research institutions to test a pneumococcal conjugate vaccine in The Gambia, West Africa. Health care experts have consistently identified pneumococcus as the most common cause of bacterial pneumonia in The Gambia. In a pattern typical of many developing areas, infant and child mortality rates in The Gambia are high, acute respiratory infections are a leading cause of death, and pneumococcus is the most common cause of these infections.
More Information For more information, contact: National Institute of Allergy and Infectious Diseases 31 Center Drive, MSC 2520 Bethesda, MD 20892-2520 http://www.niaid.nih.gov U.S. National Library of Medicine MEDLINEplus 8600 Rockville Pike Bethesda, MD 20894 1-800-338-7657 http://www.nlm.nih.gov/medlineplus/pneumonia.html U.S. Food and Drug Administration 5600 Fishers Lane Rockville MD 20857-0001 1-888-INFO-FDA (1-888-463-6332) http://www.fda.gov
16 Pneumonia
The American Lung Association 1740 Broadway New York, NY 10019 1-800-LUNG-USA (1-800-586-4872) http://www.lungusa.org/diseases National Foundation for Infectious Diseases National Coalition for Adult Immunization 4733 Bethesda Avenue, Suite 750 Bethesda, MD 20814-5228 http://www.nfid.org/factsheets/pneuadult.html For information on pneumococcal vaccine: U.S. Centers for Disease Control and Prevention National Immunization Program 1-800-232-2522 http://www.cdc.gov/nip/ U.S. National Institutes of Health National Institute on Aging Information Center 1-800-222-2225 http://www.nih.gov/nia/health/agepages/shots.htm
More Guideline Sources The guideline above on pneumonia is only one example of the kind of material that you can find online and free of charge. The remainder of this chapter will direct you to other sources which either publish or can help you find additional guidelines on topics related to pneumonia. Many of the guidelines listed below address topics that may be of particular relevance to your specific situation or of special interest to only some patients with pneumonia. Due to space limitations these sources are listed in a concise manner. Do not hesitate to consult the following sources by either using the Internet hyperlink provided, or, in cases where the contact information is provided, contacting the publisher or author directly.
Topic Pages: MEDLINEplus For patients wishing to go beyond guidelines published by specific Institutes of the NIH, the National Library of Medicine has created a vast and patient-
Guidelines 17
oriented healthcare information portal called MEDLINEplus. Within this Internet-based system are “health topic pages.” You can think of a health topic page as a guide to patient guides. To access this system, log on to http://www.nlm.nih.gov/medlineplus/healthtopics.html. From there you can either search using the alphabetical index or browse by broad topic areas. Recently, MEDLINEplus listed the following as being relevant to pneumonia: ·
Guides On Pneumonia Pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/000145.htm Pneumonia http://www.nlm.nih.gov/medlineplus/pneumonia.html Pneumonia in immunocompromised host http://www.nlm.nih.gov/medlineplus/ency/article/000093.htm
·
Other Guides Aspiration pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/000121.htm Atypical pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/000079.htm CMV - pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/000664.htm Pneumocystis carinii pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/000671.htm Mycoplasma pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/000082.htm Viral pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/000073.htm Hospital-acquired pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/000146.htm Chronic Obstructive Pulmonary Disease http://www.nlm.nih.gov/medlineplus/tutorials/copdloader.html Psittacosis http://www.nlm.nih.gov/medlineplus/ency/article/000088.htm Simple pulmonary eosinophilia http://www.nlm.nih.gov/medlineplus/ency/article/000105.htm
18 Pneumonia
Hydrocarbon pneumonia http://www.nlm.nih.gov/medlineplus/ency/article/001083.htm Legionnaire's disease http://www.nlm.nih.gov/medlineplus/ency/article/000616.htm
Within the health topic page dedicated to pneumonia, the following was recently recommended to patients: ·
General/Overviews Pneumonia Source: Mayo Foundation for Medical Education and Research http://www.mayoclinic.com/invoke.cfm?id=DS00135
·
Diagnosis/Symptoms Radiography-Chest (Chest X-ray) Source: American College of Radiology, Radiological Society of North America http://www.radiologyinfo.org/content/chest_radiography.htm
·
Specific Conditions/Aspects HIV/AIDS And Lung Disease Source: American Lung Association http://www.lungusa.org/diseases/lungaids2.html Walking Pneumonia Source: Mayo Foundation for Medical Education and Research http://www.mayoclinic.com/invoke.cfm?id=AN00137
·
Children Pneumonia Source: Nemours Foundation http://kidshealth.org/parent/infections/bacterial_viral/pneumonia. html Pneumonia (For Kids) Source: Nemours Foundation http://kidshealth.org/kid/ill_injure/sick/pneumonia.html
Guidelines 19
·
From the National Institutes of Health Pneumococcal Pneumonia Source: National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/factsheets/pneumonia.htm
·
Latest News New Measure May Help Prevent Patients With Pneumonia From Being Sent Home Too Soon Source: 06/09/2002, Agency for Healthcare Research and Quality http://www.ahrq.gov/news/press/pr2002/pneumpr.htm
·
Organizations American Lung Association http://www.lungusa.org/index.html National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/ National Institute on Aging http://www.nia.nih.gov/
·
Prevention/Screening Pneumococcal Conjugate Vaccine: What You Need to Know Source: img src='/medlineplus/images/linkpdf.gif' width='100' height='17' border=0 alt='Links to PDF File'> (National Immunization Program http://www.cdc.gov/nip/publications/VIS/visPneumoConjugate.pdf Pneumonia Prevention: It's Worth a Shot Source: National Institute on Aging http://www.nia.nih.gov/health/agepages/pneum.htm
·
Research Drug Resistant Pneumococcal Bacteria Increasing as Antibiotic Use Grows Source: American Medical Association http://www.medem.com/medlb/article_detaillb.cfm?article_ID=ZZ ZV34JJXSC&sub_cat=620
20 Pneumonia
New Measure May Help Prevent Patients With Pneumonia From Being Sent Home Too Soon Source: Agency for Healthcare Research and Quality http://www.ahrq.gov/news/press/pr2002/pneumpr.htm ·
Statistics FASTATS: Pneumonia Source: National Center for Health Statistics http://www.cdc.gov/nchs/fastats/pneumonia.htm
If you do not find topics of interest when browsing health topic pages, then you can choose to use the advanced search utility of MEDLINEplus at the following Web address: http://www.nlm.nih.gov/medlineplus/advancedsearch.html. This utility is similar to the NIH Search Utility, with the exception that it only includes material linked within the MEDLINEplus system (mostly patient-oriented information). It also has the disadvantage of generating unstructured results. We recommend, therefore, that you use this method only if you have a very targeted search. The Combined Health Information Database (CHID) CHID Online is a reference tool that maintains a database directory of thousands of journal articles and patient education guidelines on pneumonia and related conditions. One of the advantages of CHID over other sources is that it offers summaries that describe the guidelines available, including contact information and pricing. CHID’s general Web site is http://chid.nih.gov/. To search this database, go to http://chid.nih.gov/detail/detail.html. In particular, you can use the advanced search options to look up pamphlets, reports, brochures, and information kits. The following was recently posted in this archive: ·
You Can Prevent PCP in Children: A Guide for People with HIV Infection Contact: CDC National Prevention Information Network, PO Box 6003, Rockville, MD, 20849-6003, (800) 458-5231, http://cdcnpin.org. Summary: This brochure presents information about the Pneumocystic carinii pneumonia (PCP) in children with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). PCP is caused by the germ, Pneumocystic carinii. If a child has PCP, he or she probably will have fever, cough, or trouble breathing. Children with PCP
Guidelines 21
may die if the infection is not treated quickly, so parents should have their child see a doctor immediately if symptoms are present. PCP can be diagnosed only by laboratory tests. Most scientists believe that PCP is spread in the air, but they do not know if it lives in other places. The PCP germ is very common, so parents should get medical care for their child to prevent PCP. The best way to prevent PCP in children is to prevent HIV in children. Pregnant women with HIV should speak with their doctors about taking antiretroviral treatments to prevent passing HIV infection to their unborn child. Children whose mothers have HIV can take antiviral treatments and medicine to prevent PCP. The best drug for preventing PCP is trimethoprim-sulfamethoxazole, or TMP-SMX, a combination of two drugs, which is available in tablet and liquid form, and is known by the brand names Bactrim, Septra, and Cotrim. All babies born to mothers with HIV should receive TMP-SMX starting at four to six weeks old, even if it is not known yet if they have HIV. Babies who test positive for HIV should continue on TMP-SMX until reaching the age of 1 year. Reasons to wait until 4 weeks of age to begin TMP-SMX are given. Side effects of TMP-SMX may include rashes and sickness. Other medicines are available to prevent PCP, but TMP-SMX is the most successful. As children can get PCP more than once, TMP-SMX should be used for prevention purposes even after a child has had PCP. Additional sources for locating referrals, materials, and information on HIV/AIDS treatment, clinical trials, and social security benefits are provided. ·
Swallowing Problems in Adults Source: Rockville, MD: American Speech-Language-Hearing Association (ASHA). 200x. [2 p.]. Contact: Available from American Speech-Language-Hearing Association (ASHA). Product Sales, 10801 Rockville Pike, Rockville, MD 20852. (888) 498-6699. TTY (301) 897-0157. Website: www.asha.org. Price: $4.00 for 10, plus shipping and handling. Item Number: 0112338. Summary: This brochure describes dysphagia (swallowing dysfunction) in adults and emphasizes the importance of having dysphagia accurately diagnosed and treated. The brochure first explains the three phases of swallowing disorders, the oral phase, the pharyngeal phase, and the esophageal phase. The brochure then lists some causes of feeding and swallowing problems in adults, and reviews the signs and symptoms of these problems. The brochure cautions that feeding and swallowing problems can result in dehydration or poor nutrition, the risk of aspiration (food or liquid entering the airway), pneumonia or repeated upper respiratory infections that can lead to chronic lung disease, less enjoyment of eating or drinking, and embarrassment or isolation in social
22 Pneumonia
situations involving eating. Readers are encouraged to consult a physician about the possible cause of the swallowing problem. A certified speech language pathologist can perform an evaluation of feeding and swallowing and provide treatment if appropriate. The brochure outlines the steps that the speech language pathologist may utilize in the evaluation and treatment of swallowing problems. The contact information for the American Speech Language Hearing Association (ASHA) is provided. ·
About Artificial Nutrition and Hydration Source: South Deerfield, MA: Channing L. Bete Co., Inc. 1999. 15 p. Contact: Available from Channing L. Bete, Co., Inc. 200 State Road, South Deerfield, MA 01373-0200. (800) 628-7733. Fax (800) 499-6464. Price: $1.05 each for 1-99 copies; plus shipping and handling; quantity discounts available. Order number 20690A0299. Summary: This Scriptographic booklet educates readers about artificial nutrition and hydration, a technique of delivering nutrients and fluids to a patient through a tube (tube feeding) or an intravenous (IV) line. Artificial nutrition and hydration may be used for a patient who is unable to swallow, recovering from surgery, or unconscious; some people, such as those with chronic digestive diseases, use artificial nutrition and hydration at home. The booklet is designed to help patients and caregivers make potentially difficult decisions about the use of artificial nutrition and hydration. The booklet describes enteral nutrition (tube feeding) as liquid nutrients and fluids delivered to the stomach or small intestine, and parenteral nutrition (IV feeding) as a method that bypasses the digestive tract. The benefits of artificial nutrition and hydration can include better recovery, longer life, and fulfilling a patient's wishes; possible risks include sore nostrils, injury to the esophagus or stomach, abdominal discomfort, pneumonia, infections, changes in blood sugar, fluid buildup, or bone pain (after long term total parenteral nutrition). Legal issues involved with these techniques can include informed consent, the ability to make decisions, the right to request a transfer, and advanced medical directives (including living wills and power of attorney). The booklet concludes with a section focusing on the decisionmaking efforts that may be utilized regarding artificial nutrition and hydration, a section on getting treatment at home, and a section regarding care at the end of life (particularly if artificial nutrition and hydration are withheld or withdrawn as the patient nears death). One sidebar notes that the use of restraints may be necessary to keep patients from pulling out tubing or an IV line. The booklet also reminds readers that there is a variety of sources of help, including the health care team,
Guidelines 23
the ethics committee, members of the clergy, the National Hospice Organization (800-658-8898), or Choice In Dying (800-989-9455). The booklet is illustrated with cartoon figures of men, women, and children undertaking various activities of daily life and health care procedures. ·
All About GERD: How It's Caused, How It's Treated, and How You Can Help Prevent Its Return Source: Deerfield, IL: TAP Pharmaceuticals Inc. 1997. 6 p. Contact: Available from TAP Pharmaceuticals Inc. Medical Services, Bannockburn Lake Office Plaza, 2355 Waukegan Road, Deerfield, IL 60015. (800) 478-9526. Price: Single copy free. Summary: This brochure provides basic information about the cause, treatment, and prevention of gastroesophageal reflux disease (GERD). GERD is a term used for several digestive conditions caused by regurgitation, or reflux, of acid and partly digested food from the stomach into the esophagus. The stomach is protected from acid, but the esophagus is not. The most common symptom of GERD is heartburn; swallowing difficulties are also common. With reflux esophagitis, the lower end of the esophagus near the stomach becomes inflamed and sore. A more serious kind of esophagitis is called erosive esophagitis, in which a section of the lower esophagus is eroded by gastric acid. Causes of GERD include weak muscles between the esophagus and stomach, strongly acidic gastric juices, and pregnancy. Complications of GERD include sore throat or laryngitis, respiratory problems such as asthma or pneumonia, and esophageal strictures. Diagnosis is usually done with endoscopy. The brochure outlines dietary and lifestyle changes that may help ease GERD, and medications that may be prescribed, including antacids, H2 blockers, and proton pump inhibitors. The brochure concludes with a summary of the information covered and space for readers to take notes. (AA-M). The National Guideline Clearinghouse™
The National Guideline Clearinghouse™ offers hundreds of evidence-based clinical practice guidelines published in the United States and other countries. You can search their site located at http://www.guideline.gov by using the keyword “pneumonia” or synonyms. The following was recently posted:
24 Pneumonia
·
Community-acquired pneumonia. Source: Institute for Clinical Systems Improvement.; 2000 July http://www.guideline.gov/FRAMESETS/guideline_fs.asp?guideline=00 1481&sSearch_string=pneumonia
·
Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Source: American College of Chest Physicians.; 2000 April; 42 pages http://www.guideline.gov/FRAMESETS/guideline_fs.asp?guideline=00 1944&sSearch_string=pneumonia
·
Evidence-based clinical practice guideline of community-acquired pneumonia in children 60 days to 17 years of age. Source: Cincinnati Children's Hospital Medical Center.; 2000 July; 11 pages http://www.guideline.gov/FRAMESETS/guideline_fs.asp?guideline=00 1880&sSearch_string=pneumonia
·
Guidelines for prevention of nosocomial pneumonia. Source: Centers for Disease Control and Prevention.; 1994 January (updated 1997); 63 pages http://www.guideline.gov/FRAMESETS/guideline_fs.asp?guideline=00 0841&sSearch_string=pneumonia
·
Practice guidelines for the management of community-acquired pneumonia in adults. Source: Infectious Diseases Society of America.; 2000 February; 36 pages http://www.guideline.gov/FRAMESETS/guideline_fs.asp?guideline=00 1891&sSearch_string=pneumonia Healthfinder™
Healthfinder™ is an additional source sponsored by the U.S. Department of Health and Human Services which offers links to hundreds of other sites that contain healthcare information. This Web site is located at
Guidelines 25
http://www.healthfinder.gov. Again, keyword searches can be used to find guidelines. The following was recently found in this database: ·
Fight Flu and Pneumonia Summary: This publication describes the flu, explains which groups of people should get the flu shot and why, directs people on when to get the shot, and informs people on Medicare where they can go to get flu Source: Centers for Medicare and Medicaid Services (CMS), formerly the Health Care Financing Administration http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&R ecordID=3187
·
Test Your Pneumonia I.Q. Summary: Test your knowledge of pneumonia. Answer true or false to the statements online and find out what you know about this respiratory disease. Source: American Association for Respiratory Care http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&R ecordID=6171
The NIH Search Utility After browsing the references listed at the beginning of this chapter, you may want to explore the NIH Search Utility. This allows you to search for documents on over 100 selected Web sites that comprise the NIH-WEBSPACE. Each of these servers is “crawled” and indexed on an ongoing basis. Your search will produce a list of various documents, all of which will relate in some way to pneumonia. The drawbacks of this approach are that the information is not organized by theme and that the references are often a mix of information for professionals and patients. Nevertheless, a large number of the listed Web sites provide useful background information. We can only recommend this route, therefore, for relatively rare or specific conditions or disorders, or when using highly targeted searches. To use the NIH search utility, visit the following Web page: http://search.nih.gov/index.html.
26 Pneumonia
Additional Web Sources A number of Web sites that often link to government sites are available to the public. These can also point you in the direction of essential information. The following is a representative sample: ·
AOL: http://search.aol.com/cat.adp?id=168&layer=&from=subcats
·
drkoop.comÒ: http://www.drkoop.com/conditions/ency/index.html
·
Family Village: http://www.familyvillage.wisc.edu/specific.htm
·
Google: http://directory.google.com/Top/Health/Conditions_and_Diseases/
·
Med Help International: http://www.medhelp.org/HealthTopics/A.html
·
Open Directory Project: http://dmoz.org/Health/Conditions_and_Diseases/
·
Yahoo.com: http://dir.yahoo.com/Health/Diseases_and_Conditions/
·
WebMDÒHealth: http://my.webmd.com/health_topics
Vocabulary Builder The material in this chapter may have contained a number of unfamiliar words. The following Vocabulary Builder introduces you to terms used in this chapter that have not been covered in the previous chapter: Abdomen: That portion of the body that lies between the thorax and the pelvis. [NIH] Abdominal: Pertaining to the abdomen. [EU] Anal: Pertaining to the anus. [EU] Anemia: A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin. [NIH] Anesthesia: A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures. [NIH]
Antibiotic: A chemical substance produced by a microorganism which has the capacity, in dilute solutions, to inhibit the growth of or to kill other microorganisms. Antibiotics that are sufficiently nontoxic to the host are used as chemotherapeutic agents in the treatment of infectious diseases of
Guidelines 27
man, animals and plants. [EU] Antibody: An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells), or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc. [EU] Antiviral: Destroying viruses or suppressing their replication. [EU] Anus: The distal or terminal orifice of the alimentary canal. [EU] Asymptomatic: Showing or causing no symptoms. [EU] Autopsy: Postmortem examination of the body. [NIH] Azithromycin: A semi-synthetic macrolide antibiotic structurally related to erythromycin. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. [NIH] Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion. [NIH] Bacteria: Unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. [NIH] Bronchi: The larger air passages of the lungs arising from the terminal bifurcation of the trachea. [NIH] Cerebrospinal: Pertaining to the brain and spinal cord. [EU] Cervical: Pertaining to the neck, or to the neck of any organ or structure. [EU] Chlamydia: A genus of the family chlamydiaceae whose species cause a variety of diseases in vertebrates including humans, mice, and swine. Chlamydia species are gram-negative and produce glycogen. The type species is chlamydia trachomatis. [NIH] Chronic: Persisting over a long period of time. [EU] Cirrhosis: Liver disease characterized pathologically by loss of the normal microscopic lobular architecture, with fibrosis and nodular regeneration. The term is sometimes used to refer to chronic interstitial inflammation of any organ. [EU] Condoms: A sheath that is worn over the penis during sexual behavior in order to prevent pregnancy or spread of sexually transmitted disease. [NIH] Confusion: Disturbed orientation in regard to time, place, or person, sometimes accompanied by disordered consciousness. [EU]
28 Pneumonia
Conjunctivitis: Inflammation of the conjunctiva, generally consisting of conjunctival hyperaemia associated with a discharge. [EU] Cryptosporidiosis: Parasitic intestinal infection with severe diarrhea caused by a protozoan, cryptosporidium. It occurs in both animals and humans. [NIH] Cytomegalovirus: A genus of the family herpesviridae, subfamily betaherpesvirinae, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. [NIH] Dehydration: The condition that results from excessive loss of body water. Called also anhydration, deaquation and hypohydration. [EU] Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. [NIH] Diarrhea: Passage of excessively liquid or excessively frequent stools. [NIH] Disorientation: The loss of proper bearings, or a state of mental confusion as to time, place, or identity. [EU] Doxycycline: A synthetic tetracycline derivative with a range of antimicrobial activity and mode of action similar to that of tetracycline, but more effective against many species. Animal studies suggest that it may cause less tooth staining than other tetracyclines. [NIH] Dysphagia: Difficulty in swallowing. [EU] Encephalitis: Inflammation of the brain. [EU] Endoscopy: Visual inspection of any cavity of the body by means of an endoscope. [EU] Erythromycin: A bacteriostatic antibiotic substance produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. [NIH] Esophagitis: Inflammation, acute or chronic, of the esophagus caused by bacteria, chemicals, or trauma. [NIH] Fathers: Male parents, human or animal. [NIH] Gonorrhea: Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, neisseria gonorrhoeae, was isolated
Guidelines 29
by Neisser in 1879. [NIH] Heartburn: Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the esophagus. [NIH] Hepatitis: Inflammation of the liver. [EU] Herpes: Any inflammatory skin disease caused by a herpesvirus and characterized by the formation of clusters of small vesicles. When used alone, the term may refer to herpes simplex or to herpes zoster. [EU] Immunization: The induction of immunity. [EU] Immunosuppressant: An agent capable of suppressing immune responses. [EU]
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. [NIH] Laryngitis: Inflammation of the larynx, a condition attended with dryness and soreness of the throat, hoarseness, cough and dysphagia. [EU] Lobe: A more or less well-defined portion of any organ, especially of the brain, lungs, and glands. Lobes are demarcated by fissures, sulci, connective tissue, and by their shape. [EU] Lymphoma: Any neoplastic disorder of the lymphoid tissue, the term lymphoma often is used alone to denote malignant lymphoma. [EU] Membrane: A thin layer of tissue which covers a surface, lines a cavity or divides a space or organ. [EU] Meningitis: Inflammation of the meninges. When it affects the dura mater, the disease is termed pachymeningitis; when the arachnoid and pia mater are involved, it is called leptomeningitis, or meningitis proper. [EU] Mental: Pertaining to the mind; psychic. 2. (L. mentum chin) pertaining to the chin. [EU] Microbiology: The study of microorganisms such as fungi, bacteria, algae, archaea, and viruses. [NIH] Mucus: The free slime of the mucous membranes, composed of secretion of the glands, along with various inorganic salts, desquamated cells, and leucocytes. [EU] Mycobacterium: An organism of the genus Mycobacterium. [EU] Nausea: An unpleasant sensation, vaguely referred to the epigastrium and abdomen, and often culminating in vomiting. [EU] Neonatal: Pertaining to the first four weeks after birth. [EU] Nephrotic: Pertaining to, resembling, or caused by nephrosis. [EU]
30 Pneumonia
Nosocomial: Pertaining to or originating in the hospital, said of an infection not present or incubating prior to admittance to the hospital, but generally occurring 72 hours after admittance; the term is usually used to refer to patient disease, but hospital personnel may also acquire nosocomial infection. [EU] Ofloxacin: An orally administered broad-spectrum quinolone antibacterial drug active against most gram-negative and gram-positive bacteria. [NIH] Oral: Pertaining to the mouth, taken through or applied in the mouth, as an oral medication or an oral thermometer. [EU] Otitis: Inflammation of the ear, which may be marked by pain, fever, abnormalities of hearing, hearing loss, tinnitus, and vertigo. [EU] Parenteral: Not through the alimentary canal but rather by injection through some other route, as subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intravenous, etc. [EU] Pathogen: Any disease-producing microorganism. [EU] Pelvic: Pertaining to the pelvis. [EU] Penis: The male organ of copulation and of urinary excretion, comprising a root, body, and extremity, or glans penis. The root is attached to the descending portions of the pubic bone by the crura, the latter being the extremities of the corpora cavernosa, and beneath them the corpus spongiosum, through which the urethra passes. The glans is covered with mucous membrane and ensheathed by the prepuce, or foreskin. The penis is homologous with the clitoris in the female. [EU] Plasmids: Any extrachromosomal hereditary determinant. Plasmids are self-replicating circular molecules of DNA that are found in a variety of bacterial, archaeal, fungal, algal, and plant species. [NIH] Pneumonia: Inflammation of the lungs with consolidation. [EU] Preclinical: Before a disease becomes clinically recognizable. [EU] Prostate: A gland in males that surrounds the neck of the bladder and the urethra. It secretes a substance that liquifies coagulated semen. It is situated in the pelvic cavity behind the lower part of the pubic symphysis, above the deep layer of the triangular ligament, and rests upon the rectum. [NIH] Psychiatric: Pertaining to or within the purview of psychiatry. [EU] Pulmonary: Pertaining to the lungs. [EU] Radiology: A specialty concerned with the use of x-ray and other forms of radiant energy in the diagnosis and treatment of disease. [NIH] Reflux: A backward or return flow. [EU] Regurgitation: A backward flowing, as the casting up of undigested food, or the backward flowing of blood into the heart, or between the chambers of
Guidelines 31
the heart when a valve is incompetent. [EU] Saliva: The clear, viscous fluid secreted by the salivary glands and mucous glands of the mouth. It contains mucins, water, organic salts, and ptylin. [NIH] Sarcoma: A tumour made up of a substance like the embryonic connective tissue; tissue composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas are often highly malignant. [EU] Sneezing: Sudden, forceful, involuntary expulsion of air from the nose and mouth caused by irritation to the mucous membranes of the upper respiratory tract. [NIH] Sterility: 1. the inability to produce offspring, i.e., the inability to conceive (female s.) or to induce conception (male s.). 2. the state of being aseptic, or free from microorganisms. [EU] Steroid: A group name for lipids that contain a hydrogenated cyclopentanoperhydrophenanthrene ring system. Some of the substances included in this group are progesterone, adrenocortical hormones, the gonadal hormones, cardiac aglycones, bile acids, sterols (such as cholesterol), toad poisons, saponins, and some of the carcinogenic hydrocarbons. [EU] Stomach: An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the esophagus and the beginning of the duodenum. [NIH] Streptococcus: A genus of gram-positive, coccoid bacteria whose organisms occur in pairs or chains. No endospores are produced. Many species exist as commensals or parasites on man or animals with some being highly pathogenic. A few species are saprophytes and occur in the natural environment. [NIH] Thrombosis: The formation, development, or presence of a thrombus. [EU] Toxic: Pertaining to, due to, or of the nature of a poison or toxin; manifesting the symptoms of severe infection. [EU] Toxoplasmosis: An acute or chronic, widespread disease of animals and humans caused by the obligate intracellular protozoon Toxoplasma gondii, transmitted by oocysts containing the pathogen in the feces of cats (the definitive host), usually by contaminated soil, direct exposure to infected feces, tissue cysts in infected meat, or tachyzoites (proliferating forms) in blood. [EU] Transplantation: The grafting of tissues taken from the patient's own body or from another. [EU] Tuberculosis: Any of the infectious diseases of man and other animals caused by species of mycobacterium. [NIH] Urethritis: Inflammation of the urethra. [EU]
32 Pneumonia
Uterus: The hollow muscular organ in female mammals in which the fertilized ovum normally becomes embedded and in which the developing embryo and fetus is nourished. In the nongravid human, it is a pear-shaped structure; about 3 inches in length, consisting of a body, fundus, isthmus, and cervix. Its cavity opens into the vagina below, and into the uterine tube on either side at the cornu. It is supported by direct attachment to the vagina and by indirect attachment to various other nearby pelvic structures. Called also metra. [EU] Vaccination: The introduction of vaccine into the body for the purpose of inducing immunity. Coined originally to apply to the injection of smallpox vaccine, the term has come to mean any immunizing procedure in which vaccine is injected. [EU] Vaccine: A suspension of attenuated or killed microorganisms (bacteria, viruses, or rickettsiae), administered for the prevention, amelioration or treatment of infectious diseases. [EU] Vaginal: 1. of the nature of a sheath; ensheathing. 2. pertaining to the vagina. 3. pertaining to the tunica vaginalis testis. [EU] Viruses: Minute infectious agents whose genomes are composed of DNA or RNA, but not both. They are characterized by a lack of independent metabolism and the inability to replicate outside living host cells. [NIH]
Seeking Guidance 33
CHAPTER 2. SEEKING GUIDANCE Overview Some patients are comforted by the knowledge that a number of organizations dedicate their resources to helping people with pneumonia. These associations can become invaluable sources of information and advice. Many associations offer aftercare support, financial assistance, and other important services. Furthermore, healthcare research has shown that support groups often help people to better cope with their conditions.8 In addition to support groups, your physician can be a valuable source of guidance and support. Therefore, finding a physician that can work with your unique situation is a very important aspect of your care. In this chapter, we direct you to resources that can help you find patient organizations and medical specialists. We begin by describing how to find associations and peer groups that can help you better understand and cope with pneumonia. The chapter ends with a discussion on how to find a doctor that is right for you.
Associations and Pneumonia As mentioned by the Agency for Healthcare Research and Quality, sometimes the emotional side of a condition or disorder can be as taxing as the physical side.9 You may have fears or feel overwhelmed by your situation. Everyone has different ways of dealing with disease or physical injury. Your attitude, your expectations, and how well you cope with your Churches, synagogues, and other houses of worship might also have groups that can offer you the social support you need. 9 This section has been adapted from http://www.ahcpr.gov/consumer/diaginf5.htm. 8
34 Pneumonia
condition can all influence your well-being. This is true for both minor conditions and serious illnesses. For example, a study on female breast cancer survivors revealed that women who participated in support groups lived longer and experienced better quality of life when compared with women who did not participate. In the support group, women learned coping skills and had the opportunity to share their feelings with other women in the same situation. In addition to associations or groups that your doctor might recommend, we suggest that you consider the following list (if there is a fee for an association, you may want to check with your insurance provider to find out if the cost will be covered): ·
American Thoracic Society Address: American Thoracic Society 1740 Broadway, New York, NY 10019 Telephone: (212) 315-8700 Email: None Web Site: http://www.thoracic.org Background: The American Thoracic Society (ATS) is an international professional and scientific society that focuses on respiratory and critical care medicine. Established in 1905, the Society currently has approximately 12,500 members in the United States and around the world. The ATS membership is dedicated to preventing and fighting respiratory disease through research, education, patient care, and advocacy. The Society's long range goal is to decrease morbidity and mortality from respiratory disorders and life threatening acute illnesses. In keeping with these goals, the American Thoracic Society also serves as the medical section of the American Lung Association and interacts with both national and international organizations that have similar goals. One of the Society's primary activities is its annual International Scientific Conference, an international forum for physicians and scientists who work in pulmonary and critical care medicine. Sessions are held on such topics as pneumonia, asthma, critical care, tuberculosis, pediatric pulmonology, sleep apnea, environmental and occupational lung disease, nursing studies, cell biology, lung structure and function, and AIDS. The ATS also is committed to advocating for key state and federal health issues. Through its ATS Advocacy Network, the Society works to educate Congress and federal agencies about tobacco control, health care policy, environmental policy, medical reimbursement issues, research funding, and other public policy issues. The ATS has also earned full accreditation by the Accreditation Council on Continuing Medical Education for direct
Seeking Guidance 35
sponsorship of educational activities as well as joint sponsorships with ATS chapters and local Lung Associations. In addition, the ATS publishes two journals including the 'American Journal of Respiratory and Critical Care Medicine' (AJRCCM) and the 'American Journal of Respiratory Cell and Molecular Biology' (AJRCMB). The AJRCCM focuses on human biology and disease as well as animal and in vitro studies that contribute to the understanding of pathophysiology and treatment of pulmonary disease. The AJRCMB publishes papers that report significant and original observations in the area of pulmonary biology. ·
Canadian Lung Association Address: Canadian Lung Association 1900 City Park Drive, Suite 508, Blair Business Park, Gloucester, Ontario, K1J 1A3, Canada Telephone: (613) 747-6776 Fax: (613) 747-7430 Email:
[email protected] Web Site: http://www.lung.ca/ Background: The Canadian Lung Association is a national nonprofit organization that is dedicated to improving respiratory health and combating disease of and environmental threats to the lungs. The Association works to fulfill its mission by promoting research, increasing public awareness, and providing patient support programs. Established in 1900, the Association is an umbrella organization that currently consists of 10 provincial and one territorial association. Each provincial association maintains a professional staff including health educators who work with volunteers to develop and conduct community program services. One of the Association's primary objectives is to reduce tobacco use by influencing people to quit or not to start smoking, promoting smoke-free workplaces, and supporting legislation to regulate or prohibit smoking in public enclosed areas. In addition, the Canadian Lung Association is committed to supporting respiratory health and respiratory disease research at several levels. Nationally, the Association provides research funding that is administered by the Canadian Thoracic Society, the Canadian Nurses Respiratory Society, and the Physiotherapy Cardio-Respiratory Society. Each member association also supports research at the provincial level. The Canadian Lung Association also provides a variety of educational materials and has a web site on the Internet. Relevant area(s) of interest: Pneumonia
36 Pneumonia
Finding More Associations There are a number of directories that list additional medical associations that you may find useful. While not all of these directories will provide different information than what is listed above, by consulting all of them, you will have nearly exhausted all sources for patient associations.
The National Health Information Center (NHIC) The National Health Information Center (NHIC) offers a free referral service to help people find organizations that provide information about pneumonia. For more information, see the NHIC’s Web site at http://www.health.gov/NHIC/ or contact an information specialist by calling 1-800-336-4797.
DIRLINE A comprehensive source of information on associations is the DIRLINE database maintained by the National Library of Medicine. The database comprises some 10,000 records of organizations, research centers, and government institutes and associations which primarily focus on health and biomedicine. DIRLINE is available via the Internet at the following Web site: http://dirline.nlm.nih.gov/. Simply type in “pneumonia” (or a synonym) or the name of a topic, and the site will list information contained in the database on all relevant organizations.
The Combined Health Information Database Another comprehensive source of information on healthcare associations is the Combined Health Information Database. Using the “Detailed Search” option, you will need to limit your search to “Organizations” and “pneumonia”. Type the following hyperlink into your Web browser: http://chid.nih.gov/detail/detail.html. To find associations, use the drop boxes at the bottom of the search page where “You may refine your search by.” For publication date, select “All Years.” Then, select your preferred language and the format option “Organization Resource Sheet.” By making these selections and typing in “pneumonia” (or synonyms) into the “For these words:” box, you will only receive results on organizations dealing with pneumonia. You should check back periodically with this database since it is updated every 3 months.
Seeking Guidance 37
The National Organization for Rare Disorders, Inc. The National Organization for Rare Disorders, Inc. has prepared a Web site that provides, at no charge, lists of associations organized by specific conditions and diseases. You can access this database at the following Web site: http://www.rarediseases.org/cgi-bin/nord/searchpage. Select the option called “Organizational Database (ODB)” and type “pneumonia” (or a synonym) in the search box.
Online Support Groups In addition to support groups, commercial Internet service providers offer forums and chat rooms for people with different illnesses and conditions. WebMDÒ, for example, offers such a service at their Web site: http://boards.webmd.com/roundtable. These online self-help communities can help you connect with a network of people whose concerns are similar to yours. Online support groups are places where people can talk informally. If you read about a novel approach, consult with your doctor or other healthcare providers, as the treatments or discoveries you hear about may not be scientifically proven to be safe and effective.
Finding Doctors One of the most important aspects of your treatment will be the relationship between you and your doctor or specialist. All patients with pneumonia must go through the process of selecting a physician. While this process will vary from person to person, the Agency for Healthcare Research and Quality makes a number of suggestions, including the following:10 ·
If you are in a managed care plan, check the plan’s list of doctors first.
·
Ask doctors or other health professionals who work with doctors, such as hospital nurses, for referrals.
·
Call a hospital’s doctor referral service, but keep in mind that these services usually refer you to doctors on staff at that particular hospital. The services do not have information on the quality of care that these doctors provide.
10
This section is adapted from the AHRQ: www.ahrq.gov/consumer/qntascii/qntdr.htm.
38 Pneumonia
·
Some local medical societies offer lists of member doctors. Again, these lists do not have information on the quality of care that these doctors provide.
Additional steps you can take to locate doctors include the following: ·
Check with the associations listed earlier in this chapter.
·
Information on doctors in some states is available on the Internet at http://www.docboard.org. This Web site is run by “Administrators in Medicine,” a group of state medical board directors.
·
The American Board of Medical Specialties can tell you if your doctor is board certified. “Certified” means that the doctor has completed a training program in a specialty and has passed an exam, or “board,” to assess his or her knowledge, skills, and experience to provide quality patient care in that specialty. Primary care doctors may also be certified as specialists. The AMBS Web site is located at http://www.abms.org/newsearch.asp.11 You can also contact the ABMS by phone at 1-866-ASK-ABMS.
·
You can call the American Medical Association (AMA) at 800-665-2882 for information on training, specialties, and board certification for many licensed doctors in the United States. This information also can be found in “Physician Select” at the AMA’s Web site: http://www.amaassn.org/aps/amahg.htm.
Finding Specialists The American Academy of Allergy, Asthma, and Immunology (AAAAI) maintains a Physician Referral System on its Web site (http://www.aaaai.org/). The Referral System contains contact information for the organization’s 6,000 members, all medical professionals specializing in the treatment of allergies, asthma, or infectious diseases. To use this free service, go to the search form located at http://www.aaaai.org/scripts/find-adoc/main.asp and select the search criteria you would like to use by clicking on the circle to the left of the option. Then type in the information you are looking for such as the physician’s location, zip code, name, or specialty. Click the “Search” button. If your query returns information about particular physicians, click on the physician’s name for more information.
While board certification is a good measure of a doctor’s knowledge, it is possible to receive quality care from doctors who are not board certified. 11
Seeking Guidance 39
If the previous sources did not meet your needs, you may want to log on to the Web site of the National Organization for Rare Disorders (NORD) at http://www.rarediseases.org/. NORD maintains a database of doctors with expertise in various rare conditions and diseases. The Metabolic Information Network (MIN), 800-945-2188, also maintains a database of physicians with expertise in various metabolic diseases.
Selecting Your Doctor12 When you have compiled a list of prospective doctors, call each of their offices. First, ask if the doctor accepts your health insurance plan and if he or she is taking new patients. If the doctor is not covered by your plan, ask yourself if you are prepared to pay the extra costs. The next step is to schedule a visit with your chosen physician. During the first visit you will have the opportunity to evaluate your doctor and to find out if you feel comfortable with him or her. Ask yourself, did the doctor: ·
Give me a chance to ask questions about pneumonia?
·
Really listen to my questions?
·
Answer in terms I understood?
·
Show respect for me?
·
Ask me questions?
·
Make me feel comfortable?
·
Address the health problem(s) I came with?
·
Ask me my preferences about different kinds of treatments for pneumonia?
·
Spend enough time with me?
Trust your instincts when deciding if the doctor is right for you. But remember, it might take time for the relationship to develop. It takes more than one visit for you and your doctor to get to know each other.
12 This
section has been adapted from the AHRQ: www.ahrq.gov/consumer/qntascii/qntdr.htm.
40 Pneumonia
Working with Your Doctor13 Research has shown that patients who have good relationships with their doctors tend to be more satisfied with their care and have better results. Here are some tips to help you and your doctor become partners: ·
You know important things about your symptoms and your health history. Tell your doctor what you think he or she needs to know.
·
It is important to tell your doctor personal information, even if it makes you feel embarrassed or uncomfortable.
·
Bring a “health history” list with you (and keep it up to date).
·
Always bring any medications you are currently taking with you to the appointment, or you can bring a list of your medications including dosage and frequency information. Talk about any allergies or reactions you have had to your medications.
·
Tell your doctor about any natural or alternative medicines you are taking.
·
Bring other medical information, such as x-ray films, test results, and medical records.
·
Ask questions. If you don’t, your doctor will assume that you understood everything that was said.
·
Write down your questions before your visit. List the most important ones first to make sure that they are addressed.
·
Consider bringing a friend with you to the appointment to help you ask questions. This person can also help you understand and/or remember the answers.
·
Ask your doctor to draw pictures if you think that this would help you understand.
·
Take notes. Some doctors do not mind if you bring a tape recorder to help you remember things, but always ask first.
·
Let your doctor know if you need more time. If there is not time that day, perhaps you can speak to a nurse or physician assistant on staff or schedule a telephone appointment.
·
Take information home. Ask for written instructions. Your doctor may also have brochures and audio and videotapes that can help you.
This section has been adapted from the AHRQ: www.ahrq.gov/consumer/qntascii/qntdr.htm.
13
Seeking Guidance 41
·
After leaving the doctor’s office, take responsibility for your care. If you have questions, call. If your symptoms get worse or if you have problems with your medication, call. If you had tests and do not hear from your doctor, call for your test results. If your doctor recommended that you have certain tests, schedule an appointment to get them done. If your doctor said you should see an additional specialist, make an appointment.
By following these steps, you will enhance the relationship you will have with your physician.
Broader Health-Related Resources In addition to the references above, the NIH has set up guidance Web sites that can help patients find healthcare professionals. These include:14 ·
Caregivers: http://www.nlm.nih.gov/medlineplus/caregivers.html
·
Choosing a Doctor or Healthcare Service: http://www.nlm.nih.gov/medlineplus/choosingadoctororhealthcareserv ice.html
·
Hospitals and Health Facilities: http://www.nlm.nih.gov/medlineplus/healthfacilities.html
Vocabulary Builder The following vocabulary builder provides definitions of words used in this chapter that have not been defined in previous chapters: Apnea: A transient absence of spontaneous respiration. [NIH] Molecular: Of, pertaining to, or composed of molecules : a very small mass of matter. [EU] Thoracic: Pertaining to or affecting the chest. [EU] You can access this information at: http://www.nlm.nih.gov/medlineplus/healthsystem.html.
14
Clinical Trials 43
CHAPTER 3. CLINICAL TRIALS AND PNEUMONIA Overview Very few medical conditions have a single treatment. The basic treatment guidelines that your physician has discussed with you, or those that you have found using the techniques discussed in Chapter 1, may provide you with all that you will require. For some patients, current treatments can be enhanced with new or innovative techniques currently under investigation. In this chapter, we will describe how clinical trials work and show you how to keep informed of trials concerning pneumonia.
What Is a Clinical Trial?15 Clinical trials involve the participation of people in medical research. Most medical research begins with studies in test tubes and on animals. Treatments that show promise in these early studies may then be tried with people. The only sure way to find out whether a new treatment is safe, effective, and better than other treatments for pneumonia is to try it on patients in a clinical trial.
The discussion in this chapter has been adapted from the NIH and the NEI: www.nei.nih.gov/netrials/ctivr.htm.
15
44 Pneumonia
What Kinds of Clinical Trials Are There? Clinical trials are carried out in three phases: ·
Phase I. Researchers first conduct Phase I trials with small numbers of patients and healthy volunteers. If the new treatment is a medication, researchers also try to determine how much of it can be given safely.
·
Phase II. Researchers conduct Phase II trials in small numbers of patients to find out the effect of a new treatment on pneumonia.
·
Phase III. Finally, researchers conduct Phase III trials to find out how new treatments for pneumonia compare with standard treatments already being used. Phase III trials also help to determine if new treatments have any side effects. These trials--which may involve hundreds, perhaps thousands, of people--can also compare new treatments with no treatment. How Is a Clinical Trial Conducted?
Various organizations support clinical trials at medical centers, hospitals, universities, and doctors’ offices across the United States. The “principal investigator” is the researcher in charge of the study at each facility participating in the clinical trial. Most clinical trial researchers are medical doctors, academic researchers, and specialists. The “clinic coordinator” knows all about how the study works and makes all the arrangements for your visits. All doctors and researchers who take part in the study on pneumonia carefully follow a detailed treatment plan called a protocol. This plan fully explains how the doctors will treat you in the study. The “protocol” ensures that all patients are treated in the same way, no matter where they receive care. Clinical trials are controlled. This means that researchers compare the effects of the new treatment with those of the standard treatment. In some cases, when no standard treatment exists, the new treatment is compared with no treatment. Patients who receive the new treatment are in the treatment group. Patients who receive a standard treatment or no treatment are in the “control” group. In some clinical trials, patients in the treatment group get a new medication while those in the control group get a placebo. A placebo is a harmless substance, a “dummy” pill, that has no effect on pneumonia. In other clinical trials, where a new surgery or device (not a medicine) is being tested, patients in the control group may receive a “sham treatment.” This
Clinical Trials 45
treatment, like a placebo, has no effect on pneumonia and does not harm patients. Researchers assign patients “randomly” to the treatment or control group. This is like flipping a coin to decide which patients are in each group. If you choose to participate in a clinical trial, you will not know which group you will be appointed to. The chance of any patient getting the new treatment is about 50 percent. You cannot request to receive the new treatment instead of the placebo or sham treatment. Often, you will not know until the study is over whether you have been in the treatment group or the control group. This is called a “masked” study. In some trials, neither doctors nor patients know who is getting which treatment. This is called a “double masked” study. These types of trials help to ensure that the perceptions of the patients or doctors will not affect the study results. Natural History Studies Unlike clinical trials in which patient volunteers may receive new treatments, natural history studies provide important information to researchers on how pneumonia develops over time. A natural history study follows patient volunteers to see how factors such as age, sex, race, or family history might make some people more or less at risk for pneumonia. A natural history study may also tell researchers if diet, lifestyle, or occupation affects how a disease or disorder develops and progresses. Results from these studies provide information that helps answer questions such as: How fast will a condition or disorder usually progress? How bad will the condition become? Will treatment be needed? What Is Expected of Patients in a Clinical Trial? Not everyone can take part in a clinical trial for a specific condition or disorder. Each study enrolls patients with certain features or eligibility criteria. These criteria may include the type and stage of a condition or disorder, as well as, the age and previous treatment history of the patient. You or your doctor can contact the sponsoring organization to find out more about specific clinical trials and their eligibility criteria. If you are interested in joining a clinical trial, your doctor must contact one of the trial’s investigators and provide details about your diagnosis and medical history. If you participate in a clinical trial, you may be required to have a number of medical tests. You may also need to take medications and/or undergo
46 Pneumonia
surgery. Depending upon the treatment and the examination procedure, you may be required to receive inpatient hospital care. Or, you may have to return to the medical facility for follow-up examinations. These exams help find out how well the treatment is working. Follow-up studies can take months or years. However, the success of the clinical trial often depends on learning what happens to patients over a long period of time. Only patients who continue to return for follow-up examinations can provide this important long-term information.
Recent Trials on Pneumonia The National Institutes of Health and other organizations sponsor trials on various conditions and disorders. Because funding for research goes to the medical areas that show promising research opportunities, it is not possible for the NIH or others to sponsor clinical trials for every disease and disorder at all times. The following lists recent trials dedicated to pneumonia.16 If the trial listed by the NIH is still recruiting, you may be eligible. If it is no longer recruiting or has been completed, then you can contact the sponsors to learn more about the study and, if published, the results. Further information on the trial is available at the Web site indicated. Please note that some trials may no longer be recruiting patients or are otherwise closed. Before contacting sponsors of a clinical trial, consult with your physician who can help you determine if you might benefit from participation. ·
A Safety and Efficacy Study of Hospitalized Patients with CommunityAcquired Pneumonia and Sepsis Condition(s): Community-Acquired Pneumonia and Sepsis Study Status: This study is currently recruiting patients. Sponsor(s): ICOS Purpose - Excerpt: The objective of this sutdy is to demonstrate the safety and efficacy of IC14 in the treatment ofhospitalized patients with community-acquired pneumonia and sepsis. Phase(s): Phase II Study Type: Interventional Contact(s): Mari Maurer, RN,BSN 425.415.5302
[email protected]; Washington; ICOS Corporation, Bothell, Washington, 98021, United States; Recruiting; Mari Maurer 425-415-5302
[email protected]
16
These are listed at www.ClinicalTrials.gov.
Clinical Trials 47
Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00042588;jsessionid=5471C3 D423969012E2E20478C1362870 ·
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients Condition(s): Anemia, Sickle Cell; Pneumonia Study Status: This study is currently recruiting patients. Sponsor(s): FDA Office of Orphan Products Development Purpose - Excerpt: This is a study to determine if oral arginine will increase nitric oxide in sickle cell disease (SCD) patients with acute chest syndrome (ACS). It will also assess the effects of arginine in the body and how the body uses nitric oxide in ACS. Phase(s): Phase II Study Type: Interventional Contact(s): California; Children's Hospital Oakland, Oakland, California, 94609, United States; Recruiting; Lori A. Styles, M.D. 510-428-3553
[email protected]; Lori A. Styles, M.D., Principal Investigator Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00029731;jsessionid=5471C3 D423969012E2E20478C1362870
·
Early Inhaled Nitric Oxide for Respiratory Failure in Newborns Condition(s): Hypertension, Pulmonary; Respiratory Insufficiency; Infant, Newborn, Diseases; Meconium Aspiration; Persistent Fetal Circulation Syndrome; Pneumonia, Aspiration; Respiratory Distress Syndrome Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Child Health and Human Development (NICHD); Canadian Institutes of Health Research; INO Therapeutics Purpose - Excerpt: Inhaled nitric oxide reduces the risk of temporary lung bypass in term and near-term infants with severe respiratory failure. Term and near-term infants with mild to moderate respiratory failure on a ventilator are randomized to inhaled nitric oxide to 100 percent oxygen to determine if administration of inhaled nitric oxide earlier in their course or to infants with less severe respiratory failure decreases the incidence of death or ECMO. The neurodevelopment of infants will be evaluated at 18 to 24 months of age. Phase(s): Phase III
48 Pneumonia
Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00005773;jsessionid=5471C3 D423969012E2E20478C1362870 ·
Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Condition(s): Pneumonia Study Status: This study is currently recruiting patients. Sponsor(s): Pfizer Purpose - Excerpt: A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens. Phase(s): Phase IV Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00035347;jsessionid=5471C3 D423969012E2E20478C1362870
·
New Antibiotic to treat patients with community-acquired pneumonia due to a specific bacteria (S. pneumoniae pneumonia) Condition(s): Pneumonia, Pneumococcal; Infections; Gram-Positive Bacterial Infections
Community
Acquired
Study Status: This study is currently recruiting patients. Purpose - Excerpt: This study will treat patients who have a communityacquired pneumonia that is due to a specific bacteria (S. pneumoniae)
Clinical Trials 49
Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00035269;jsessionid=5471C3 D423969012E2E20478C1362870 ·
Pediatric Community-Acquired Pneumonia Condition(s): Pneumonia Study Status: This study is currently recruiting patients. Sponsor(s): Johnson Development, L.L.C.
&
Johnson
Pharmaceutical
Research
and
Purpose - Excerpt: Community-acquired pneumonia is a leading cause of sickness (morbidity) and death (mortality) due to an infectious disease in children. Four (4)bacteria are important causes of these infections in children and in adults. Although levofloxacin is a highly effective and safe treatment for community-acquired pneumonia in adults, it has not been used extensively in children with community-acquired pneumonia. There is a concern about the safety of this agent because it is observed that young laboratory animals given single high doses of this drug may develop abnormalities in the soft tissue of the weight bearing joints. However, the experience over the past years with use of this drug to treat children with a variety of serious infectious diseases suggests that the adverse events associated with levofloxacin in children are similar to those reported in adults. Opinions expressed by experts in the field of pediatric diseases suggest that this class of drugs have been used safely to treat children and should be considered as an option or another choice of therapy in serious contagious diseases. The purpose of this study is to compare the effectiveness and safety of levofloxacin for the treatment of community-acquired pneumonia in infants, children, and adolescents (age 6 months to 16 years) to the usual medications used to treat this disease. Because the pathogens that cause community-acquired pneumonia in children are identical to those that cause communityacquired pneumonia in adults, the dosing regimens of levofloxacin in children were chosen to achieve similar blood levels that occur with a currently recommended dose to treat community-acquired pneumonia in adults (500 mg once daily for 7 to 14 days). Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below
50 Pneumonia
Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00034736;jsessionid=5471C3 D423969012E2E20478C1362870 ·
Randomized Study of Two Interventions for Liquid Aspiration: ShortTerm and Long-Term Effects Condition(s): Pneumonia, Aspiration Study Status: This study is currently recruiting patients. Sponsor(s): National Institute on Deafness and Other Communication Disorders (NIDCD) Purpose - Excerpt: The purpose of this study is to determine whether chin-down posture or use of a thickened liquid diet is more effective in the prevention of aspiration and aspiration pneumonia in patients with Parkinson's disease and/or dementia. Liquid aspiration is the most common type of aspiration in older populations, especially those suffering from debilitation, dementia, and depression. Pneumonia may develop as a consequence of aspiration and is the fifth leading cause of death in the US among persons age 65 years and over. Current treatment involves either use of chin-down position with swallowing or use of thickened liquids in the diet, without any clear evidence supporting the use of one treatment over the other. This is a Phase III inpatient and/or outpatient study in which all participants will be randomly assigned to either the chin-down position or the thickened liquid treatment group based on swallowing function during a modified barium swallow. This study is scheduled to recruit patients for a three-year period; participation by each individual patient spans no more than three months after entry. Phase(s): Phase III Study Type: Interventional Contact(s): Carol Caperton 1-301-897-5700 ext. 4237; Wisconsin; University of Wisconsin at Madison & multiple other U.S. locations, Madison, Wisconsin, United States; Recruiting. Study chairs or principal investigators: Dr. Joanne Robbins, Study Chair; Dr. Jeri Logemann, Principal Investigator Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00000362;jsessionid=5471C3 D423969012E2E20478C1362870
Clinical Trials 51
·
A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Glaxo Wellcome Purpose - Excerpt: To assess whether high dose or low dose atovaquone suspension is more effective than aerosolized pentamidine as prophylaxis against Pneumocystis carinii pneumonia (PCP) in high-risk HIV-infected patients. To compare the safety of chronic administration of the three regimens in patients with advanced HIV disease. To determine the relationship between steady state atovaquone plasma concentrations and prophylactic efficacy against PCP. Phase(s): Phase III Study Type: Interventional Contact(s): Florida; Goodgame Med Group, Maitland, Florida, 32751, United States; Bay Area AIDS Consortium, Tampa, Florida, 33609, United States; New York; Saint Vincent's Hosp and Med Ctr, New York, New York, 10011, United States; Ohio; Holmes Hosp, Cincinnati, Ohio, 452670405, United States; Virginia; Hampton Roads Med Specialists, Hampton, Virginia, 23666, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002340;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis carinii Pneumonia (PCP) in Patients with AIDS Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Jacobus Pharmaceutical Purpose - Excerpt: Evaluate the effectiveness rate of dapsone plus trimethoprim as a therapy for the first episode of Pneumocystis carinii pneumonia (PCP) in AIDS patients. Compare the rates and severity of adverse effects using dapsone versus trimethoprim - sulfamethoxazole (TMP / PurposeX). Establish relative toxicities with regard to suitability for outpatient treatment. Study Type: Interventional
52 Pneumonia
Contact(s): New Jersey; Jacobus Pharmaceutical Co, Princeton, New Jersey, 08540, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002283;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Comparison of Two Types of Injected Nutritional Supplements in Patients with AIDS and Pneumocystis carinii Pneumonia (PCP) Condition(s): HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Abbott Laboratories Purpose - Excerpt: The objectives of this study are: To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent. Study Type: Interventional Contact(s): New Jersey; East Orange Veterans Administration Med Ctr, East Orange, New Jersey, 07018, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002275;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis carinii Pneumonia Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): U.S. Bioscience Purpose - Excerpt: To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in European patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).
Clinical Trials 53
Study Type: Interventional Contact(s): Pennsylvania; United States Bioscience Conshohocken, Pennsylvania, 19428, United States
Inc,
West
Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002103;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis carinii Pneumonia. Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): U.S. Bioscience Purpose - Excerpt: To provide trimetrexate glucuronate to immunosuppressed patients with Pneumocystis carinii pneumonia (PCP) for whom this investigational compound could provide significant medical benefit. Study Type: Interventional Contact(s): Pennsylvania; United States Bioscience Conshohocken, Pennsylvania, 19428, United States
Inc,
West
Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002102;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis carinii Pneumonia in AIDS Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): LyphoMed Purpose - Excerpt: This is a randomized double-blinded controlled study comparing aerosolized pentamidine with trimethoprim plus sulfamethoxazole (TMP / PurposeX). The latter drug will be administered intravenously for at least 5 days, then changed to oral administration if warranted by the patient's clinical condition. Study Type: Interventional Contact(s): Illinois; LyphoMed Inc, Rosemont, Illinois, 60018, United States
54 Pneumonia
Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002056;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Fisons Purpose - Excerpt: To evaluate and compare the safety, tolerability, and effectiveness of long-term biweekly administration of 1 of 2 doses of aerosol pentamidine when used as a prophylactic agent in patients who have had multiple episodes of AIDS associated Pneumocystis carinii pneumonia (PCP). Study Type: Interventional Contact(s): District of Columbia; Veterans Administration Med Ctr, Washington, District of Columbia, 20422, United States; Georgetown Univ, Washington, District of Columbia, 20007, United States; Illinois; Northwestern Univ Med School, Chicago, Illinois, 60611, United States; Massachusetts; Beth Israel Deaconess - West Campus, Boston, Massachusetts, 02215, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002055;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis carinii Pneumonia in Patients With AIDS Post First Episode PCP Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Fisons Purpose - Excerpt: To evaluate and compare the safety, tolerability, and efficacy of biweekly administration of aerosol pentamidine versus placebo when used as a prophylactic agent in patients who have recovered from their first episode of AIDS-associated Pneumocystis carinii pneumonia (PCP).
Clinical Trials 55
Study Type: Interventional Contact(s): New York; Fisons Corp, Rochester, New York, 14603, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002053;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Fisons Purpose - Excerpt: To evaluate the safety, tolerability, and description of time to Pneumocystis carinii pneumonia (PCP) for long-term biweekly administration of 1 of 2 doses of aerosol pentamidine when used as a prophylactic agent in patients who have had one episode of AIDSassociated PCP. Study Type: Interventional Contact(s): New York; Fisons Corp, Rochester, New York, 14603, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002054;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis carinii Pneumonia in AIDS Patients Who are Intolerant of Trimethoprim / Sulfamethoxazole Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Glaxo Wellcome Purpose - Excerpt: To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who are intolerant of therapy with trimethoprim / sulfamethoxazole (TMP / SMX) by comparing the incidence of premature discontinuation of therapy due to toxicity. To compare the efficacy of 566C80 with intravenous (IV) pentamidine for the treatment of mild to moderate PCP in the same population.
56 Pneumonia
Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00001996;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Randomized, Double-Blind, Placebo Controlled Study of lLeucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis carinii Pneumonia in Patients with the Acquired Immunodeficiency Syndrome Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Lederle Laboratories Purpose - Excerpt: The primary objective of the study is to evaluate the effectiveness of l-leucovorin in preventing toxicity from high dose trimethoprim / sulfamethoxazole (TMP / SMX) used as a therapy for Pneumocystis carinii pneumonia (PCP) in patients with AIDS. Study Type: Interventional Contact(s): California; San Francisco Gen Hosp, San Francisco, California, 941102859, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002002;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP) Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): U.S. Bioscience Purpose - Excerpt: To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine). Study Type: Interventional
Clinical Trials 57
Contact(s): Pennsylvania; United States Bioscience Inc, West Conshohocken, Pennsylvania, 19428, United States. Study chairs or principal investigators: Feinberg J, Study Chair Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002434;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Study of Trimetrexate Plus Pneumocystis Carinii Pneumonia
Leucovorin
in Children with
Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): U.S. Bioscience Purpose - Excerpt: To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in pediatric patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine). Study Type: Interventional Contact(s): Pennsylvania; United States Bioscience Inc, West Conshohocken, Pennsylvania, 19428, United States. Study chairs or principal investigators: Feinberg J, Study Chair Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002317;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis carinii Pneumonia (PCP) in Patients with AIDS Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): LyphoMed Purpose - Excerpt: To compare parenteral versus inhaled pentamidine in patients with documented Pneumocystis carinii pneumonia (PCP) with AIDS. Study Type: Interventional Contact(s): Illinois; LyphoMed Inc, Rosemont, Illinois, 60018, United States
58 Pneumonia
Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002292;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: The purpose of this study is to see how often Pneumocystis carinii pneumonia (PCP) occurs in HIV-positive patients who have stopped taking medications that help prevent PCP. The risk of developing PCP may be decreased when an HIV-positive patient's CD4 cell counts (cells of the immune system which fight infection) are more than 200 cells/mm3. This study looks at whether it is acceptable to stop PCP prevention treatment in these patients. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00000908;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Treatment IND for 566C80 Therapy of Pneumocystis carinii Pneumonia Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Glaxo Wellcome Purpose - Excerpt: To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80. Study Type: Interventional Contact(s): North Carolina; Glaxo Wellcome Inc, Research Triangle Park, North Carolina, 27709, United States
Clinical Trials 59
Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00001991;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients with Pneumocystis carinii Pneumonia and Serious Intolerance to Approved Therapies Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To determine the safety and effectiveness of an investigational drug trimetrexate (TMTX) with leucovorin rescue (LCV) in the treatment of Pneumocystis carinii pneumonia (PCP) in patients who have AIDS, are HIV positive, or are at high risk for HIV infection, and who have demonstrated serious adverse effects from the conventional therapies for PCP. The drugs usually used to treat PCP in AIDS patients (trimethoprim / sulfamethoxazole and pentamidine) have had to be discontinued in many patients because of severe adverse effects. Currently there are no proven alternatives to these drugs. TMTX was chosen for this trial because it has been found to be very active against the PCP organism in laboratory tests. In a preliminary trial, TMTX in combination with LCV has been effective against PCP with fewer and less severe adverse effects. Phase(s): Phase III Study Type: Interventional Contact(s): New Jersey; Warner-Lambert Parke-Davis, Morris Plains, New Jersey, 07950, United States. Study chairs or principal investigators: Feinberg J, Study Chair Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00001016;jsessionid=5471C3 D423969012E2E20478C1362870
·
An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Fisons
60 Pneumonia
Purpose - Excerpt: To evaluate the safety, tolerability, and efficacy of long term, bi-weekly administration of aerosol pentamidine when used as a prophylactic agent in patients who have had at least two or more episodes of AIDS-associated Pneumocystis carinii pneumonia (PCP). Study Type: Interventional Contact(s): New York; Fisons Corp, Rochester, New York, 14603, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002030;jsessionid=5471C3 D423969012E2E20478C1362870 ·
Dapsone 100 mg Versus 50 as Primary Prophylaxis for Pneumocystis carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): Jacobus Pharmaceutical Purpose - Excerpt: To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3. To determine whether the long-term toxicities associated with daily dapsone in this population are tolerable. Study Type: Interventional Contact(s): California; UCLA CARE Ctr, Los Angeles, California, 90095, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002043;jsessionid=5471C3 D423969012E2E20478C1362870
·
Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis carinii Pneumonia Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): U.S. Bioscience; Jacobus Pharmaceutical Purpose - Excerpt: To evaluate the safety of the combination of trimetrexate glucuronate (TMTX) and dapsone with leucovorin
Clinical Trials 61
protection versus trimethoprim/sulfamethoxazole (TMP/SMX) in patients with AIDS and moderately severe Pneumocystis carinii pneumonia (PCP). To determine the pharmacokinetic parameters of TMTX, leucovorin, and dapsone and of TMP/SMX when given to patients with AIDS and moderately severe PCP. Phase(s): Phase I Study Type: Interventional Contact(s): California; Los Angeles County / Health Research Assoc / Drew Med Ctr, Los Angeles, California, 90033, United States Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00002120;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Controlled Comparative Trial of Trimethoprim - Sulfamethoxazole Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT) Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To determine if the drug combination trimethoprim/sulfamethoxazole (TMP/SMX), given by mouth, and the drug pentamidine (PEN), given by inhaled aerosol, are effective in preventing a relapse of Pneumocystis carinii pneumonia (PCP) when they are given to patients who have recovered from a first episode of PCP and are being given zidovudine (AZT) to treat primary HIV infection. AZT prolongs survival in patients with AIDS and decreases the occurrence of opportunistic infections such as PCP. However, PCP recurs in about 43 percent of patients receiving AZT, indicating a need for other treatments to reduce the relapse rate. The two medications to be tested in this study, TMP / SMX, and aerosolized PEN, have also been partially effective in preventing recurrence of PCP. It is hoped that the combination of AZT with these medications will be more effective than AZT or one of the medications alone. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below
62 Pneumonia
Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00000727;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis carinii Pneumonia in AIDS Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To compare the safety and effectiveness of drug therapy with aerosolized pentamidine (PEN) with that of conventional therapy, trimethoprim plus sulfamethoxazole (TMP / SMX) in the treatment of Pneumocystis carinii pneumonia (PCP) in patients who have AIDS, are HIV positive, or are at high risk for HIV infection. New treatments are needed for PCP, a common lung infection in patients with AIDS, because many patients treated with the two standard treatments, PEN given by injections and TMP / SMX, have had adverse effects that required a change in treatment. There is also a high relapse rate after the standard treatments. Preliminary experiments in humans suggest that aerosolized PEN is as effective as the standard treatments for PCP, and causes few adverse effects. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00000715;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with advanced HIV disease and T4 cell count < 200 cells/mm3. To establish the range of pentamidine (PEN) deposition in AIDS patients participating in ACTG 021 and ACTG 081. To identify factors (breathing pattern, pulmonary function) that may
Clinical Trials 63
be important in affecting the actual dose delivered to a given patient. The specific system that is used to deliver PEN to the lungs may determine whether a therapeutically effective dose is attained in the lungs. Therefore, this study will establish the amount of PEN that is deposited in the lungs of patients enrolled in protocols ACTG 021 and ACTG 081, who are being treated with PEN administered from the Marquest Respirgard II nebulizer. Study Type: Interventional Contact(s): New York; SUNY - Stony Brook, Stony Brook, New York, 117948153, United States. Study chairs or principal investigators: GC Smaldone, Study Chair Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00001003;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID); Fujisawa Pharmaceutical Purpose - Excerpt: Primary: To compare the pharmacokinetics of biweekly and monthly dose regimens of intravenous pentamidine in HIV-infected infants and children who require PCP prophylaxis and who are intolerant to oral trimethoprim - sulfamethoxazole. To determine the safety and tolerance of these regimens in this patient population. Secondary: To obtain information on the rate of PCP breakthrough in infants and children receiving parenteral pentamidine prophylaxis. Prophylaxis against Pneumocystis carinii pneumonia is recommended for all HIV-infected children considered to be at high risk. In children younger than 5 years of age with intolerance to trimethoprim sulfamethoxazole, parenteral pentamidine may be a successful alternative. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00001027;jsessionid=5471C3 D423969012E2E20478C1362870
64 Pneumonia
·
A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is terminated. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID); Jacobus Pharmaceutical; Fujisawa Pharmaceutical Purpose - Excerpt: To compare the safety and efficacy of aerosolized pentamidine and dapsone in the prevention of Pneumocystis carinii pneumonia (PCP) in high-risk HIV-infected patients who are intolerant to trimethoprim and/or sulfonamides. Both aerosolized pentamidine and dapsone have been shown to prevent PCP, but both drugs cause side effects. This study attempts to determine which drug is more efficacious as prophylaxis against PCP in patients who cannot tolerate trimethoprim/sulfamethoxazole. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00001028;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with HIV infection and T4 cell count less than 200 cells/mm3. All persons completing at least 8 weeks of therapy on 081 will be offered the opportunity to participate in the nested study (ACTG 981) of systemic antifungal therapy (fluconazole) versus local therapy (Clotrimazole) for the prevention of serious fungal disease. Persons with HIV disease who are receiving AZT are at risk for PCP, toxoplasmosis, bacterial pneumonia, and other serious infections. It is therefore important to find drugs that can be given along with AZT to control these infections. Aerosolized pentamidine (PEN) has been shown to be useful in preventing PCP and is expected to lower the 2-year risk of PCP. Both trimethoprim / sulfamethoxazole (TMP / SMX) and dapsone
Clinical Trials 65
probably also provide effective preventive treatment against PCP, and both may be useful in preventing toxoplasmosis and extrapulmonary pneumocystosis. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00000991;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Study of Trimetrexate in the Treatment of Pneumocystis carinii Pneumonia (PCP) in Patients with AIDS Not Previously Treated for PCP Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia (PCP) in AIDS patients TMTX is an experimental new drug which is effective for treatment of PCP, but has been given to only a few patients. Therefore it is not certain if TMTX is better, the same as, or not as effective as conventional drugs against PCP. Phase(s): Phase I Study Type: Interventional Contact(s): California; Los Angeles County - USC Med Ctr, Los Angeles, California, 90033, United States. Study chairs or principal investigators: Masur H, Study Chair Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00000998;jsessionid=5471C3 D423969012E2E20478C1362870
·
A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis carinii Pneumonia Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID)
66 Pneumonia
Purpose - Excerpt: To study the safety and effectiveness of trimetrexate (TMTX) plus leucovorin calcium rescue (LCV) in the treatment of Pneumocystis carinii pneumonia (PCP) in patients who have AIDS, patients who are HIV positive, or those for whom laboratory confirmation of HIV infection has not yet been established if they are at high risk for HIV infection, and who have not responded to standard treatments or who have demonstrated severe or life-threatening intolerance to both conventional therapies for PCP. The drugs trimethoprim / sulfamethoxazole (TMP / SMX) and pentamidine, usually used to treat PCP in AIDS patients, have proven ineffective in many patients and have had to be discontinued in many other patients because of severe side effects. TMTX was chosen for this trial because it was found to be very active against the PCP organism in laboratory tests and, in a preliminary trial in combination with LCV, there was a high response rate without severe toxicity. Phase(s): Phase III Study Type: Interventional Contact(s): New Jersey; Warner-Lambert Parke-Davis, Morris Plains, New Jersey, 07950, United States. Study chairs or principal investigators: Feinberg J, Study Chair Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00000724;jsessionid=5471C3 D423969012E2E20478C1362870 ·
A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis carinii Pneumonia Condition(s): Pneumonia, Pneumocystis carinii; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To evaluate the delivery of a single dose of aerosolized pentamidine to children; to evaluate the tolerance of pentamidine administration by mask; to compare intravenous pentamidine first dose pharmacokinetics (blood levels) in children with information previously collected on adults; and to compare plasma pentamidine levels in children after an aerosolized treatment with levels previously collected on adults. Pneumocystis carinii pneumonia (PCP) is the most common serious infection in children with AIDS and is associated with a high death rate. Current approved treatment includes intravenous trimethoprim - sulfamethoxazole (TMP / SMX) and intravenous pentamidine, which are both effective in treatment of the first episode of
Clinical Trials 67
PCP pneumonia. However, both therapies have a 50 percent or greater incidence of adverse reactions. Because of serious toxicities, drug treatment has had to be discontinued. Animal studies show that aerosolized pentamidine (pentamidine given through inhalation) is as effective as intravenous pentamidine. It is hoped that the aerosolized route will be less toxic than intravenous pentamidine. The study is the first step in evaluating the delivery of aerosolized pentamidine to children. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/show/NCT00000974;jsessionid=5471C3 D423969012E2E20478C1362870
Benefits and Risks17 What Are the Benefits of Participating in a Clinical Trial? If you are interested in a clinical trial, it is important to realize that your participation can bring many benefits to you and society at large: ·
A new treatment could be more effective than the current treatment for pneumonia. Although only half of the participants in a clinical trial receive the experimental treatment, if the new treatment is proved to be more effective and safer than the current treatment, then those patients who did not receive the new treatment during the clinical trial may be among the first to benefit from it when the study is over.
·
If the treatment is effective, then it may improve health or prevent diseases or disorders.
·
Clinical trial patients receive the highest quality of medical care. Experts watch them closely during the study and may continue to follow them after the study is over.
·
People who take part in trials contribute to scientific discoveries that may help other people with pneumonia. In cases where certain conditions or
This section has been adapted from ClinicalTrials.gov, a service of the National Institutes of Health: http://www.clinicaltrials.gov/ct/gui/c/a1r/info/whatis?JServSessionIdzone_ct=9jmun6f2 91. 17
68 Pneumonia
disorders run in families, your participation may lead to better care or prevention for your family members. The Informed Consent Once you agree to take part in a clinical trial, you will be asked to sign an “informed consent.” This document explains a clinical trial’s risks and benefits, the researcher’s expectations of you, and your rights as a patient.
What Are the Risks? Clinical trials may involve risks as well as benefits. Whether or not a new treatment will work cannot be known ahead of time. There is always a chance that a new treatment may not work better than a standard treatment. There is also the possibility that it may be harmful. The treatment you receive may cause side effects that are serious enough to require medical attention.
How Is Patient Safety Protected? Clinical trials can raise fears of the unknown. Understanding the safeguards that protect patients can ease some of these fears. Before a clinical trial begins, researchers must get approval from their hospital’s Institutional Review Board (IRB), an advisory group that makes sure a clinical trial is designed to protect patient safety. During a clinical trial, doctors will closely watch you to see if the treatment is working and if you are experiencing any side effects. All the results are carefully recorded and reviewed. In many cases, experts from the Data and Safety Monitoring Committee carefully monitor each clinical trial and can recommend that a study be stopped at any time. You will only be asked to take part in a clinical trial as a volunteer giving informed consent. What Are a Patient’s Rights in a Clinical Trial? If you are eligible for a clinical trial, you will be given information to help you decide whether or not you want to participate. As a patient, you have the right to: ·
Information on all known risks and benefits of the treatments in the study.
Clinical Trials 69
·
Know how the researchers plan to carry out the study, for how long, and where.
·
Know what is expected of you.
·
Know any costs involved for you or your insurance provider.
·
Know before any of your medical or personal information is shared with other researchers involved in the clinical trial.
· Talk openly with doctors and ask any questions. After you join a clinical trial, you have the right to: ·
Leave the study at any time. Participation is strictly voluntary. However, you should not enroll if you do not plan to complete the study.
·
Receive any new information about the new treatment.
·
Continue to ask questions and get answers.
·
Maintain your privacy. Your name will not appear in any reports based on the study.
·
Know whether you participated in the treatment group or the control group (once the study has been completed).
What about Costs? In some clinical trials, the research facility pays for treatment costs and other associated expenses. You or your insurance provider may have to pay for costs that are considered standard care. These things may include inpatient hospital care, laboratory and other tests, and medical procedures. You also may need to pay for travel between your home and the clinic. You should find out about costs before committing to participation in the trial. If you have health insurance, find out exactly what it will cover. If you don’t have health insurance, or if your insurance company will not cover your costs, talk to the clinic staff about other options for covering the cost of your care. What Should You Ask before Deciding to Join a Clinical Trial? Questions you should ask when thinking about joining a clinical trial include the following: ·
What is the purpose of the clinical trial?
70 Pneumonia
·
What are the standard treatments for pneumonia? Why do researchers think the new treatment may be better? What is likely to happen to me with or without the new treatment?
·
What tests and treatments will I need? Will I need surgery? Medication? Hospitalization?
·
How long will the treatment last? How often will I have to come back for follow-up exams?
·
What are the treatment’s possible benefits to my condition? What are the short- and long-term risks? What are the possible side effects?
·
Will the treatment be uncomfortable? Will it make me feel sick? If so, for how long?
·
How will my health be monitored?
·
Where will I need to go for the clinical trial? How will I get there?
·
How much will it cost to be in the study? What costs are covered by the study? How much will my health insurance cover?
·
Will I be able to see my own doctor? Who will be in charge of my care?
·
Will taking part in the study affect my daily life? Do I have time to participate?
·
How do I feel about taking part in a clinical trial? Are there family members or friends who may benefit from my contributions to new medical knowledge?
Keeping Current on Clinical Trials Various government agencies maintain databases on trials. The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and physicians with current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to their Web site (www.clinicaltrials.gov) and search by “pneumonia” (or synonyms).
Clinical Trials 71
While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: ·
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
·
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
·
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
General References The following references describe clinical trials and experimental medical research. They have been selected to ensure that they are likely to be available from your local or online bookseller or university medical library. These references are usually written for healthcare professionals, so you may consider consulting with a librarian or bookseller who might recommend a particular reference. The following includes some of the most readily available references (sorted alphabetically by title; hyperlinks provide rankings, information and reviews at Amazon.com): ·
A Guide to Patient Recruitment : Today’s Best Practices & Proven Strategies by Diana L. Anderson; Paperback - 350 pages (2001), CenterWatch, Inc.; ISBN: 1930624115; http://www.amazon.com/exec/obidos/ASIN/1930624115/icongroupinterna
·
A Step-By-Step Guide to Clinical Trials by Marilyn Mulay, R.N., M.S., OCN; Spiral-bound - 143 pages Spiral edition (2001), Jones & Bartlett Pub; ISBN: 0763715697; http://www.amazon.com/exec/obidos/ASIN/0763715697/icongroupinterna
·
The CenterWatch Directory of Drugs in Clinical Trials by CenterWatch; Paperback - 656 pages (2000), CenterWatch, Inc.; ISBN: 0967302935; http://www.amazon.com/exec/obidos/ASIN/0967302935/icongroupinterna
·
The Complete Guide to Informed Consent in Clinical Trials by Terry Hartnett (Editor); Paperback - 164 pages (2000), PharmSource Information
72 Pneumonia
Services, Inc.; ISBN: 0970153309; http://www.amazon.com/exec/obidos/ASIN/0970153309/icongroupinterna ·
Dictionary for Clinical Trials by Simon Day; Paperback - 228 pages (1999), John Wiley & Sons; ISBN: 0471985961; http://www.amazon.com/exec/obidos/ASIN/0471985961/icongroupinterna
·
Extending Medicare Reimbursement in Clinical Trials by Institute of Medicine Staff (Editor), et al; Paperback 1st edition (2000), National Academy Press; ISBN: 0309068886; http://www.amazon.com/exec/obidos/ASIN/0309068886/icongroupinterna
·
Handbook of Clinical Trials by Marcus Flather (Editor); Paperback (2001), Remedica Pub Ltd; ISBN: 1901346293; http://www.amazon.com/exec/obidos/ASIN/1901346293/icongroupinterna
Vocabulary Builder The following vocabulary builder gives definitions of words used in this chapter that have not been defined in previous chapters: Antifungal: Destructive to fungi, or suppressing their reproduction or growth; effective against fungal infections. [EU] Arginine: An essential amino acid that is physiologically active in the Lform. [NIH] Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous. [NIH] Bronchiolitis: Inflammation of the bronchioles. [NIH] Ceftriaxone: Broad-spectrum cephalosporin antibiotic with a very long halflife and high penetrability to usually inaccessible infections, including those involving the meninges, eyes, inner ears, and urinary tract. [NIH] Clindamycin: An antibacterial agent that is a semisynthetic analog of lincomycin. [NIH] Clotrimazole: An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. [NIH] Emulsions: Colloids of two immiscible liquids where either phase may be either fatty or aqueous; lipid-in-water emulsions are usually liquid, like milk or lotion and water-in-lipid emulsions tend to be creams. [NIH]
Clinical Trials 73
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. [NIH] Hypertension: Persistently high arterial blood pressure. Various criteria for its threshold have been suggested, ranging from 140 mm. Hg systolic and 90 mm. Hg diastolic to as high as 200 mm. Hg systolic and 110 mm. Hg diastolic. Hypertension may have no known cause (essential or idiopathic h.) or be associated with other primary diseases (secondary h.). [EU] Idiopathic: Of the nature of an idiopathy; self-originated; of unknown causation. [EU] Inhalation: The drawing of air or other substances into the lungs. [EU] Leucovorin: The active metabolite of folic acid. Leucovorin is used principally as its calcium salt as an antidote to folic acid antagonists which block the conversion of folic acid to folinic acid. [NIH] Lipid: Any of a heterogeneous group of flats and fatlike substances characterized by being water-insoluble and being extractable by nonpolar (or fat) solvents such as alcohol, ether, chloroform, benzene, etc. All contain as a major constituent aliphatic hydrocarbons. The lipids, which are easily stored in the body, serve as a source of fuel, are an important constituent of cell structure, and serve other biological functions. Lipids may be considered to include fatty acids, neutral fats, waxes, and steroids. Compound lipids comprise the glycolipids, lipoproteins, and phospholipids. [EU] Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the intestinal glands, bile pigments, fatty acids, amniotic fluid, and intrauterine debris. It constitutes the first stools passed by a newborn. [NIH] Neutropenia: Leukopenia in which the decrease in white blood cells is chiefly in neutrophils. [EU] Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of Pneumocystis carinii pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. [NIH]
Pharmacokinetics: The action of drugs in the body over a period of time, including the processes of absorption, distribution, localization in tissues, biotransformation, and excretion. [EU] Prophylaxis: The prevention of disease; preventive treatment. [EU] Recurrence: The return of a sign, symptom, or disease after a remission. [NIH] Refractory: Not readily yielding to treatment. [EU] Subacute: Somewhat acute; between acute and chronic. [EU] Subclinical: Without clinical manifestations; said of the early stage(s) of an
74 Pneumonia
infection or other disease or abnormality before symptoms and signs become apparent or detectable by clinical examination or laboratory tests, or of a very mild form of an infection or other disease or abnormality. [EU] Systemic: Pertaining to or affecting the body as a whole. [EU] Thrombocytopenia: Decrease in the number of blood platelets. [EU] Toxicity: The quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. [EU] Transaminase: Aminotransferase (= a subclass of enzymes of the transferase class that catalyse the transfer of an amino group from a donor (generally an amino acid) to an acceptor (generally 2-keto acid). Most of these enzymes are pyridoxal-phosphate-proteins. [EU] Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [NIH]
75
PART II: ADDITIONAL RESOURCES AND ADVANCED MATERIAL
ABOUT PART II In Part II, we introduce you to additional resources and advanced research on pneumonia. All too often, patients who conduct their own research are overwhelmed by the difficulty in finding and organizing information. The purpose of the following chapters is to provide you an organized and structured format to help you find additional information resources on pneumonia. In Part II, as in Part I, our objective is not to interpret the latest advances on pneumonia or render an opinion. Rather, our goal is to give you access to original research and to increase your awareness of sources you may not have already considered. In this way, you will come across the advanced materials often referred to in pamphlets, books, or other general works. Once again, some of this material is technical in nature, so consultation with a professional familiar with pneumonia is suggested.
Studies 77
CHAPTER 4. STUDIES ON PNEUMONIA Overview Every year, academic studies are published on pneumonia or related conditions. Broadly speaking, there are two types of studies. The first are peer reviewed. Generally, the content of these studies has been reviewed by scientists or physicians. Peer-reviewed studies are typically published in scientific journals and are usually available at medical libraries. The second type of studies is non-peer reviewed. These works include summary articles that do not use or report scientific results. These often appear in the popular press, newsletters, or similar periodicals. In this chapter, we will show you how to locate peer-reviewed references and studies on pneumonia. We will begin by discussing research that has been summarized and is free to view by the public via the Internet. We then show you how to generate a bibliography on pneumonia and teach you how to keep current on new studies as they are published or undertaken by the scientific community.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and pneumonia, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the
78 Pneumonia
format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type in “pneumonia” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is a sample of what you can expect from this type of search: ·
Prognosis of Streptococcus Pneumoniae-Induced Hemolytic Uremic Syndrome Source: Pediatric Nephrology. 16(4): 362-365. April 2001. Contact: Available from Springer-Verlag. Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094. (201) 348-4033. Summary: Streptococcus pneumoniae induced hemolytic uremic syndrome (HUS) is known to be a severe acute disease leading to death in one third of cases, but data regarding the long term followup are lacking. This article reports on a series of 11 patients with HUS induced by the bacteria Streptococcus pneumoniae; all patients had meningitis and pneumonia. Among 9 patients with a severe acute infectious disease, 3 died from meningitis (infection of the meninges, or outer membranes of the brain) and 1 from neurological sequelae after a partial recovery of renal (kidney) function. The mean duration of dialysis was 32 days in patients with acute renal failure (ARF) who survived the acute infectious period. Cortical necrosis (tissue death) was documented in five of six kidney specimens. Among the 7 surviving patients, 5 developed end stage renal disease (ESRD) between 4 and 17 years later. The authors note that S. pneumoniae induced HUS is a rare disease, and they recommend the use of a registry of patients, in order to follow prospectively a larger number of patients. 1 table. 21 references.
·
Implications of Oral Infections on Systemic Diseases in the Institutionalized Elderly with a Special Focus on Pneumonia Source: Annals of Periodontology. 3(1): 262-275. July 1998. Contact: Available from American Academy of Periodontology. Suite 800, 737 North Michigan Avenue, Chicago, IL 60611. (312) 787-5518. Fax (312) 787-3983. Website: www.perio.org. Summary: This article considers the implications of oral infections on systemic diseases in the institutionalized elderly; the author offers a special focus on pneumonia. The extent to which oral organisms cause systemic infections through hematogenous (through the blood)
Studies 79
dissemination in this population is still unknown. The author hypothesizes that a more likely and common route of systemic infection by oral microorganisms is through aspiration of oropharyngeal fluids containing oral pathogenic microorganisms, which colonize the lower respiratory tract and cause pneumonia. Respiratory pathogens emerge in the dental plaque of elderly patients with very poor oral hygiene and severe periodontal disease. This is also a problem in intensive care units in the hospital setting. Selective digestive decontamination, a technique involving the topical application of antimicrobials to reduce the risk of colonization of the respiratory tract, has been used to reduce the incidence of nosocomial pneumonia in the acute care setting of hospitals. This technique has not been employed in the nursing home setting. The author concludes by discussing the parameters of studying this problem, including ethical issues, and research design. 2 tables. 117 references. (AA-M). ·
Impact of Oral Diseases on Systemic Health in the Elderly: Diabetes Mellitus and Aspiration Pneumonia Source: Journal of Public Health Dentistry. 60(4): 313-320. Fall 2000. Contact: Available from American Association of Public Health Dentistry. 3760 SW Lyle Court, Portland, OR 97221. (503) 242-0712. Fax (503) 242-0721. E-mail:
[email protected]. Summary: Evidence is increasing that oral health has important impacts on systemic health. This article presents data from the third National Health and Nutrition Examination Survey (NHANES III) describing the prevalence of dental caries and periodontal diseases in the older adult population. The authors then evaluate published reports and present data from clinical and epidemiological studies on relationships among oral health status, chronic oral infections (including caries and periodontitis), and certain systemic diseases, specifically focusing on type 2 diabetes and aspiration pneumonia. Both of these diseases increase in occurrence and impact in older age groups. The NHANES III data demonstrate that dental caries (cavities) and periodontal diseases occur with substantial frequency and represent a burden of unmet treatment need in older adults. The authors found clinical and epidemiological evidence to support considering periodontal infection a risk factor for poor glycemic control in type 2 diabetes; however, there is limited representation of older adults in reports of this relationship. For aspiration pneumonia, several lines of evidence support oral health status as an important etiologic factors. Additional clinical studies designed specifically to evaluate the effects of treating periodontal infection on glycemic control and improving oral health status in reducing the risk of
80 Pneumonia
aspiration pneumonia are needed. Although the associations are complicated, there is evidence to support recommending oral care regimens in protocols for managing type 2 diabetes and preventing aspiration pneumonia. 8 tables. 71 references.
Federally Funded Research on Pneumonia The U.S. Government supports a variety of research studies relating to pneumonia and associated conditions. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.18 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally-funded biomedical research projects conducted at universities, hospitals, and other institutions. Visit the CRISP Web site at http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket. You can perform targeted searches by various criteria including geography, date, as well as topics related to pneumonia and related conditions. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally-funded studies use animals or simulated models to explore pneumonia and related conditions. In some cases, therefore, it may be difficult to understand how some basic or fundamental research could eventually translate into medical practice. The following sample is typical of the type of information found when searching the CRISP database for pneumonia: ·
Project Title: Clinical Decision Rules to Pediatric Pneumonia Principal Investigator & Institution: Mahabee-Gittens, E M.; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2000; Project Start 1-SEP-2000; Project End 1-AUG2002 Summary: Radiographic examination of the chest is done on patients with symptoms of a lower respiratory tract infection (LRI) primarily to confirm or exclude the presence of a radiographic infiltrate consistent with pneumonia. However, the 1995 National Health Survey showed that the prevalence of pneumonia in children under 5 years of age with
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
18
Studies 81
respiratory infection was only approximately 2.8%. Even among pediatric patients presenting to the emergency department (ED), radiographic pneumonia was present in only 7% to 19% of patients with LRI symptoms. Despite this relatively low proportion of chest radiographs (CXRs) that reveal radiographic pneumonia, many such patients are routinely referred for a CXR by their primary care or ED physician. As a consequence, patients with respiratory infection, but without radiographic pneumonia, often have CXRs, resulting in excess radiation exposure and additional cost. Numerous studies have been published on pediatric pneumonia, however there is still no consensus opinion about how to accurately diagnose this disease based on a combination of historical and physical examination findings, nor is there agreement that a CXR is always needed to diagnose this disease in children with respiratory symptoms. The purpose of this study is to develop decision rules that will predict radiographic pneumonia in patients age 2 months to 59 months of age with symptoms of LRI. Subsequent studies will validate the decision rules and determine the cost effectiveness of applying the rules. This study will be conducted in the ED of Children's Hospital Medical Center during October 2000 through September 2001. All patients with LRI symptoms will be approached for enrollment. Detailed history and physical examination variables will be assessed on each patient and all patients will receive a CXR. Each CXR will be reviewed by 2 blinded radiologists and a consensus reading will be obtained. Variables that are strongly associated with radiographic pneumonia (p<0.05) will be analyzed by multivariate techniques. Decision rules will be developed of the best combination of predictor variables for pneumonia on CXR. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Host and Viral Factors in SIV Pneumonia Principal Investigator & Institution: Zink, M. C.; Professor; Comparative Medicine; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2000; Project Start 0-SEP-1997; Project End 1-AUG2002 Summary: Tropism of HIV for macrophages contributes to primary HIV pneumonia whereas replication in lymphocytes leads to immunosuppression and secondary opportunistic infections. The two main forms of primary HIV-induced pneumonia are lymphocytic interstitial pneumonia (LIP) and diffuse infiltrative lymphocytosis syndrome (DILS), and individuals with these conditions survive longer and have fewer opportunistic infections than those who do not. Like HIV,
82 Pneumonia
SIV replicates in both CD4+ lymphocytes and monocytes/macrophages, but is mainly detected in cells of macrophage lineage in the lung. Specific strains of SIV cause lesions in the lungs of juvenile macaques that resemble HIV lymphoid interstitial pneumonia, and macaques with these lesions also survive longer. This application proposes a multidisciplinary approach to identify viral and host factors that contribute to pulmonary disease. The hypothesis to be tested in these studies is that while many viral strains enter the lung in infected blood, only certain macrophagetropic strains establish themselves in pulmonary tissue, possibly related to expression of specific viral co-receptors in the lung. It also hypothesized that the lymphocytic pneumonia is indicative of effective immunologic restraint of macrophage-tropic viral burden and thus improved prognosis. For these studies, macaques will be inoculated with SIV and euthanized during the initial stage of viral replication (3 weeks p.i.), during the stage of clinical quiescence (3 months p.i.), and during terminal clinical diseases. 1) Pulmonary and systemic immune responses, pulmonary lesions, and viral load will be measured in these macaques to determine at what stage of infection lymphocytic interstitial pneumonia appears, whether lymphocytic interstitial pneumonia is indicative of effective pulmonary antiviral immune responses, and whether the effectiveness of pulmonary immune responses predicts outcome of infection. 2) The levels of expression of pro-inflammatory molecules (cell adhesion molecules, chemokine receptors, chemokines, and cytokines) in lung tissue and bronchoalveolar cells will be measured throughout SIV infection and correlated with pulmonary and peripheral viral load with host immune responses. 3) The viral strains and genotypes that replicate productively in lungs of animals infected with SIV will be identified to determine if specific virus strains are associated with the development of LIP. Replication of viruses isolated from the lung of infected macaques in primary cultures of peripheral blood-derived macrophages and alveolar macrophages will be measured. Virus isolates from lung will be characterized for co-receptor usage (chemokine receptors) to determine if differences exist between macrophage-tropic viruses isolated from the peripheral blood and the lung. 4) The cytokines, chemokines, and chemokine receptors that are expressed in alveolar macrophages and peripheral blood-derived macrophages infected with different strains of virus will be identified. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Host Response to Post-Operative Pneumonia Principal Investigator & Institution: Knight, Paul R.; Professor and Vice Chairman; Anesthesiology; State University of New York at Buffalo Capen Hall Buffalo, Ny 14260
Studies 83
Timing: Fiscal Year 2001; Project Start 1-JUL-2001; Project End 1-MAY2006 Summary: (Verbatim from the Applicant's Abstract): Anesthesia/surgery predisposes the patient to develop nosocomial pneumonia by mechanisms that are not completely defined. The presence of a viral respiratory tract infection (RTI) during anesthesia/surgery further complicates the host antibacterial response. Evidence from our laboratory has demonstrated anesthesia/surgery induces changes in cytokine response (e.g., TNFalpha, MIP-2, IFNgamma), leukocyte recruitment, and lung injury to influenza RTI. These responses are also critical to innate host defenses against bacterial pathogens. Our focus is to examine cellular mechanisms during a viral RTI that predispose the host to a postsurgical bacterial pneumonia. We hypothesize that anesthesia/surgery will change host responses differently during distinct periods in the course of a viral RTI by altering expression of pro- and antiinflammatory cytokines, thereby decreasing antibacterial defenses. Aim #1 will assess the effects of anesthesia/surgery during influenza on bacterial clearance, inflammatory cell influx, and cytokine expression an Escherichia coli challenge. We predict that laparotomy during influenza will promote the relative expression of MCP-1 and IL-10 over TNFalpha, MIP-2, and IFNgamma. Aim #2: will assess ex vivo the combined effect of laparotomy and influenza on a) LPS stimulated aMphi cytokine expression and phagocytic activity, and b) the ability of in vitro antiMCP1, antiIL-10, or IFNgamma administration to improve M dysfunction. We postulate that laparotomy during influenza will alter aMphi regulatory functions and decrease effector functions as a result of selective enhancement of expression anti-compared to proinflammatory cytokines. Finally, in Aim #3, we will examine the contribution of endogenous cytokines in the suppression of antibacterial defenses following laparotomy during influenza by selective cytokine manipulations. Bacterial clearance, inflammatory cell influx, and cytokine levels will be assessed. We anticipate that neutralization of IL-10 or MCP-1, administration of IFNgamma, or increased TNFalphaexpression will improve antibacterial host defenses following laparotomy during physical signs of influenza. These studies will examine mechanisms that lead to alterations in bacterial clearance post-surgically following a viral RTI, assess the pathogenesis of post-surgical pneumonia in general, and suggest immune adjuvant strategies to prevent this complication. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
84 Pneumonia
·
Project Title: Immunology of Bacterial Pneumonia in Htlv-Ii Infection Principal Investigator & Institution: Jarvis, Gary A.; Northern California Institute Res & Educ for Research and Education San Francisco, Ca 94121 Timing: Fiscal Year 2000; Project Start 1-MAR-2000; Project End 8-FEB2003 Summary: (Adapted from the Applicant's Abstract): This projects seeks to understand the immunologic basis for the epidemiological outcome observation of an increased incidence of bacterial pneumonia in HTLV-IIinfected blood donors. In a study of persons with both HTLV-II seropositivity and intravenous drug use, an increased risk for bacterial pneumonia compared to patients with neither risk was found. A similar finding of increased risk for bacterial pneumonia in HTLV-II-infected individuals was observed in a clinical outcome analysis of blood donors who participated in a Retroviral Epidemiological Donors Study. Since the cell tropism of HTLV-II infection includes CD4+ and CD8+ T cells, B cells and monocytes, the investigators will determine whether HTLV-II infection predisposes to bacterial pneumonia by creating immune dysfunction in these cells which are known to be critical for natural protection against pneumococcal pneumonia, the most common cause of bacterial pneumonia in individuals with immune dysfunction. Studies planned for the next five years address the immune status of HTLV-IIinfected persons. HTLV-II-infected and -uninfected individuals will be vaccinated with the pneumococcal 23-valent polysaccharide vaccine, and their qualitative and quantitative antibody responses will be investigated by determining the isotype and IgG subclass distribution, concentration, avidity and opsonic function of specific pneumococcal capsular antibodies. The same individuals will also be vaccinated with tetanus toxoid protein antigen as a control for antibody response to a separate class of antigen, and their antibody responses measured. The effect of HTLV-II infection of T cells on the proliferative and antibody-secreting functions of B lymphocytes will be tested. CD4+ and CD8+ T cells will be isolated from HTLV-II-infected persons using immunobeads, cocultivated with normal B lymphocytes, and the functional activity of the B cells assessed using mitogen stimulation and ELISA antibody quantitation assays. Levels of B cell regulatory cytokines produced by infected and uninfected T cells will be measured by ELISA. Levels of immune response markers IL2 receptor on CD8+ T cells, and CD21 and CD35 on B cells will be determined by flow cytometry. The phagocytic and bactericidal function of PMN and of human macrophages derived from the monocytes from HTLV-II-infected individuals will be tested and compared to the function of those cells from uninfected persons. Human CD4+ and CD8+ T cells will be isolated using immunobeads and
Studies 85
quantities of macrophage and PMN regulatory cytokines produced by HTLV-II-infected and -uninfected T Cells will be measured by ELISA. The effect of HTLV-II infection of human T cells on cytokine-dependent activation of macrophages and PMN will be studied using functional assays of pneumococcal phagocytic killing. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Long Term Mortality of Community Aquired Pneumonia Principal Investigator & Institution: Mortensen, Eric M.; Medicine; University of Pittsburgh at Pittsburgh 4200 5Th Ave Pittsburgh, Pa 15260 Timing: Fiscal Year 2000; Project Start 1-JUL-1999 Summary: Community-acquired pneumonia (CAP) affects over four million persons annually, and is the sixth leading cause of death in the United States. Although numerous studies have assessed short-term mortality of Pneumonia, there have been few studies on the long-term mortality of this illness, improved understanding of the long-term mortality of patients with CAP is needed so physicians have accurate knowledge upon which to base treatment decisions and for discussions with patients and families. In this study, we wish to build upon the work of the Pneumonia Patient Outcomes Research Team (PORT) cohort study to improve our understanding of the long-term mortality of patients with CAP. The Pneumonia PORT cohort study was a 29-month, prospective, multi-center of 2287 patients who were followed for up to 90-days postdiagnosis. Using the National Death Index and death certificate data from the Nova Scotia Department of Vital Statistics, we will obtain mortality information five years after the initial diagnosis of CAP. We hypothesize that decreased functional status, age, and burden of comorbid illness are independent predictors of long-term mortality of patients with CAP. We will use univariate and multivariate Cox's proportional hazard modeling to determine the independent variables associated with long-term mortality. This study will provide significant insights into the long-term prognosis of patients with CAP. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
·
Project Title: Novel Anti-Bacterial Therapy for Gram Negative Pneumonia Principal Investigator & Institution: Murthy, Kanneganti; Inotek Corporation 100 Cummings Ctr, Ste 419E Beverly, Ma 01915 Timing: Fiscal Year 2001; Project Start 1-SEP-2001; Project End 8-FEB-2003 Summary: (provided by applicant):In spite of aggressive antibiotic therapy and supportive care, gram negative pneumonia remains a major
86 Pneumonia
cause of death and prolonged hospitalization. To address this unmet need, Inotek is developing an antibody-based strategy that targets flagellin, a critical virulence factor of motile gram negative pathogens. Flagella is required for effective bacterial invasion of epithelium. Moreover, flagellin is a highly potent trigger of NF-kappa B activation and pro-inflammatory gene expression, and thus may contribute to the excessive deleterious host response to regional infection. Both active and passive immunization strategies that target the N-terminal domain of flagellin reduce mortality in LD9O-100 murine models of Serratia marcescens induced acute pneumonia to less than 10 percent. This level of protection is associated with a 90 percent reduction in bacterial cfu in the lung, a 95 percent decrease in pulmonary neutrophil infiltration, and a 50 percent reduction in the incidence of bacteremia. Because the Nterminus is highly conserved, immune responses are cross-protective against a broad spectrum of gram negative pathogens. The central objective of the Phase I SBIR is to obtain proof of principle that anti-Nterminal flagellin mAb's are protective in vivo against a broad spectra of lethal infection.We will test the in vivo protective action of 14 proprietary murine mAb's in a murine model of acute gram negative bacterial pneumonia produced by intratracheal bacterial inoculation of E. coil. Specific outcome variables will include: 1) Pharmacodynamic profile; 2) Therapeutic window of opportunity; and 3) Spectrum of activity against Pseudomonas aeruginosa, Serratia marcescens, and Enterobacter cloacae. In a follow-on Phase II SBIR, we will use the peptide corresponding to the lead epitopes identified in Phase I in order to produce a human mAb.We will then advance the lead mAb technology towards commercialization by 1) optimizing in vitro yield and purity, 2) characterizing in vivo half-life, and 3) performing safety and tolerance studies in two species. These milestones will provide a foundation for IND submission and the first clinical trials of a human anti-flagellin broad-spectrum mAb. Proposed Commercial Application: Since there are no marketed anti-inflammatory agents that are safe and effective for the adjunctive therapy of gram negative pnenmocda, it is difficult to predict the future market size and trend. We anticipate, based upon the numbers of hospitalized patients with severe pneumonia, that the market exceeds that for sepsis. Thus, a very conservative estimate of the domestic market may be $200-400 million per annum. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Predictors of Postoperative Atelectasis Pneumonia Principal Investigator & Institution: Brooks-Brunn, Jo A.; Assoc Scientist, Sch of Nursing; Medicine; Indiana Univ-Purdue Univ at Indianapolis 355 N Lansing Indianapolis, in 46202
Studies 87
Timing: Fiscal Year 2000; Project Start 5-JAN-1997; Project End 1-DEC2001 Summary: (Adapted from investigator's abstract) Postoperative pulmonary complications (PPCs) are frequent and associated with increased morbidity, mortality, hospital length of stay and resource utilization. Atelectasis and pneumonia account for >80% of reported PPCs. The objective of this study is to develop predictive models for stratifying the risk of clinically significant atelectasis and/or pneumonia using readily accessible or existing clinical data in an adult abdominal and cardiothoracic surgical population. The long term goal is to develop predictive model(s) for use in the clinical setting to guide preoperative and postoperative pulmonary care. The primary aim of this study is to develop, compare and validate models to predict the risk of clinically significant atelectasis and/or pneumonia following abdominal or cardiothoracic procedures by assessing combinations of risk factors available at differing time periods during the surgical episode of care. Secondary aims are to compare the incidence of clinically significant atelectasis and/or pneumonia following abdominal and cardiothoracic procedures and postoperative length of stay between patients who develop these complications and those who do not. Four institutions will be utilized for data collection and the target population is adults who are undergoing elective abdominal or cardiothoracic procedures with general anesthesia. The target sample size is 1500 subjects over a three year period. Multi-criteria definitions will be used to measure the outcomes of clinically significant atelectasis and pneumonia as not to overestimate the incidence. The risk factors of interest are: increased age, impaired preoperative level of cognitive function, history of chronic lung disease, preexisting comorbid diseases, low or high body mass index (BMI), increased preoperative length of stay, smoking history, absence of preoperative respiratory education, high anesthesia physical risk status (ASA), increased duration of anesthesia, type and location of surgical procedure, incision direction and length, duration of intubation/mechanical ventilation in the postanesthesia period, pain management, postoperative mobility, administration of H2 blockers/antacids and presence of a nasogastric tube. Data will be collected on each subject prior to surgery and on a daily basis until hospital discharge. Logistic regression analysis will be used to examine the risk factors for univariate effects on clinically significant atelectasis and pneumonia and to develop and compare the multivariate models. Models will be evaluated for utility and goodness-of-fit. A split-sample technique will be used for model validation. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
88 Pneumonia
·
Project Title: Risk Factors for Drug Resistant Pneumococcal Pneumonia Principal Investigator & Institution: Metlay, Joshua P.; Medicine; University of Pennsylvania 3451 Walnut Philadelphia, Pa 19104 Timing: Fiscal Year 2000; Project Start 1-APR-2000; Project End 1-MAR2004 Summary: Adapted from the Applicant's Abstract): The emergence of antimicrobial drug resistance among isolates of S. pneumoniae threatens to have a major impact on the management of patients with communityacquired pneumonia (CAP). S. pneumoniae is the most common cause of CAP and adequate pneumococcal coverage is at the center of empirical guidelines for the management of this disease. Yet, risk factors for infection with drug-resistant vs. drug-susceptible S. pneumoniae are controversial and the clinical impact of in vitro levels of resistance is poorly understood. This study will focus on resistance to penicillin because penicillin and related ,8-lactam antimicrobials are a major component of current empirical treatment options for patients with CAP. Thus, understanding the risk factors for penicillin resistance can make a major contribution to the empirical management of these patients. The primary aim of this study is to identify risk factors for penicillin drug resistance in patients with bacteremic pneumococcal pneumonia. The primary study hypothesis is that both individual and community risk factors independently predict infection with penicillin resistant S. pneumoniae in patients with bacteremic pneumococcal pneumonia. A secondary hypothesis is that the duration of prior antibiotic use is a strong independent predictor of penicillin resistance in these patients. The secondary aims of this study are (1) to develop a prediction rule for penicillin resistance in patients with bacteremic pneumococcal pneumonia and (2) to measure the impact of different levels of penicillin resistance on medical outcomes in these patients. The hypotheses for these secondary aims are that (1) a prediction rule can be developed which accurately categorizes patients into high and low risk groups in order to improve the empirical selection of antimicrobial therapy for patients with CAP and (2) the in vitro level of penicillin resistance, alone, is a poor predictor of medical outcomes, but categorization of the adequacy of antimicrobial drug coverage, based on drug susceptibility profiles and pharmacodynamic drug considerations, will be a strong predictor of medical outcomes. This study is a population-based, casecontrol study, enrolling all hospitalized patients diagnosed with bacteremic pneumococcal pneumonia within the Pennsylvania Delaware Valley. Risk factors will be identified through patient interview and outpatient and inpatient medical record review. Pneumococcal drug resistance will be categorized at our microbiology laboratory with
Studies 89
standardized susceptibility testing of all pneumococcal blood isolates. Finally, a cohort study will be completed within the study design, by examining outcomes for all patients, stratifying by pneumococcal drug susceptibility and adequacy of antimicrobial drug coverage. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Smoking and Ethanol-Induced Defects in Pneumonia Defense Principal Investigator & Institution: Gentry-Nielsen, Martha J.; Medicine; Creighton University 2500 California St Omaha, Ne 68178 Timing: Fiscal Year 2002; Project Start 1-DEC-2001; Project End 0-NOV2004 Summary: (provided by applicant): The goal of this application is to use a novel rat model to study the compounding effects of cigarette smoke and alcohol abuse on susceptibility to severe pneumococcal pneumonia. Pneumonia is a major cause of morbidity and mortality in alcoholics, and the pneumococcus is the most common bacterial cause. Alcoholics have a higher incidence of pneumococcal pneumonia and they have a greater likelihood of developing bacteremia, which increases their mortality rate. Although scientists have studied the deleterious effects of ethanol ingestion on resistance to infectious diseases for years, the concurrent effects of smoking have been ignored. Because 80-90% of alcoholics smoke and >50% of multi-pack/day smokers are alcohol dependent, it is imperative to consider the additional effects of smoking when studying alcohol-induced defects in host defense against respiratory infections. Our hypothesis is that smoking exacerbates the detrimental effects of ethanol ingestion on host defense mechanisms critical for protection against lethal pneumococcal pneumonia. To test this hypothesis, rats will be exposed twice daily to cigarette smoke or room air in whole body chambers. Half of the rats also will be fed ethanol in a liquid diet. In Specific Aim 1, the rats will be infected intranasally, and the numbers of pneumococci reaching their lungs will be quantified by plate-counts. Movement of the organisms into the lungs will be correlated with alterations in the ciliary beat frequency of the rats' tracheal epithelial cells. In Specific Aim 2, novel in vitro assays will be used to determine the effects of ethanol ingestion, with and without smoke exposure, on the ability of the rats' pulmonary neutrophils to phagocytose and kill pneumococci. In Specific Aim 3, quantitative blood cultures will be used to determine the separate and combined effects of smoke exposure and ethanol ingestion on bacteremia development after establishment of pneumonia. Bacteremia will be correlated with mortality for 10-days
90 Pneumonia
post-infection with the use of a hypothermia model to predict death and determine the appropriate time for euthanasia. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: ELR-CXC Chemokines in Lung Antibacterial Host Defense Principal Investigator & Institution: Standiford, Theodore J.; Professor; Internal Medicine; University of Michigan at Ann Arbor Ann Arbor, Mi 48109 Timing: Fiscal Year 2002; Project Start 1-DEC-1996; Project End 0-NOV2005 Summary: (provided by applicant): Bacterial pneumonia is the second most common cause of hospital-acquired infection, and is leading cause of death among all nosocomial infections. Innate, or natural immunity, is the principal pathway for effective elimination of bacterial organisms from the lung. While ELR-CXC chemokines have been shown to be expressed during the generation of Th1 cell-mediated immune responses against intracellular microbial pathogens, the contribution of this family of chemokines to innate immunity against common gram-positive and gram-negative bacterial pathogens is unknown. We have focused this competitive renewal on ELR-CXC chemokines, as our preliminary observations indicate that the in-vivo depletion of selected ELR-CXC chemokines substantially impairs bacterial clearance and survival of mice with pneumonia due to Klebsiella pneumoniae. It is the hypothesis of this proposal that ELR-CXC chemokines are integral components of the innate neutrophil-dependent immune response against gram-negative bacterial infection of the lung. A murine model of Klebsiella pneumonia will be employed to achieve the following specific aims: 1) to determine the time course of expression and cellular sources of ELR-CXC chemokines and their common receptor (CXCR3) during the evolution of gram-negative bacterial pneumonia; 2) to determine the contribution of ELR-CXC chemokines and their receptor to leukocyte recruitment, proinflammatory cytokine expression, bacterial clearance, survival in Klebsiella pneumonia using specific neutralizing antibodies or knockout mice; 3) to determine the effect of IP-10 or MIG administration/transgenic expression on proinflammatory cytokine expression, bacterial clearance, and survival in murine Klebsiella pneumonia in-vivo and on alveolar macrophage effector cell function invitro; and 4) to identify endogenous signals that regulate the expression of ELR-CXC chemokines during the evolution of Klebsiella pneumonia in-vivo and in isolated lung cells in-vitro. Elucidation of specific cellular and molecular mechanisms of lung antibacterial host defense, in
Studies 91
conjunction with the use of novel gene therapy approaches will provide important insights into the treatment of patients with serious multi-drug resistant bacterial infections of the lung. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Multicity Study Of Quality Of Care For HIV-Related TB Principal Investigator & Institution: Bennett, Charles L.; Associate Director; Medicine; Northwestern University 633 Clark St Evanston, Il 60208 Timing: Fiscal Year 2000; Project Start 0-SEP-1996; Project End 0-JUN2002 Summary: (Adapted from Applicant's Abstract) HIV-infection and tuberculosis (TB) have had a major impact among injection and noninjection drug users, especially in New York, Chicago, Los Angeles, and Miami where nosocomial outbreaks of multidrug resistant TB among HIV-infected individuals have occurred. In this proposed competing continuation, we will build on our ongoing projects that evaluate quality of care for HIV-related Pneumocystis carinii pneumonia (PCP) and community acquired pneumonia (CAP) in several cities. In particular, we propose to assess the quality of TB care for HIV-infected individuals, both in-hospital (the majority of HIV-related TB cases are reported to Health Departments from inpatient settings) and subsequently as outpatients. Among HIV-infected inpatients with pulmonary symptoms, the differential diagnosis includes PCP, CAP, or TB. While our ongoing studies will provide important information on the quality of care that HIV-infected drug users and non-drug users receive for PCP or CAP, little is known about quality of TB care for these individuals. Our earlier studies found that PCP care varies widely, with poorer outcomes among drug users in the years 1987- 1990 and preliminary findings from 19951997 indicating high rates of discharge against medical advice and low rates of use of confirmatory diagnostic tests. In contrast, for HIV-related TB, our preliminary findings indicate that drug users may receive better inpatient care. Among high-risk HIV-infected individuals, rates of early suspicion for TB were higher for drug users in our 1987- 1990 data sets as well as in early looks at the 1995-1997 data from the PCP study. However, in our pilot project for HIV-related TB patients in Chicago, we found evidence of clinically relevant variations in HIV-related inpatient TB care. In particular, one Chicago hospital with few HIV-infected drug users had poor rates of TB recognition, infrequent use of isolation rooms, delayed early initiation of anti-TB therapy, and a nosocomial outbreak of MDr TB (the most recent reported outbreak), while other Chicago hospitals with larger numbers of drug users had > 80%-90% rates of TB suspicion and
92 Pneumonia
early isolation. We propose a 1995-1998 evaluation of quality of care, outcomes, and resource use for patients with HIV-infection and M TB to evaluate for drug users versus other HIV-infected individuals the following: in-hospital care (timing and appropriateness of initial anti-TB medications, use of resources such as isolation rooms, rapid methods for diagnosing TB, and outcomes) and outpatient care (timeliness of referral to directly observed therapy, drug therapy use, completion or not, and survival). This study, in conjunction with our already funded projects, will allow us to provide insights about the quality of care for HIV-related TB, CAP, and PCP in Chicago, New York, Los Angeles, and Miami, and will be the largest study of quality of care for HIV-related pneumonia. These issues are especially important in light of the findings that (1) poor TB care was associated with a nosocomial outbreak of MDr TB; (2) drug users may receive better inpatient TB care; (3) delayed referral to DOT has been associated with poorer survival rates; and (4) homelessness, but not drug use, was the most important predictor of incomplete outpatient TB care in one small study. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
E-Journals: PubMed Central19 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).20 Access to this growing archive of e-journals is free and unrestricted.21 To search, go to http://www.pubmedcentral.nih.gov/index.html#search, and type “pneumonia” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for pneumonia in the PubMed Central database: ·
A Histologically Distinctive Interstitial Pneumonia Induced by Overexpression of the Interleukin 6, Transforming Growth Factor [beta]1, or Platelet-Derived Growth Factor B Gene by M Yoshida, J
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html. 20 With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 21 The value of PubMed Central, in addition to its role as an archive, lies the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print. 19
Studies 93
Sakuma, S Hayashi, K Abe, I Saito, S Harada, M Sakatani, S Yamamoto, N Matsumoto, Y Kaneda, and T Kishmoto; 1995 October 10 http://www.pubmedcentral.nih.gov/articlerender.fcgi?rendertype=abst ract&artid=40843 ·
A Mouse Model for Investigating the Molecular Pathogenesis of Adenovirus Pneumonia by HS Ginsberg, LL Moldawer, PB Sehgal, M Redington, PL Kilian, RM Chanock, and GA Prince; 1991 March 1 http://www.pubmedcentral.nih.gov/articlerender.fcgi?rendertype=abst ract&artid=51082
·
Amplified-Fragment Length Polymorphism Analysis versus MacroRestriction Fragment Analysis for Molecular Typing of Streptococcus pneumoniae Isolates by Johan van Eldere, Paul Janssen, Annette Hoefnagels-Schuermans, Stefaan van Lierde, and Willy E. Peetermans; 1999 June http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=85030&ren dertype=external
·
Antimicrobial Resistance and Serotype Distribution of Streptococcus pneumoniae Strains Causing Childhood Infections in Bangladesh, 1993 to 1997 by Samir K. Saha, N. Rikitomi, M. Ruhulamin, H. Masaki, M. Hanif, Maksuda Islam, K. Watanabe, K. Ahmed, K. Matsumoto, R. B. Sack, and T. Nagatake; 1999 March http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=84560&ren dertype=external
·
Asthma after childhood pneumonia: six year follow up study by Christopher E Clark, Jacqueline M Coote, David A T Silver, and David M G Halpin; 2000 June 3 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=27396
·
Bacteremic Pneumonia Caused by a Single Clone of Streptococcus pneumoniae with Different Optochin Susceptibilities by Hsiu-Yuan Tsai, Po-Ren Hsueh, Lee-Jene Teng, Ping-Ing Lee, Li-Min Huang, ChinYun Lee, and Kwen-Tay Luh; 2000 January http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=88751&ren dertype=external
·
Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials by A Messori, S Trippoli, M Vaiani, M Gorini, and A Corrado; 2000 November 4 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=27516
·
Breast Milk Transmission of a Panton-Valentine Leukocidin-Producing Staphylococcus aureus Strain Causing Infantile Pneumonia by Isabelle Le Thomas, Patricia Mariani-Kurkdjian, Anne Collignon, Alain Gravet,
94 Pneumonia
Olivier Clermont, Naima Brahimi, Joel Gaudelus, Yannick Aujard, Jean Navarro, Francois Beaufils, and Edouard Bingen; 2001 February http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=87805&ren dertype=external ·
Characteristics of virus-specific CD8 + T cells in the liver during the control and resolution phases of influenza pneumonia by Gabrielle T. Belz, John D. Altman, and Peter C. Doherty; 1998 November 10 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24906
·
Chlamydia pneumoniae in a Free-Ranging Giant Barred Frog (Mixophyes iteratus) from Australia by Lee Berger, Kym Volp, Sarah Mathews, Rick Speare, and Peter Timms; 1999 July http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=85174&ren dertype=external
·
Clinical features of culture-proven Mycoplasma pneumoniae infections at King Abdulaziz University Hospital, Jeddah, Saudi Arabia by Tariq A. Madani and Aisha A. Al-Ghamdi; 2001 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=35282
·
Clinical Update:Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL study by Donald Farquhar; 2000 September 19 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=80189&ren dertype=external
·
Clinical Use of Capillary PCR To Diagnose Mycoplasma Pneumonia by Junichi Honda, Takafumi Yano, Mikako Kusaba, Junko Yonemitsu, Hiromoto Kitajima, Megumi Masuoka, Kaori Hamada, and Kotaro Oizumi; 2000 April http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=86449&ren dertype=external
·
Comparison of Nucleic Acid Amplification, Serology, and Microbiologic Culture for Diagnosis of Rhodococcus equi Pneumonia in Foals by Debra C. Sellon, Thomas E. Besser, Sally L. Vivrette, and Rebecca S. McConnico; 2001 April http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=87926&ren dertype=external
Studies 95
·
Comparison of PCR, Culture, and Serological Tests for Diagnosis of Mycoplasma pneumoniae Respiratory Tract Infection in Children by J. W. Dorigo-Zetsma, S. A. J. Zaat, P. M. E. Wertheim-van Dillen, L. Spanjaard, J. Rijntjes, G. van Waveren, J. S. Jensen, A. F. Angulo, and J. Dankert; 1999 January http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=84154&ren dertype=external
·
Coronavirus and Pasteurella Infections in Bovine Shipping Fever Pneumonia and Evans' Criteria for Causation by Johannes Storz, Xiaoqing Lin, Charles W. Purdy, Vladimir N. Chouljenko, Konstantin G. Kousoulas, Frederick M. Enright, William C. Gilmore, Robert E. Briggs, and Raymond W. Loan; 2000 September http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=87376&ren dertype=external
·
Determination of Penicillin Resistance in Streptococcus pneumoniae and Use of Co-Trimoxazole in Treatment of Pneumococcal Pneumonia by M. K. Lalitha, Anand Manoharan, Rekha Pai, and Kurien Thomas; 1999 August http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=85338&ren dertype=external
·
Development of a Genomics-Based PCR Assay for Detection of Mycoplasma pneumoniae in a Large Outbreak in New York State by Alfred L. Waring, Tanya A. Halse, Charles K. Csiza, Cynthia J. Carlyn, Kimberlee Arruda Musser, and Ronald J. Limberger; 2001 April http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=87943&ren dertype=external
·
Diagnosis and Differentiation of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis Infections in Pigs by PCR Amplification of the p36 and p46 Genes by J. Caron, M. Ouardani, and S. Dea; 2000 April http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=86451&ren dertype=external
·
Discovery of virulence genes of Legionella pneumophila by using signature tagged mutagenesis in a guinea pig pneumonia model by Paul H. Edelstein, Martha A. C. Edelstein, Futoshi Higa, and Stanley Falkow; 1999 July 6 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=22210
·
Drug points:Eosinophilic pneumonia induced by dapsone by D Jaffuel, B Lebel, D Hillaire-Buys, J Pene, P Godard, F-B Michel, J-P Blayac, J Bousquet, and P Demolyi; 1998 July 18 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=28611
96 Pneumonia
·
Effect of routine zinc supplementation on pneumonia in children aged 6 months to 3 years: randomised controlled trial in an urban slum by Nita Bhandari, Rajiv Bahl, Sunita Taneja, Tor Strand, Kare Molbak, Rune Johan Ulvik, Halvor Sommerfelt, and Maharaj K Bhan; 2002 June 8 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=115208
·
Evaluation of a Rapid Immunochromatographic Test for Detection of Streptococcus pneumoniae Antigen in Urine Samples from Adults with Community-Acquired Pneumonia by David R. Murdoch, Richard T. R. Laing, Graham D. Mills, Noel C. Karalus, G. Ian Town, Stanley Mirrett, and L. Barth Reller; 2001 October http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=88378&ren dertype=external
·
Genotyping of Mycoplasma pneumoniae Clinical Isolates Reveals Eight P1 Subtypes within Two Genomic Groups by J. Wendelien Dorigo-Zetsma, Jacob Dankert, and Sebastian A. J. Zaat; 2000 March http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=86314&ren dertype=external
·
Impact of breast feeding on admission for pneumonia during postneonatal period in Brazil: nested case-control study by Juraci A Cesar, Cesar G Victora, Fernando C Barros, Ina S Santos, and Jose A Flores; 1999 May 15 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=27869
·
Impact of nosocomial pneumonia on the outcome of mechanicallyventilated patients by J Sole Violan, C Sanchez-Ramirez, A Padron Mujica, JA Cardenosa Cendrero, J Arroyo Fernandez, and F Rodriguez de Castro; 1998 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=28997
·
Incidence of Upper Respiratory Tract Mycoplasma pneumoniae Infections among Outpatients in Rhone-Alpes, France, during Five Successive Winter Periods by Marie-Paule Layani-Milon, Isabelle Gras, Martine Valette, Jacques Luciani, Jean Stagnara, Michele Aymard, and Bruno Lina; 1999 June http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=84933&ren dertype=external
Studies 97
·
Indirect Enzyme-Linked Immunosorbent Assay for Detection of Immunoglobulin G Reactive with a Recombinant Protein Expressed from the Gene Encoding the 116-Kilodalton Protein of Mycoplasma pneumoniae by Michael F. Duffy, Kevin G. Whithear, Amir H. Noormohammadi, Philip F. Markham, Michael Catton, Jennie Leydon, and Glenn F. Browning; 1999 April http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=88644&ren dertype=external
·
Interaction between Mycoplasma hyopneumoniae and Swine Influenza Virus by Eileen L. Thacker, Brad J. Thacker, and Bruce H. Janke; 2001 July http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=88180&ren dertype=external
·
Loss of HMW1 and HMW3 in noncytadhering mutants of Mycoplasma pneumoniae occurs post-translationally by Phillip L. Popham, TaeWook Hahn, Kathleen A. Krebes, and Duncan C. Krause; 1997 December 9 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=28418
·
Molecular Detection of Mycoplasma pneumoniae in Adults with Community-Acquired Pneumonia Requiring Hospitalization by J. Wendelien Dorigo-Zetsma, Roel P. Verkooyen, H. Pieter van Helden, Hans van der Nat, and Jules M. van den Bosch; 2001 March http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=87901&ren dertype=external
·
Multidrug-Resistant Streptococcus pneumoniae in Poland: Identification of Emerging Clones by Karin Overweg, Peter W. M. Hermans, Krzysztof Trzcinski, Marcel Sluijter, Ronald de Groot, and Waleria Hryniewicz; 1999 June http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=84938&ren dertype=external
·
Mycoplasma hyopneumoniae Potentiation of Porcine Reproductive and Respiratory Syndrome Virus-Induced Pneumonia by Eileen L. Thacker, Patrick G. Halbur, Richard F. Ross, Roongroje Thanawongnuwech, and Brad J. Thacker; 1999 March http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=84495&ren dertype=external
98 Pneumonia
·
Pathogenesis of Influenza Virus-Induced Pneumonia: Involvement of Both Nitric Oxide and Oxygen Radicals by T Akaike, Y Noguchi, S Ijiri, K Setoguchi, M Suga, YM Zheng, B Dietzschold, and H Maeda; 1996 March 19 http://www.pubmedcentral.nih.gov/articlerender.fcgi?rendertype=abst ract&artid=39817
·
Pneumocystis carinii f. sp. hominis DNA in Immunocompetent Health Care Workers in Contact with Patients with P. carinii Pneumonia by Robert F. Miller, Helen E. Ambrose, and Ann E. Wakefield; 2001 November http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=88458&ren dertype=external
·
Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: How are we doing? by Colin G. Stevenson, Margaret A. McArthur, Monika Naus, Erika Abraham, and Allison J. McGeer; 2001 May 15 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=81067
·
Quantitative Detection of Streptococcus pneumoniae in Nasopharyngeal Secretions by Real-Time PCR by Oliver Greiner, Philip J. R. Day, Philipp P. Bosshard, Fatime Imeri, Martin Altwegg, and David Nadal; 2001 September http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=88308&ren dertype=external
·
Rapid-Cycle PCR for Detection and Typing of Mycoplasma pneumoniae in Clinical Specimens by Fanrong Kong, Susanna Gordon, and Gwendolyn L. Gilbert; 2000 November http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=87576&ren dertype=external
·
Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults by Kazuhiro Usui, Yoji Sasahara, Ryushi Tazawa, Koichi Hagiwara, Satoshi Tsukada, Toshio Miyawaki, Shigeru Tsuchiya, and Toshihiro Nukiwa; 2001 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=56209
·
Research Paper:Assessing the Quality of Clinical Data in a Computerbased Record for Calculating the Pneumonia Severity Index by Dominik Aronsky and Peter J. Haug; 2000 January http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=61455
Studies 99
·
Role of Early Genes in Pathogenesis of Adenovirus Pneumonia by HS Ginsberg, RL Horswood, RM Chanock, and GA Prince; 1990 August 15 http://www.pubmedcentral.nih.gov/articlerender.fcgi?rendertype=abst ract&artid=54498
·
Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study by Patrick Schoffski, Mathias Freund, R Wunder, D Petersen, C H Kohne, H Hecker, U Schubert, and A Ganser; 1998 August 8 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=28631
·
Sensitive and Specific Method for Rapid Identification of Streptococcus pneumoniae Using Real-Time Fluorescence PCR by James C. McAvin, Patricia A. Reilly, Robert M. Roudabush, William J. Barnes, Ann Salmen, Glen W. Jackson, Kathleen K. Beninga, Alicia Astorga, Ferne K. McCleskey, William B. Huff, Debra Niemeyer, and Kenton L. Lohman; 2001 October http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=88370&ren dertype=external
·
Transmission of Pneumocystis carinii DNA from a Patient with P. carinii Pneumonia to Immunocompetent Contact Health Care Workers by Sergio L. Vargas, Carolina A. Ponce, Francis Gigliotti, Ana V. Ulloa, Susana Prieto, Maria P. Munoz, and Walter T. Hughes; 2000 April http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=86483&ren dertype=external
·
Treatment of Pneumocystis carinii Pneumonia with 1,3-[beta]-Glucan Synthesis Inhibitors by DM Schmatz, MA Romancheck, LA Pittarelli, RE Schwartz, RA Fromtling, KH Nollstadt, FL Vanmiddlesworth, KE Wilson, and MJ Turner; 1990 August 1 http://www.pubmedcentral.nih.gov/articlerender.fcgi?rendertype=abst ract&artid=54447
·
Two Actinobacillus pleuropneumoniae Serotype 8 Reference Strains in Circulation by Trine Gram, Peter Ahrens, and Oystein Angen; 2000 January http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=88757&ren dertype=external
100 Pneumonia
·
Usefulness of PCR and Antigen Latex Agglutination Test with Samples Obtained by Transthoracic Needle Aspiration for Diagnosis of Pneumococcal Pneumonia by Amparo Garcia, Beatriz Roson, Jose Luis Perez, Ricard Verdaguer, Jordi Dorca, Jordi Carratala, Aurora Casanova, Frederic Manresa, and Francesc Gudiol; 1999 March http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=84531&ren dertype=external
·
Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling by Hans-Jurgen Woske, Thomas Roding, Ines Schulz, and Hartmut Lode; 2001 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=31581
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine. The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to the public.22 If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with pneumonia, simply go to the PubMed Web site at www.ncbi.nlm.nih.gov/pubmed. Type “pneumonia” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for “pneumonia” (hyperlinks lead to article summaries): ·
Production of immunoglobulin pneumoniae from animals. Author(s): Proctor M, Manning PJ.
A
protease
by
Streptococcus
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
22
Studies 101
Source: Infection and Immunity. 1990 September; 58(9): 2733-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=2117567&dopt=Abstract ·
Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia. Author(s): Nacul LC, Kirkwood BR, Arthur P, Morris SS, Magalhaes M, Fink MC. Source: Bmj (Clinical Research Ed.). 1997 August 30; 315(7107): 505-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9329303&dopt=Abstract
·
Sequence-selective binding to DNA of cis- and trans- butamidine analogues of the anti-Pneumocystis carinii pneumonia drug pentamidine. Author(s): Bailly C, Donkor IO, Gentle D, Thornalley M, Waring MJ. Source: Molecular Pharmacology. 1994 August; 46(2): 313-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8078493&dopt=Abstract
·
Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. Author(s): Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1996 April; 14(4): 1071-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8648359&dopt=Abstract
·
Shark oil pneumonia. An overlooked entity. Author(s): Asnis DS, Saltzman HP, Melchert A. Source: Chest. 1993 March; 103(3): 976-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8449116&dopt=Abstract
·
Squalene-induced extrinsic lipoid pneumonia: serial radiologic findings in nine patients. Author(s): Lee JY, Lee KS, Kim TS, Yoon HK, Han BK, Han J, Chung MP, Kwon OJ.
102 Pneumonia
Source: Journal of Computer Assisted Tomography. 1999 SeptemberOctober; 23(5): 730-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10524857&dopt=Abstract ·
TCM differential treatment of child hood persisting pneumonia--a report of 52 cases. Author(s): Bao J. Source: J Tradit Chin Med. 1998 September; 18(3): 174-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10453606&dopt=Abstract
·
The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. Author(s): Park DR, Sherbin VL, Goodman MS, Pacifico AD, Rubenfeld GD, Polissar NL, Root RK. Source: The Journal of Infectious Diseases. 2001 August 1; 184(3): 268-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=11443551&dopt=Abstract
·
The impact of vitamin A supplementation given during a pneumonia episode on the subsequent morbidity of children. Author(s): Nacul LC, Arthur P, Kirkwood BR, Morris SS, Cameiro AC, Benjamin AF. Source: Tropical Medicine & International Health : Tm & Ih. 1998 August; 3(8): 661-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9735936&dopt=Abstract
·
The woman with pneumonia. Author(s): Fritts HW Jr. Source: Pharos Alpha Omega Alpha Honor Med Soc. 1999 Fall; 62(4): 35. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10992921&dopt=Abstract
·
Therapeutic failure of trimethoprim/sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Author(s): al-Tawfiq JA, Sorensen SJ, Cushing HE.
Studies 103
Source: The Annals of Pharmacotherapy. 1999 April; 33(4): 413-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10332530&dopt=Abstract ·
Vitamin A supplementation and severity of pneumonia in children admitted to the hospital in Dar es Salaam, Tanzania. Author(s): Fawzi WW, Mbise RL, Fataki MR, Herrera MG, Kawau F, Hertzmark E, Spiegelman D, Ndossi G. Source: The American Journal of Clinical Nutrition. 1998 July; 68(1): 18792. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9665113&dopt=Abstract
·
Zinc supplementation prevents diarrhoea and pneumonia Author(s): Yamey G. Source: Bmj (Clinical Research Ed.). 1999 December 11; 319(7224): 1521A. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10591705&dopt=Abstract
Vocabulary Builder Actinobacillus: A genus of pasteurellaceae described as gram-negative, nonsporeforming, nonmotile, facultative anaerobes. Most members are found both as pathogens and commensal organisms in the respiratory, alimentary, and genital tracts of animals. [NIH] Adjuvant: A substance which aids another, such as an auxiliary remedy; in immunology, nonspecific stimulator (e.g., BCG vaccine) of the immune response. [EU] Agammaglobulinemia: An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood. [NIH] Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. [NIH] Anesthesiology: A specialty concerned with the study of anesthetics and anesthesia. [NIH] Anthropology: The science devoted to the comparative study of man. [NIH] Antibacterial: A substance that destroys bacteria or suppresses their growth or reproduction. [EU]
104 Pneumonia
Antigen: Any substance which is capable, under appropriate conditions, of inducing a specific immune response and of reacting with the products of that response, that is, with specific antibody or specifically sensitized Tlymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (q.v.) combines with antibody or a specific receptor on a lymphocyte. Abbreviated Ag. [EU] Antimicrobial: Killing microorganisms, or suppressing their multiplication or growth. [EU] Assay: Determination of the amount of a particular constituent of a mixture, or of the biological or pharmacological potency of a drug. [EU] Capillary: Any one of the minute vessels that connect the arterioles and venules, forming a network in nearly all parts of the body. Their walls act as semipermeable membranes for the interchange of various substances, including fluids, between the blood and tissue fluid; called also vas capillare. [EU]
Cardiovascular: Pertaining to the heart and blood vessels. [EU] Chemotherapy: The treatment of disease by means of chemicals that have a specific toxic effect upon the disease - producing microorganisms or that selectively destroy cancerous tissue. [EU] Coronary: Encircling in the manner of a crown; a term applied to vessels; nerves, ligaments, etc. The term usually denotes the arteries that supply the heart muscle and, by extension, a pathologic involvement of them. [EU] Cortical: Pertaining to or of the nature of a cortex or bark. [EU] Cytokines: Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. [NIH] Cytostatic: An agent that suppresses cell growth and multiplication. [EU] Cytotoxic: Pertaining to or exhibiting cytotoxicity. [EU] Decontamination: The removal of contaminating material, such as radioactive materials, biological materials, or chemical warfare agents, from a person or object. [NIH] Dermatitis: Inflammation of the skin. [EU] Diarrhoea: Abnormal frequency and liquidity of faecal discharges. [EU] Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetics. It is a hydroxy derivative of daunorubicin and is used in treatment of both leukemia and solid tumors. [NIH]
Studies 105
Endogenous: Developing or originating within the organisms or arising from causes within the organism. [EU] Enterobacter: Gram-negative gas-producing rods found in feces of man and other animals, sewage, soil, water, and dairy products. [NIH] Enzyme: A protein molecule that catalyses chemical reactions of other substances without itself being destroyed or altered upon completion of the reactions. Enzymes are classified according to the recommendations of the Nomenclature Committee of the International Union of Biochemistry. Each enzyme is assigned a recommended name and an Enzyme Commission (EC) number. They are divided into six main groups; oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. [EU] Epidemiological: Relating to, or involving epidemiology. [EU] Epithelium: The covering of internal and external surfaces of the body, including the lining of vessels and other small cavities. It consists of cells joined by small amounts of cementing substances. Epithelium is classified into types on the basis of the number of layers deep and the shape of the superficial cells. [EU] Epitopes: Sites on an antigen that interact with specific antibodies. [NIH] Escherichia: A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms occur in the lower part of the intestine of warmblooded animals. The species are either nonpathogenic or opportunistic pathogens. [NIH] Ethanol: A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages. [NIH] Euthanasia: The act or practice of putting to death people or animals suffering from incurable conditions or diseases. [NIH] Flagellin: A protein with a molecular weight of 40,000 isolated from bacterial flagella. At appropriate pH and salt concentration, three flagellin monomers can spontaneously reaggregate to form structures which appear identical to intact flagella. [NIH] Fluorescence: The property of emitting radiation while being irradiated. The radiation emitted is usually of longer wavelength than that incident or absorbed, e.g., a substance can be irradiated with invisible radiation and emit visible light. X-ray fluorescence is used in diagnosis. [NIH] Folklore: The common orally transmitted traditions, myths, festivals, songs, superstitions, and stories of all peoples. [NIH] Gastrointestinal: Pertaining to or communicating with the stomach and
106 Pneumonia
intestine, as a gastrointestinal fistula. [EU] Genotype: The genetic constitution of the individual; the characterization of the genes. [NIH] Ginseng: An araliaceous genus of plants that contains a number of pharmacologically active agents used as stimulants, sedatives, and tonics, especially in traditional medicine. [NIH] Glucose: D-glucose, a monosaccharide (hexose), C6H12O6, also known as dextrose (q.v.), found in certain foodstuffs, especially fruits, and in the normal blood of all animals. It is the end product of carbohydrate metabolism and is the chief source of energy for living organisms, its utilization being controlled by insulin. Excess glucose is converted to glycogen and stored in the liver and muscles for use as needed and, beyond that, is converted to fat and stored as adipose tissue. Glucose appears in the urine in diabetes mellitus. [EU] Hematology: A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues. [NIH] Hypothermia: A low body temperature, as that due to exposure in cold weather or a state of low temperature of the body induced as a means of decreasing metabolism of tissues and thereby the need for oxygen, as used in various surgical procedures, especially on the heart, or in an excised organ being preserved for transplantation. [EU] Hypoxemia: Deficient oxygenation of the blood; hypoxia. [EU] Immunity: The condition of being immune; the protection against infectious disease conferred either by the immune response generated by immunization or previous infection or by other nonimmunologic factors (innate i.). [EU] Incision: 1. cleft, cut, gash. 2. an act or action of incising. [EU] Indicative: That indicates; that points out more or less exactly; that reveals fairly clearly. [EU] Infantile: Pertaining to an infant or to infancy. [EU] Infarction: 1. the formation of an infarct. 2. an infarct. [EU] Infiltration: The diffusion or accumulation in a tissue or cells of substances not normal to it or in amounts of the normal. Also, the material so accumulated. [EU] Influenza: An acute viral infection involving the respiratory tract. It is marked by inflammation of the nasal mucosa, the pharynx, and conjunctiva, and by headache and severe, often generalized, myalgia. [NIH] Ingestion: The act of taking food, medicines, etc., into the body, by mouth. [EU]
Studies 107
Inpatients: Persons admitted to health facilities which provide board and room, for the purpose of observation, care, diagnosis or treatment. [NIH] Interstitial: Pertaining to or situated between parts or in the interspaces of a tissue. [EU] Intubation: The insertion of a tube into a body canal or hollow organ, as into the trachea or stomach. [EU] Islam: A monotheistic religion promulgated by the Prophet Mohammed with Allah as the deity. [NIH] Kerosene: A refined petroleum fraction used as a fuel as well as a solvent. [NIH]
Klebsiella: A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms arrange singly, in pairs, or short chains. This genus is commonly found in the intestinal tract and is an opportunistic pathogen that can give rise to bacteremia, pneumonia, urinary tract and several other types of human infection. [NIH] Legionella: Gram-negative aerobic rods, isolated from surface water, mud, or thermally polluted lakes or streams. It is pathogenic for man and it has no known soil or animal sources. [NIH] Lesion: Any pathological or traumatic discontinuity of tissue or loss of function of a part. [EU] Lethal: Deadly, fatal. [EU] Leukaemia: An acute or chronic disease of unknown cause in man and other warm-blooded animals that involves the blood-forming organs, is characterized by an abnormal increase in the number of leucocytes in the tissues of the body with or without a corresponding increase of those in the circulating blood, and is classified according of the type leucocyte most prominently involved. [EU] Lymphocytic: Pertaining to, characterized by, or of the nature of lymphocytes. [EU] Lymphocytosis: effusion. [NIH]
Excess of normal lymphocytes in the blood or in any
Mediator: An object or substance by which something is mediated, such as (1) a structure of the nervous system that transmits impulses eliciting a specific response; (2) a chemical substance (transmitter substance) that induces activity in an excitable tissue, such as nerve or muscle; or (3) a substance released from cells as the result of the interaction of antigen with antibody or by the action of antigen with a sensitized lymphocyte. [EU] Microbiological: Pertaining to microbiology : the science that deals with microorganisms, including algae, bacteria, fungi, protozoa and viruses. [EU] Microorganism: A microscopic organism; those of medical interest include
108 Pneumonia
bacteria, viruses, fungi and protozoa. [EU] Mobility: Capability of movement, of being moved, or of flowing freely. [EU] Monocytes: Large, phagocytic mononuclear leukocytes produced in the vertebrate bone marrow and released into the blood; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. [NIH] Motility: The ability to move spontaneously. [EU] Mucosa: A mucous membrane, or tunica mucosa. [EU] Mutagenesis: Process of generating genetic mutations. It may occur spontaneously or be induced by mutagens. [NIH] Myeloma: A tumour composed of cells of the type normally found in the bone marrow. [EU] Necrosis: The sum of the morphological changes indicative of cell death and caused by the progressive degradative action of enzymes; it may affect groups of cells or part of a structure or an organ. [EU] Nephrology: A subspecialty of internal medicine concerned with the anatomy, physiology, and pathology of the kidney. [NIH] Neutralization: An act or process of neutralizing. [EU] Neutrophil: Having an affinity for neutral dyes. [EU] Outpatients: Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided. [NIH] Oxygenation: The process of supplying, treating, or mixing with oxygen. No:1245 - oxygenation the process of supplying, treating, or mixing with oxygen. [EU] Paclitaxel: Antineoplastic agent isolated from the bark of the Pacific yew tree, Taxus brevifolia. Paclitaxel stabilizes microtubules in their polymerized form and thus mimics the action of the proto-oncogene proteins C-MOS. [NIH] Paediatric: Of or relating to the care and medical treatment of children; belonging to or concerned with paediatrics. [EU] Pasteurella: The oldest recognized genus of the family pasteurellaceae. It consists of several species. Its organisms occur most frequently as coccobacillus or rod-shaped and are gram-negative, nonmotile, facultative anaerobes. Species of this genus are found in both animals and humans. [NIH] Pediatrics: A medical specialty concerned with maintaining health and providing medical care to children from birth to adolescence. [NIH] Phagocytosis: Endocytosis of particulate material, such as microorganisms or cell fragments. The material is taken into the cell in membrane-bound vesicles (phagosomes) that originate as pinched off invaginations of the
Studies 109
plasma membrane. Phagosomes fuse with lysosomes, forming phagolysosomes in which the engulfed material is killed and digested. [EU] Postoperative: Occurring after a surgical operation. [EU] Preoperative: Preceding an operation. [EU] Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from incidence, which refers to the number of new cases in the population at a given time. [NIH] Proportional: Being in proportion : corresponding in size, degree, or intensity, having the same or a constant ratio; of, relating to, or used in determining proportions. [EU] Protease: Proteinase (= any enzyme that catalyses the splitting of interior peptide bonds in a protein). [EU] Proxy: A person authorized to decide or act for another person, for example, a person having durable power of attorney. [NIH] Pseudomonas: A genus of gram-negative, aerobic, rod-shaped bacteria widely distributed in nature. Some species are pathogenic for humans, animals, and plants. [NIH] Radiotherapy: The treatment of disease by ionizing radiation. [EU] Receptor: 1. a molecular structure within a cell or on the surface characterized by (1) selective binding of a specific substance and (2) a specific physiologic effect that accompanies the binding, e.g., cell-surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments, and immunoglobulins and cytoplasmic receptors for steroid hormones. 2. a sensory nerve terminal that responds to stimuli of various kinds. [EU] Recombinant: 1. a cell or an individual with a new combination of genes not found together in either parent; usually applied to linked genes. [EU] Reconstitution: 1. a type of regeneration in which a new organ forms by the rearrangement of tissues rather than from new formation at an injured surface. 2. the restoration to original form of a substance previously altered for preservation and storage, as the restoration to a liquid state of blood serum or plasma that has been dried and stored. [EU] Remission: A diminution or abatement of the symptoms of a disease; also the period during which such diminution occurs. [EU] Rhodococcus: A bacterial genus of the order actinomycetales. [NIH] Secretion: 1. the process of elaborating a specific product as a result of the activity of a gland; this activity may range from separating a specific substance of the blood to the elaboration of a new chemical substance. 2. any substance produced by secretion. [EU]
110 Pneumonia
Serology: The study of serum, especially of antigen-antibody reactions in vitro. [NIH] Species: A taxonomic category subordinate to a genus (or subgenus) and superior to a subspecies or variety, composed of individuals possessing common characters distinguishing them from other categories of individuals of the same taxonomic level. In taxonomic nomenclature, species are designated by the genus name followed by a Latin or Latinized adjective or noun. [EU] Spectrum: A charted band of wavelengths of electromagnetic vibrations obtained by refraction and diffraction. By extension, a measurable range of activity, such as the range of bacteria affected by an antibiotic (antibacterial s.) or the complete range of manifestations of a disease. [EU] Sporadic: Neither endemic nor epidemic; occurring occasionally in a random or isolated manner. [EU] Staphylococcus: A genus of gram-positive, facultatively anaerobic, coccoid bacteria. Its organisms occur singly, in pairs, and in tetrads and characteristically divide in more than one plane to form irregular clusters. Natural populations of Staphylococcus are membranes of warm-blooded animals. Some species are opportunistic pathogens of humans and animals. [NIH]
Sucralfate: A basic aluminum complex of sulfated sucrose. It is advocated in the therapy of peptic, duodenal, and prepyloric ulcers, gastritis, reflux esophagitis, and other gastrointestinal irritations. It acts primarily at the ulcer site, where it has cytoprotective, pepsinostatic, antacid, and bile acidbinding properties. The drug is only slightly absorbed by the digestive mucosa, which explains the absence of systemic effects and toxicity. [NIH] Tetanus: A disease caused by tetanospasmin, a powerful protein toxin produced by clostridium tetani. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form. [NIH] Tomography: The recording of internal body images at a predetermined plane by means of the tomograph; called also body section roentgenography. [EU]
Topical: Pertaining to a particular surface area, as a topical anti-infective applied to a certain area of the skin and affecting only the area to which it is applied. [EU] Ulcer: A local defect, or excavation, of the surface of an organ or tissue; which is produced by the sloughing of inflammatory necrotic tissue. [EU]
Studies 111
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. [NIH] Ventilation: 1. in respiratory physiology, the process of exchange of air between the lungs and the ambient air. Pulmonary ventilation (usually measured in litres per minute) refers to the total exchange, whereas alveolar ventilation refers to the effective ventilation of the alveoli, in which gas exchange with the blood takes place. 2. in psychiatry, verbalization of one's emotional problems. [EU] Vindesine: Vinblastine derivative with antineoplastic activity against acute leukemia, lung cancer, carcinoma of the breast, squamous cell carcinoma of the esophagus, head, and neck, and Hodgkin's and non-Hodgkin's lymphomas. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols. [NIH] Virulence: The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. [NIH]
Patents 113
CHAPTER 5. PATENTS ON PNEUMONIA Overview You can learn about innovations relating to pneumonia by reading recent patents and patent applications. Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.23 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available to patients with pneumonia within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available to patients with pneumonia. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information.
23Adapted
from The U. S. Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
114 Pneumonia
Patents on Pneumonia By performing a patent search focusing on pneumonia, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an example of the type of information that you can expect to obtain from a patent search on pneumonia: ·
Aspiration screening process for assessing post surgery patient's risk for pneumonia Inventor(s): Addington; W. Robert (118 Tradewinds Terrace, Indialantic, FL 32903), Stephens; Robert E. (5224 N.W. Bluff Dr., Parkville, MO 64152) Assignee(s): none reported Patent Number: 6,004,268 Date filed: April 21, 1998 Abstract: Whether a post surgery intubated patient is at risk for aspiration-based pneumonia is determined by requiring the patient to inhale an aerosol of tartaric acid that will stimulate a sensory innervation of the patient's larynx, if functionally recovered, thereby causing the patient to cough. The resulting cough or lack of cough is graded to determine whether the patient is at risk for pneumonia caused by the aspiration of matter present in the patient's mouth. In a further embodiment, the inability or difficulty of a patient to voluntarily expel potentially threatening fluid and matter from the patient's airway can be remedied by repeated applications of the aerosol chemostimulant spray. Excerpt(s): The present invention relates in general to the field of post surgery patient recovery, and is particularly directed to an involuntary cough-based process for determining whether a patient, who has undergone general anesthesia, is at risk for developing aspiration-based pneumonia. This is accomplished by causing the patient to inhale an aerosol chemostimulant that will stimulate a fully functional (recovered) sensory innervation of the patient's larynx, causing the patient to involuntarily cough. If the patient fails to cough, however, it is inferred that the patient's involuntary cough reflex is not yet fully functional, and that the patient is at risk of developing aspiration-based pneumonia. ...
Patents 115
Unfortunately, there is currently no mechanism for accurately determining whether or not the patient's ability to involuntarily clear the airway has been fully restored. Instead, because each patient's anesthesia recovery time is different, the standard medical practice is to have a skilled medical practitioner (e.g., anesthesiologist) observe the patient, and then make an `educated guess` that the patient's anesthetic state has completely subsided, and that it is `reasonably safe` to extubate the patient, and allow the patient to receive fluids and/or nutrients by mouth. If the patient's involuntary cough reflex is not yet fully restored, however, the patient is at considerable risk of developing pneumonia, as a result of entry into the airway from the patient's mouth of what would otherwise be expelled secretion and/or foreign matter that could be a substrate for breeding bacteria. ... In accordance with a first embodiment of the present invention, the potential problem of post surgery aspirationbased pneumonia, discussed above, is readily determined by means of an aerosol-based screening process, that determines the ability of an extubated post-op recovery patient, whose involuntary cough reflex in the larynx have been previously anesthetized (as by the application of a general anesthetic) or compromised by intubation, to cough involuntarily and thereby clear the patient's airway of secretion and/or foreign matter that could be a substrate for breeding bacteria and cause pneumonia. Web site: http://www.delphion.com/details?pn=US06004268__ ·
Compositions and treatments for pneumonia in animals Inventor(s): Potter; Andrew A. (Saskatoon, CA) Assignee(s): University of Saskatchewan (Saskatoon, CA) Patent Number: 5,849,531 Date filed: May 31, 1995 Abstract: New proteins and subunit antigens from P. haemolytica for use in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The subunit antigens include immunogenic amino acid sequences of P. haemolytica fimbrial protein, P. haemolytica plasmin receptor protein, and P. haemolytica 50K outer membrane protein and P. haemolytica leukotoxin. The antigens can be used in a vaccine composition, either alone or in combination. Also disclosed are methods of vaccination as well as methods of making the subunit antigens employed in the vaccines. Excerpt(s): The present invention relates generally to subunit antigens, vaccine compositions, and methods of administering the same. More particularly, the present invention relates to Pasteurella haemolytica
116 Pneumonia
proteins for use in stimulating immunity against pneumonia. ... Exposure of the animal to stress, plus infection with a variety of viruses, as described above, appears to make the animal susceptible to fibrinous pneumonia caused by P. haemolytica, and to a lesser extent, Pasteurella multocida. For a general background on shipping fever see Yates, W. D. G. (1982) Can. J. Comp. Med. 46:225-263. ... P. haemolytica also causes enzootic pneumonia and can infect a wide range of animals, in addition to cattle, including economically important species such as sheep, swine, horses and fowl. P. haemolytica is also frequently found in the upper respiratory tract of healthy animals. Pneumonia develops when the bacteria infects the lungs of these animals. Protection against Pasteurellaassociated diseases is therefore economically important to the agricultural industry. Web site: http://www.delphion.com/details?pn=US05849531__ ·
Methods of combating Pneumocystis compounds useful therefor
carinii
pneumonia
and
Inventor(s): Tidwell; Richard R. (Chapel Hill, NC), Dykstra; Christine C. (Chapel Hill, NC), Hall; James E. (Chapel Hill, NC) Assignee(s): The University of North Carolina at Chapel Hill (Chapel Hill, NC) Patent Number: 5,578,631 Date filed: April 24, 1995 Abstract: Disclosed is a method of combating Pneumocystis carinii Pneumonia in a subject in need of such treatment. The method comprises administering to to the subject an effective Pneumocystis cariniicombating amount of a bis-benzimidazole compound such as bis[5-(2imidazolyl)-2-benzimidazolyl]methane, 1,4-bis[5-2-imidazolyl)-2benzimidazolyl]butane, or a pharmaceutically acceptable salt thereof. Pharmaceutical formulations for carrying out the method and novel compounds are also disclosed, along with methods of combating Giardia lamblia. Excerpt(s): The present invention relates to methods of combatting Pneumocystis carinii Pneumonia with bis-benzimidazoles, and novel bisbenzimidazoles useful therefore. ... Pentamidine isethionate is presently marketed by LyphoMed, Inc. under the trademark Pentam, for intravenous and intramuscular injection, and is indicated for the treatment of pneumonia due to Pneumocystis carinii, the latter ailment typically being referred as "PCP". The importance of pentamidine isethionate has dramatically escalated recently due to the marked
Patents 117
increase of patients suffering from PCP. The increase in the afflicted patient population is an unfortunate consequence of the increasing presence of the Acquired Immunodeficiency Syndrome ("AIDS"). It is now estimated that approximately 70 percent of AIDS patients contract PCP. Because of the high incidence of PCP in AIDS patients, pentamidine isethionate has found utility not only in the treatment of PCP, but also of prophylaxis, in preventing or delaying the initial onset or recurrence of PCP, especially in AIDS patients. ... A fourth aspect of the present invention is the use of compounds of Formula (I) above for the preparation of a medicament for combating Pneumocystis carinii Pneumonia. Web site: http://www.delphion.com/details?pn=US05578631__ ·
Method of preventing Pneumocystis pentamidine in an aerosol form
carinii
pneumonia
using
Inventor(s): Bernard; Edward M. (New York, NY), Armstrong; Donald (New York, NY) Assignee(s): Sloan-Kettering Institute for Cancer Research (New York, NY) Patent Number: 5,262,157 Date filed: December 20, 1988 Abstract: Pneumocystis carinii pneumonia may be prevented in a subject susceptible to infection by Pneumocystis carinii by administering to the subject an amount of a pentamidine in aerosol form effective to prevent infection by Pneumocystis carinii and thus prevent Pneumocystis carinii pneumonia. Also, this invention provides a composition for the prevention of Pneumocystis carinii pneumonia which comprises an amount of a pentamidine effective to prevent infection by Pneumocystis carinii and thus prevent Pneumocystis carinii pneumonia in aerosol form and a pharmaceutically acceptable carrier. Excerpt(s): Pneumocystis carinii pneumonia (PCP) is the most common life-threatening opportunistic infection in patients with acquired immunodeficiency syndrome (AIDS). There is no safe and effective prophylaxis for this infection in patients with AIDS. Prevention of PCP would mean a reduction in mortality, morbidity, and medical costs. Treatment of the infection is costly, facilities for its diagnosis and treatment are scarce, and the number of people at risk is increasing. ... Pneumonia due to Pneumocystis carinii occurs in patients with AIDS and in cancer and organ transplant patients. The infection has also been seen in epidemics among premature and malnourished infants. The report in
118 Pneumonia
1981 of PCP in otherwise healthy male homosexuals signaled the emergence of the AIDS epidemic (1). More than 65% of AIDS patients develop PCP (2). In many cases the development of PCP is the first sign of immune dysfunction and thus provides the basis for the diagnosis of AIDS. ... Pneumocystis carinii pneumonia may be prevented in a subject susceptible to infection by Pneumocystis carinii by administering to the subject an amount of a pentamidine in aerosol form effective to prevent infection by Pneumocystis carinii and thus prevent Pneumocystis carinii pneumonia. Web site: http://www.delphion.com/details?pn=US05262157__ ·
Diamidines and bis(imidazolines) for the treatment of and prophylaxis against pneumocystis carinii pneumonia Inventor(s): Tidwell; Richard R. (Chapel Hill, NC), Geratz; Dieter J. (Chapel Hill, NC), Ohemeng; Kwasi A. (Clinton, NJ), Hall; James E. (Chapel Hill, NC) Assignee(s): University of North Carolina at Chapel Hill (Chapel Hill, NC) Patent Number: 4,933,347 Date filed: October 25, 1988 Abstract: Certain new diamidine and bis(imidazoline) compounds having activity against Pneumocystis carinii pneumonia are disclosed along with formulations and methods for treating Pneumocystis carinii pneumonia employing said compounds. Excerpt(s): This application relates, in general, to methods for treating Pneumocystis carinii pneumonia and in particular to new compounds which are pharmaceutically active against Pneumocystis carinii, to pharmaceutical formulations containing such compounds, and to methods for the treatment of, and prophylaxis against, Pneumocystis carinii pneumonia. ... Pentamidine isethionate is presently marketed by LyphoMed, Inc. under the trademark Pentam, for intravenous and intramuscular injection, and is indicated for the treatment of pneumonia due to Pneumocystis carinii, the latter ailment typically being referred as "PCP". The importance of pentamidine isethionate has dramatically escalated recently due to the marked increase of patients suffering from PCP. The increase in the afflicted patient population is an unfortunate consequence of the increasing presence of the Acquired Immunodeficiency Syndrome ("AIDS"). It is now estimated that approximately 70 percent of AIDS patients contract PCP. Because of the high incidence of PCP in AIDS patients, pentamidine isethionate has
Patents 119
found utility not only in the treatment of PCP, but also for prophylaxis, in preventing or delaying the initial onset or recurrence of PCP, especially in AIDS patients. ... One especially important aspect of the present invention is the provision of a method for treating Pneumocystis carinii pneumonia. This method comprises administering to a patient suffering from Pneumocystis carinii pneumonia, a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. Heretofore, pentamidine was one of only a few compounds of a structure similar to the structure to the compounds of Formula I that has been known to be effective in the treatment of, or prophylaxis against Pneumocystis carinii pneumonia. The only other diamidines known to have some effectiveness against PCP are dibromopropamidine, stilbamidine and hydroxystilbamidine. Web site: http://www.delphion.com/details?pn=US04933347__ ·
Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine Inventor(s): Smith; James W. (Indianapolis, IN), Bartlett; Marilyn S. (Indianapolis, IN), Queener; Sherry F. (Indianapolis, IN) Assignee(s): Indiana University Foundation (Bloomington, IN) Patent Number: 4,835,140 Date filed: August 20, 1987 Abstract: The combination of clindamycin and primaquine or pharmaceutical salts thereof is effective in treating patients with Pneumocystis carinii pneumonia. Excerpt(s): This invention is a novel treatment of patients having Pneumocystis carinii pneumonia. ... An estimated one to one and one-half million people in the United States are infected with a human retrovirus, the human immunodeficiency virus type I, HIV-1, which is the etiological agent of acquired immunodeficiency syndrome, AIDS, Norman, C., Science, 661-662 (1986). Of those infected, an estimated two hundred and fifty thousands people will develop AIDS in the next five years, Curran, J.W., et al., Science, 1352-1357 (1985). Pneumocystis carinii pneumonia is the most common life threatening infection in patients with aids. The infection occurs at least once in as many as eighty percent of AIDS patients and about one third of the total number of episodes of pneumocystis carinii pneumonia are fatal. Fewer than one half of the AIDS patients treated with conventional drugs, either trimethoprim/sulfamethoxazole or pentamidine, are able to complete a full course of therapy because a majority of these patients develop one or
120 Pneumonia
more serious adverse reactions such as severe rash, neutropenia, thrombocytopenia, anemia, liver disfunction, renal failure or disturbances in serum glucose, calcium or sodium levels. ... The abstract, Prognostic Factors in Pneumocystis carinii Pneumonia (PCP) in AIDS, presented at the 1985 annual meeting of the American Society for Microbiology by Perez, G., et al., discloses treating AIDS patients with trimethoprim sulfa, pentamidine, or combinations of both including concurrent treatment with clindamycin. Web site: http://www.delphion.com/details?pn=US04835140__ ·
Method for the control of shipping fever pneumonia in cattle Inventor(s): Irwin; Michael R. (New City, NY) Assignee(s): American Cyanamid Co. (Stamford, CT) Patent Number: 4,282,210 Date filed: December 20, 1979 Abstract: There is provided a method for the control of shipping fever pneumonia in cattle, comprising administering to said cattle an immunizing amount of an infectious bovine rhinotracheitis virus vaccine and a potentiating amount of a potentiator therefor, selected from the group consisting of pharmaceutically acceptable salts of dl 6-phenyl2,3,5,6-tetrahydroimidazo[2,1-b]thiazole and pharmaceutically acceptable salts of 1(-)6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole. This invention also relates to a method for reducing morbidity associated with shipping fever pneumonia in cattle by the parenteral treatment of said cattle with from 2 mg/kg to 8 mg/kg of animal body weight of a pharmaceutically acceptable salt of dl 6-phenyl-2,3,5,6tetrahydroimidazo[2,1-b]thiazole or 1(-)6-phenyl-2,3,5,6tetrahydroimidazo[2,1-b]thiazole and a prophylactically effective amount of infectious bovine rhinotracheitis virus vaccine. Excerpt(s): Shipping fever is generally recognized, by those involved in the beef cattle industry, as the disease responsible for a major portion of the economic losses encountered in the production and handling of cattle. The syndrome is characterized clinically by fever, acute inflammation of the airways, nasal discharge, anorexia, depression, fibrimous pneumonia, necrosis of the tissues involved, and is a major cause of death among young cattle. The disease is most frequently encountered in feedlots following shipping and is responsible for an estimated annual loss to the industry of one hundred million dollars. This loss is directly attributable to mortality associated with the disease, the high costs of prophylaxis and
Patents 121
treatment, the loss of weight and condition, and incomplete recovery from the disease which results in poorer weight gains. Web site: http://www.delphion.com/details?pn=US04282210__
Patent Applications on Pneumonia As of December 2000, U.S. patent applications are open to public viewing.24 Applications are patent requests which have yet to be granted (the process to achieve a patent can take several years). The following patent applications have been filed since December 2000 relating to pneumonia: ·
Method for indentifying increased risk of death from community acquired pneumonia Inventor(s): Wunderink, Richard Glenn ; (Germantown, TN), Waterer, Grant William ; (Yokine, AU) Correspondence: Licata & Tyrrell P.C.; 66 E. Main Street; Marlton; NJ; 08053; US Patent Application Number: 20020086016 Date filed: October 10, 2001 Abstract: This invention relates to diagnostic methods based upon a particular genotype in the Tumor Necrosis Factor (TNF.alpha.) gene, more specifically, an adenine and guanine ("GA") at the -308 site (or AA) rather than the GG at this locus. More specifically, this invention relates to a method for diagnosis of increased risk of death in patients with community-acquired pneumonia (CAP) and diagnosing pre-disposition or susceptibility to increased risk of death in patients who develop CAP, by screening for the presence of this polymorphism. The invention also relates to compositions for screening for the polymorphism and improved treatment choices for patients having the polymorphism of the present invention.The invention also relates to screening assays and therapeutic and prophylactic methods. Excerpt(s): This invention relates to diagnostic methods based upon a particular genotype in the Tumor Necrosis Factor (TNF.alpha.) gene, more specifically, a guanine (G) to adenine (A) transition at the -308 site in one of the TNF.alpha.genes giving a GA (or adenine adenine genotype, AA) genotype rather than the GG genotype at this locus. More specifically, this invention relates to a method for diagnosis of increased risk of death in patients with community-acquired pneumonia (CAP) and
24
This has been a common practice outside the United States prior to December 2000.
122 Pneumonia
diagnosing pre-disposition or susceptibility to increased risk of death in patients who develop CAP, by screening for the presence of this A allele risk polymorphism. The invention also relates to compositions for screening for the polymorphism and improved treatment choices for patients having the polymorphism of the present invention. The invention also relates to screening assays and therapeutic and prophylactic methods. ... Pneumonia is a common clinical entity, particularly among the elderly. A thorough understanding of the epidemiology and microbiology of community-acquired pneumonia (CAP) is essential for appropriate diagnosis and management. Although the microbiology of CAP has remained relatively stable over the last decade, there is new information on the incidence of atypical pathogens, particularly in patients not admitted to hospital, and new information on the incidence of pathogens in cases of severe CAP and in CAP in the elderly. Recent studies have provided new data on risk factors for mortality in CAP, which can assist the clinician in decisions about the need for hospital admission. The emergence of antimicrobial resistance in Streptococcus pneumonia, the organism responsible for most cases of CAP, has greatly affected the approach to therapy, especially in those patients who are treated empirically. Guidelines for the therapy of CAP have been published by the American Thoracic Society, the British Thoracic Society, and, most recently, the Infectious Diseases Society of America and others. These guidelines differ in their emphasis on empirical versus pathogenic-specific management. ... CAP remains a significant health problem and patients continue to die despite receiving appropriate antibiotic therapy. Modification of the host immune response, both anti- and pro-inflammatory approaches, has yet to live up to the promise of improved outcome. Despite this, there is significant reason for optimism. Some immunomodulatory therapies clearly have efficacy in some patients. As the understanding of the immune response to pneumonia improves our ability to tailor specific therapies for individual patients will also improve, hopefully avoiding the deleterious effects that have so far prevented the development of an effective immune based therapy. The possibility of delivering cytokines directly to the lung, is a particularly promising way of achieving the desired pulmonary effect without systemic side effects. Corticosteroids are currently unique in that they have a proven role in the therapy of pneumonia due to P. carinii. The development of pathogen specific therapies, such as INF for L. pneumophila, based on an improved understanding of host-pathogen interactions, are awaited. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 123
Keeping Current In order to stay informed about patents and patent applications dealing with pneumonia, you can access the U.S. Patent Office archive via the Internet at no cost to you. This archive is available at the following Web address: http://www.uspto.gov/main/patents.htm. Under “Services,” click on “Search Patents.” You will see two broad options: (1) Patent Grants, and (2) Patent Applications. To see a list of granted patents, perform the following steps: Under “Patent Grants,” click “Quick Search.” Then, type “pneumonia” (or synonyms) into the “Term 1” box. After clicking on the search button, scroll down to see the various patents which have been granted to date on pneumonia. You can also use this procedure to view pending patent applications concerning pneumonia. Simply go back to the following Web address: http://www.uspto.gov/main/patents.htm. Under “Services,” click on “Search Patents.” Select “Quick Search” under “Patent Applications.” Then proceed with the steps listed above.
Vocabulary Builder Adenine: A purine base and a fundamental unit of adenine nucleotides. [NIH] Anorexia: Lack or loss of the appetite for food. [EU] Antigens: Substances that are recognized by the immune system and induce an immune reaction. [NIH] Disposition: A tendency either physical or mental toward certain diseases. [EU]
Epidemic: Occurring suddenly in numbers clearly in excess of normal expectancy; said especially of infectious diseases but applied also to any disease, injury, or other health-related event occurring in such outbreaks. [EU] Giardia: A genus of flagellate intestinal protozoa parasitic in various vertebrates, including humans. Characteristics include the presence of four pairs of flagella arising from a complicated system of axonemes and cysts that are ellipsoidal to ovoidal in shape. [NIH] Immunogenic: Producing immunity; evoking an immune response. [EU] Innervation: 1. the distribution or supply of nerves to a part. 2. the supply of nervous energy or of nerve stimulus sent to a part. [EU] Intramuscular: Within the substance of a muscle. [EU] Larynx: An irregularly shaped, musculocartilaginous tubular structure, lined with mucous membrane, located at the top of the trachea and below
124 Pneumonia
the root of the tongue and the hyoid bone. It is the essential sphincter guarding the entrance into the trachea and functioning secondarily as the organ of voice. [NIH] Medicament: A medicinal substance or agent. [EU] Proteins: Polymers of amino acids linked by peptide bonds. The specific sequence of amino acids determines the shape and function of the protein. [NIH]
Reflex: 1; reflected. 2. a reflected action or movement; the sum total of any particular involuntary activity. [EU] Serum: The clear portion of any body fluid; the clear fluid moistening serous membranes. 2. blood serum; the clear liquid that separates from blood on clotting. 3. immune serum; blood serum from an immunized animal used for passive immunization; an antiserum; antitoxin, or antivenin. [EU] Substrate: A substance upon which an enzyme acts. [EU]
Books 125
CHAPTER 6. BOOKS ON PNEUMONIA Overview This chapter provides bibliographic book references relating to pneumonia. You have many options to locate books on pneumonia. The simplest method is to go to your local bookseller and inquire about titles that they have in stock or can special order for you. Some patients, however, feel uncomfortable approaching their local booksellers and prefer online sources (e.g. www.amazon.com and www.bn.com). In addition to online booksellers, excellent sources for book titles on pneumonia include the Combined Health Information Database and the National Library of Medicine. Once you have found a title that interests you, visit your local public or medical library to see if it is available for loan.
Book Summaries: Federal Agencies The Combined Health Information Database collects various book abstracts from a variety of healthcare institutions and federal agencies. To access these summaries, go to http://chid.nih.gov/detail/detail.html. You will need to use the “Detailed Search” option. To find book summaries, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer. For the format option, select “Monograph/Book.” Now type “pneumonia” (or synonyms) into the “For these words:” box. You will only receive results on books. You should check back periodically with this database which is updated every 3 months. The following is a typical result when searching for books on pneumonia:
126 Pneumonia
·
USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected With Human Immunodeficiency Virus in Latin America and the Caribbean: A Summary. . [USPHS / IDSA Contact: Pan American Health Organization, 525 23rd St NW, Washington, DC, 20037, (202) 974-3000, http://www.paho.org. Summary: This book presents guidelines for the prevention of opportunistic infections in people living with the HIV virus. Infections such as Pneumonia, Toxoplasmic Encephalitis, Tuberculosis, Cytomegalovirus and many more are described in detail. This book provides guidelines to a)prevent exposure to microorganisms; b)prevent the first episode of the disease by vaccination; c)prevent the recurrence of the disease by long-term treatment. This report also includes drug therapies for the prevention of opportunistic infections in adults, children, and pregnant women. An appendix is included in the book with the World Health Organization's (WHO) classification of the AIDS stages and their treatment. Special detail is given to those diseases that are more common in Latin America and the Caribbean.
·
The Medical Management of AIDS in Women Contact: John Wiley and Sons, Incorporated, 605 3rd Ave 10th Fl, New York, NY, 10158, (800) 225-5945. Summary: This book provides an overview of the medical treatment of female patients with AIDS. The book covers modes of transmission, contraception, gender-specific manifestations, and conditions common in HIV-infected women. The chapters are organized into the following sections: epidemiology, transmission, and pathophysiology; natural history of HIV in women; management of HIV infection in women; and prevention of HIV infection. One chapter is dedicated to each of the opportunistic infections associated with HIV disease in women, including toxoplasmosis, pneumocystis carinii pneumonia, systemic fungal infections, and enteric protozoan infections. Much of the book focuses on the special issues and concerns related to the HIV-positive pregnant patient, including antiviral therapy, breastfeeding, and perinatal transmission.
·
A Holistic Protocol for the Immune System Contact: Tree of Life Publications, PO Box 126, Joshua Tree, CA, 92252. Summary: This self-help manual presents a holistic approach, or natural healing process, for patients with a compromised immune system. The author outlines a four-stage protocol to treat AIDS and HIV, kill the body's parasites, rebuild the adrenal and thyroid glands, rid the body of
Books 127
bacteria and fungi, and repair the immune system. Each phase of this protocol will last approximately four to six weeks. Following the introduction, the author provides detailed descriptions of the holistic protocols and products, and an overview of AIDS, HIV, herpes, hepatitis, chronic fatigue syndrome, candidiasis, Kaposi's sarcoma, cytomegalovirus, Pneumocystis carinii pneumonia (PCP), and staphylococcus and streptococcus infections. ·
Pneumocystis Carinii Pneumonia Contact: Marcel Dekker, Incorporated, 270 Madison Ave, New York, NY, 10016, (800) 228-1160. Summary: This book presents a comprehensive examination of all aspects of Pneumocystis carinii pneumonia (PCP). This form of pneumonia is prevalent among people with AIDS and other immunosuppressed patients. The author has included a review of recent advances in basic biology, epidemiology, pathophysiology, clinical features, diagnosis, treatment, and prevention of this opportunistic infection. The book contains a treatment section detailing important topics in drug development and includes discussions of pentamidine; folate antagonists; primaquine, other 8-aminoquinolines, and clindamycin; hydroxynapthoquinones, glucan synthetase inhibitors, and corticosteroids.
·
At Risk Contact: Berkley Publishing Group, 200 Madison Ave, New York, NY, 10016, (212) 951-8800. Summary: This novel tells the story of Amanda, an 11-year-old girl who develops AIDS from a blood transfusion. The book deals with her family's feelings, from denial, anger, blaming, and depression to final acceptance. It examines the misconceptions about AIDS and the discrimination individuals with HIV disease suffer from the community. The book follows the progression of Amanda's disease, and her discovery of a friend she can talk to about her feelings. Eventually, Amanda dies from Pneumocystis carinii pneumonia (PCP), but not before she makes out a will, carefully giving away her possessions to the people she cares about.
128 Pneumonia
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes & Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in PrintÒ). The following have been recently listed with online booksellers as relating to pneumonia (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): ·
Community-Acquired Pneumonia by Thomas J. Marrie (Editor); ISBN: 0306464322; http://www.amazon.com/exec/obidos/ASIN/0306464322/icongroupin terna
·
Diagnosis and Management of Pneumonia and Other Respiratory Infections by Alan Fein, et al; ISBN: 1884735428; http://www.amazon.com/exec/obidos/ASIN/1884735428/icongroupin terna
·
Interstitial Pneumonia of Unknown Etiology (1990); ISBN: 4130681516; http://www.amazon.com/exec/obidos/ASIN/4130681516/icongroupin terna
·
Interstitial Pneumonia of Unknown Etiology (Japan Intractable Diseases Research Foundation Publication No. 27) by Michiyoshi Harasawa, et al; ISBN: 0860084523; http://www.amazon.com/exec/obidos/ASIN/0860084523/icongroupin terna
·
Mechanism - Treatment - Prevention of Aspiration Pneumonia (Theodor Billroth) by Karel B. Absolon, J. Lee Sedwitz (1999); ISBN: 0930329708; http://www.amazon.com/exec/obidos/ASIN/0930329708/icongroupin terna
·
Mycoplasma pneumoniae infection Serological, aetiological and epidemiological studies by Klaus Lind; ISBN: 8774373064; http://www.amazon.com/exec/obidos/ASIN/8774373064/icongroupin terna
·
Nosocomial Pneumonia by William R. Jarvis (Editor); ISBN: 0824703847; http://www.amazon.com/exec/obidos/ASIN/0824703847/icongroupin terna
·
Pneumocystis Carinii Pneumonia by Peter D. Walzer (Editor); ISBN: 0824788540;
Books 129
http://www.amazon.com/exec/obidos/ASIN/0824788540/icongroupin terna ·
Pneumocystis Carinii Pneumonia: Pathogenesis, Diagnosis, Treatment (Lung Biology in Health and Disease, Vol 22) by Lowell S. Young (Editor) (1984); ISBN: 0824770773; http://www.amazon.com/exec/obidos/ASIN/0824770773/icongroupin terna
·
Pneumonia by Bartlett (2000); ISBN: 0444008438; http://www.amazon.com/exec/obidos/ASIN/0444008438/icongroupin terna
·
Pneumonia - pocketbook by Simon Godfrey, Robert Wilson (1996); ISBN: 1853172413; http://www.amazon.com/exec/obidos/ASIN/1853172413/icongroupin terna
·
Pneumonia and Pneumococcal Infections by Lambert; ISBN: 0808912879; http://www.amazon.com/exec/obidos/ASIN/0808912879/icongroupin terna
·
Pneumonia, with Special Reference to Pneumococcus Lobar Pneumonia by Benjamin White, Roderick Heffron (1969); ISBN: 0674674448; http://www.amazon.com/exec/obidos/ASIN/0674674448/icongroupin terna
·
Pneumonia: Medical Subject Analysis Reference and Research Guidebook by Dominic L. Stannic (1987); ISBN: 0881645931; http://www.amazon.com/exec/obidos/ASIN/0881645931/icongroupin terna
·
Pneumonias: A Clinical Approach to Infectious Diseases of the Lower Respiratory Tract by Matthew E. Levison; ISBN: 072367020X; http://www.amazon.com/exec/obidos/ASIN/072367020X/icongroupi nterna
·
Respiratory Infections (1994); ISBN: 0881674605; http://www.amazon.com/exec/obidos/ASIN/0881674605/icongroupin terna
·
Respiratory infections : diagnosis and management ; ISBN: 0890049262; http://www.amazon.com/exec/obidos/ASIN/0890049262/icongroupin terna
·
Respiratory Infections: Diagnosis and Management by James E. Pennington (Editor); ISBN: 0781701732;
130 Pneumonia
http://www.amazon.com/exec/obidos/ASIN/0781701732/icongroupin terna ·
Serodiagnosis of the Infectious Diseases: Mycoplasma Pneumoniae by Nevio Cimolai (1999); ISBN: 0792385683; http://www.amazon.com/exec/obidos/ASIN/0792385683/icongroupin terna
·
Severe Community Acquired Pneumonia (Perspectives on Critical Care Infectious Diseases, Volume 3) by Jordi Rello (Editor), Kenneth Leeper (Editor); ISBN: 0792373383; http://www.amazon.com/exec/obidos/ASIN/0792373383/icongroupin terna
·
Streptococcus Pneumoniae: Molecular Biology & Mechanisms of Disease by Alexander Tomasz (Editor); ISBN: 0913113859; http://www.amazon.com/exec/obidos/ASIN/0913113859/icongroupin terna
·
The Pneumonias by Monroe Karetzky, et al (1993); ISBN: 038797945X; http://www.amazon.com/exec/obidos/ASIN/038797945X/icongroupi nterna
·
Ventilator-Associated Pneumonia by Richard D. Wunderink (Editor), Jordi Rello (Editor); ISBN: 0792374444; http://www.amazon.com/exec/obidos/ASIN/0792374444/icongroupin terna
The National Library of Medicine Book Index The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, http://locatorplus.gov/, and then select “Search LOCATORplus.” Once you are in the search area, simply type “pneumonia” (or synonyms) into the search box, and select “books only.” From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine:25 In addition to LOCATORPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a “Books” button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. Currently, the majority of the links are between the books and PubMed. In the future, more links will be created between the books and other types of
25
Books 131
·
Assessment of the variation and outcomes of pneumonia: Pneumonia Patient Outcomes Research Team (PORT) final report: June 28, 1996. Author: Wishwa N. Kapoor, principal investigator; Year: 1997; [Washington, D.C.: Agency for Health Care Policy and Research, 1997]
·
Community-acquired pneumonia. Author: edited by Thomas J. Marrie; Year: 2001; New York: Kluwer Academic / Plenum Publishers, c2001; ISBN: 0306464322 http://www.amazon.com/exec/obidos/ASIN/0306464322/icongroupin terna
·
Contribution to the clinical history of croupous pneumonia: a report of eleven cases of croupous pneumonia occurring in private practice between the dates of Feb. and June, 1878. Author: by D. Webster Prentiss ..; Year: 1879; [Washington, D.C.?: s.n. 1879?]
·
Current status of mycoplasma pneumoniae infections with special emphasis on epidemiology, clinical manifestations, and therapy. Author: Göran Sterner; Year: 1988; Stockholm: Abbott Scandinavia, c1988
·
Dissemination of guidelines for pneumonia length of stay: abstract, executive summary, and final report. Author: [author, Michael J. Fine]; Year: 2000; Pittsburgh: Pittsburgh Univ. PA, [2000]
·
Macrolides in community-acquired pneumonia and otitis media. Author: overview prepared by Christine Perras; Year: 1997; Ottawa, Ont.: Canadian Coordinating Office for Health Technology Assessment, [1997]
·
Medical record abstraction form and guidelines for assessing quality of care for hospitalized patients with AIDS-related pneumocystis carinii pneumonia. Author: Charles Bennett ... [et al.]; Year: 1993; Santa Monica, CA: Rand, 1993
·
Medical record abstraction form and guidelines for assessing quality of care for hospitalized patients with pneumonia. Author: Carol Pindar Roth ... [et al.]; Year: 1988; Santa Monica, CA: Rand, [1988]
·
Mycoplasma pneumoniae antibody assays. Author: M. Sillis ... [et al.]; Year: 1998; London: Department of Health, 1998; ISBN: 1858399467
·
New fluoroquinolones in community-acquired pneumonia: a clinical and economic evaluation. Author: Colleen J. Metge...[et al.]; Year: 2001; Ottawa, Ont.: Canadian Coordinating Office for Health Technology Assessment, [2001]; ISBN: 1894620143 (print)
·
Nosocomial pneumonia. Author: edited by William R. Jarvis; Year: 2000; New York: Marcel Dekker, c2000; ISBN: 0824703847 (alk. paper)
information, such as gene and protein sequences and macromolecular structures. See http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.
132 Pneumonia
http://www.amazon.com/exec/obidos/ASIN/0824703847/icongroupin terna ·
Overlap in the clinical presentation and treatment of malaria and pneumonia in children: report of a meeting (Geneva, 8 April 1991). Author: Programme for the Control of Acute Respiratory Infections, Division for the Control of Diarrhoeal and Acute Respiratory; Year: 1992; Geneva: World Health Organization, c1992
·
Pneumonia and related infections in young children: an annotated selective bibliography. Author: Programme for the Control of Acute Respiratory Infections; Year: 9999; Geneva: World Health Organization, 1993-
·
Pneumonia in the elderly. Author: K. Joy Robertson; Year: 1992; [S.l: s.n., 1992?]
·
Pneumonia. Author: Simon Godfrey, Robert Wilson; Year: 1996; London: Martin Dunitz, 1996; ISBN: 1853172413 http://www.amazon.com/exec/obidos/ASIN/1853172413/icongroupin terna
·
Pneumonias. Author: by Douglas M. Borland; Year: 1941; New Delhi: B. Jain Publishers, 1991
·
Report on the prevention of mortality and disablement due to measles and pneumonia in children. Author: by A. Salusbury MacNalty; with a preliminary memorandum on administraative measures against measles by S.W. Wheaton; Year: 1918; London: H.M.S.O., 1918
·
Serodiagnosis of the infectious diseases: mycoplasma pneumoniae. Author: Nevio Cimolai; Year: 1999; Boston: Kluwer Academic, c1999; ISBN: 0792385683 (alk. paper) http://www.amazon.com/exec/obidos/ASIN/0792385683/icongroupin terna
·
Severe community acquired pneumonia. Author: edited by Jordi Rello and Kenneth Leeper, Jr; Year: 2001; Boston: Kluwer Academic Publishers, c2001; ISBN: 0792373383 (hardback: alk. paper) http://www.amazon.com/exec/obidos/ASIN/0792373383/icongroupin terna
·
Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. Author: World Health Organization Pneumonia Vaccine Trial Investigators' Group; Year: 2001; Geneva: Dept of Vaccines and Biologicals, World Health Organization, 2001
·
Ventilator-associated pneumonia. Author: edited by Richard G. Wunderink, Jordi Rello; Year: 2001; Boston: Kluwer, c2001; ISBN: 0792374444 (alk. paper)
Books 133
http://www.amazon.com/exec/obidos/ASIN/0792374444/icongroupin terna
Chapters on Pneumonia Frequently, pneumonia will be discussed within a book, perhaps within a specific chapter. In order to find chapters that are specifically dealing with pneumonia, an excellent source of abstracts is the Combined Health Information Database. You will need to limit your search to book chapters and pneumonia using the “Detailed Search” option. Go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find book chapters, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Book Chapter.” By making these selections and typing in “pneumonia” (or synonyms) into the “For these words:” box, you will only receive results on chapters in books. The following is a typical result when searching for book chapters on pneumonia: ·
Role of Antibiotics in Comfort Care Source: in Olson, E.; Chichin, E.R.; Libow, L.S., eds. Controversies in Ethics in Long-Term Care. New York, NY: Springer Publishing Company. 1996. p. 91-107. Contact: Springer Publishing Company. 536 Broadway, New York, NY 10012-9904. (212) 431-4370; FAX (212) 941-7842. Price: $34.95 (for the book). ISBN: 0826186009. Summary: This book chapter examines the role of antibiotics in comfort care for end-stage dementia patients, and suggests a flexible approach to deciding when to provide or forgo antibiotic therapy. The authors discuss what is meant by comfort care, whether the usual outcomes of antibiotic treatment are consistent with the goals of comfort care, when the use of antibiotics may be considered comfort care, and when the use of antibiotics is more likely to be burdensome. They suggest that the characterization of any treatment option is based on its ability to influence both symptom relief (quality of life) and survival (quantity of life), and propose that antibiotic therapy may be considered comfort care when it is uniquely effective at relieving symptoms. They also present the examples of pneumonia, urinary tract infection, and infected pressure sores to show how the proposed approach to decision making applies to the problem of infection in end-stage dementia patients residing in longterm care facilities. These examples also illustrate how optimal comfort care is achieved when an antibiotic's unique effectiveness is weighed
134 Pneumonia
against its potential to prolong life, in comparison with alternative palliative measures. The authors conclude with a proposal for a flexible approach to comfort care that takes into account the patient's premorbid quality of life, the type of infection, and the likely response in terms of both quality and quantity of life. 22 references. ·
Infection Source: Cambridge, MA: Harvard University Press. 1991. 13 p. Contact: Available from Harvard University Press. 79 Garden Street, Cambridge, MA 02138-9983. (617) 495-2577 or (617) 495-2480. Price: $24.95 plus shipping and handling. ISBN: 067464235X. Summary: This chapter, from a patient education book about organ transplantation, discusses the task of preventing infection in patients who have received donor organs. Topics include the role of good tissue typing and matching in prevention of infection; reducing the risks of infection; preoperative, perioperative and postoperative measures taken to reduce the risk of infection; a timetable used to divide the times when the recipient is susceptible; urinary tract infection; pneumonia; special viral infections including general infections like influenza and those infections for which the transplant